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Background: Not only does IBD lead to nutritional deficiencies, but also nutrients 
influence its pathophysiology:  exclusive enteral nutrition (EEN) is an effective primary 
treatment in Crohn’s disease; and vitamin D (VitD) is involved in its pathogenesis and 
course. 
Aims: We hypothesised that nutrients impact on the course of IBD. We therefore studied 
the effect of EEN i) on long term clinical course in children; ii) on CD58, a costimulatory 
molecule at the intestinal epithelial cell (IEC) lines, iii) adults with Crohn’s disease. We 
examined the possible effect of serum vitamin D levels on the course of IBD and also the 
possible role of ethnicity in our paediatric and adult populations that were treated with 
EEN but also in our general adult population.  
 
Results  
Chapter II: 56 paediatric patients with Crohn’s disesase were followed up for 5 years. 
57% of patients achieved remission after 6 weeks of EEN. Achievement of clinical 
remission within 6 weeks of EEN was significantly associated with a longer time to 
relapse and to treatment escalation. VitD deficiency was common; and those patients who 
were deficient were significantly more likely to require corticosteroids and also needed 
thiopurines sooner. 
Chapter III: CD58 was expressed in the IEC isolated from IBD patients and healthy 
controls. EN down-regulated the expression of CD58 on  IEC lines. 
Chapter IV: 22 adult patients with Crohn’s disease with a mean age of 30.8 years were 
given EEN and followed up for a mean time of 1.9 years. 22.7% of patients went into 
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clinical remission and 77.3% experienced a clinical response. By the end of follow up 
63.6% (14/22) of patients had clinically relapsed and 36.4% required surgery during their 
follow up. There was no difference between South Asian and Caucasian patients in the 
disease outcomes after administration of EEN. 
Chapter V: Bangladeshis were more often vitamin D deficient than white Caucasian 
patients; however vitamin D status was not associated with the course of IBD.  
Bangladeshis developed perianal disease and required thiopurines earlier in their disease 
course. Bangladeshi patients with UC had more extensive disease.  
 
Conclusions: EEN, when successful, improves the long term outcome of Crohn’s disease 
in children, possibly in part, by down-regulating CD58 on the IEC. VitD deficiency may 
influence the clinical course of IBD; however our results were contradictory between 
children and adults and significantly limited by the assessment of the vitamin D level at a 
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               CHAPTER I: INTRODUCTION
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1.1 Inflammatory bowel disease 
Crohn’s disease (CD) and ulcerative colitis (UC) represent the two main forms of 
inflammatory bowel disease. [1] UC was first described in the mid 19th century and CD, 
initially in 1913 by Kennedy Dalziel (Dalziel’s disease) [2] and subsequently in 1932 as 
regional enteritis. [3] The incidence of IBD varies over different populations and has 
changed over time. In the past 50 years, the incidence of UC initially increased and then 
stabilized, while the incidence of CD continued to increase, mainly driven by CD in 
younger people. [4] The incidence and prevalence of IBD is highest in North America, 
Western Europe and UK (figure 1.1). [5] The prevalence of CD in North America is 
estimated between 26 and 198.5 cases per 100,000 of population, with an incidence rate 
of 3.1 to 14.6 new cases per 100,000 of population per year. 400 - 600,000 patients are 
affected. [6] In UK, the prevalence of CD has been reported about 157/100,000 with an 
incidence rate of 9.56 new cases per 100,000 population per year. [7] The prevalence of 
UC is 7.6 – 246/100,000 with an incidence rate of 1.2 – 20.3 new cases per 100,000 of 
population per year, with the wide range possibly implying different exposure to genetic 
and environmental risk factors. [3] The incidence of IBD is higher among countries with 
a western lifestyle; for example in Australia and New Zealand the reported incidence and 
prevalence rates of IBD are comparable to those of western Europe and North America. 
A recent study in Victoria in Australia, calculated and incidence rate of 29.3 new cases 
per 100,000 of population per year for the period 2007-2008, one of the highest reported 
in literature. [8] In Canterbury in New Zealand the estimated prevalence of IBD is about 
332/100,000 , again one of the highest ever reported, with cases being more prevalent 
among Causians, of higher socioeconomic status living in a city. [9]  
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Similarly, in Europe, the incidence of IBD in Western European countries has been 
estimated to be twice that of the less wealthy Eastern European countries. [10] However, 
the diference in incidence between Eastern and Western European countries seems to 
decline: A recent Epicom study reports an incidence rate of 14/100,000 in Western 
Europe compared to 11.3/100,000 in Eastern Europe. [11] In fact, there is a worldwide 
trend towards an increase in the incidence and prevalence of IBD. It has been 
increasingly reported in countries where used to be rare, such as South Korea, China, 
India, Iran, North Africa, Thailand and French West Indies. [5] A systematic meta-
analysis of the epidemiology of CD in China, reported that after 1980, it is increasingly 
prevalent in urban areas of the country, estimating a prevalence of 30.000-40,000 patients 
, which is probably an underestimate given the geographical and demographic complexity 
of China. [12] Similarly, a sharp rise in the incidence and prevalence of IBD has been 
reported in other Asian countries such as Japan, Hong Kong and South Korea. [4]  
 
 
Figure 1.1. : The global map of IBD incidence. Taken from Cosnes et al, 
Gastroenterology 2011: 140: 1785 - 1794.  
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Crohn’s disease is usually firstly diagnosed among adult patients aged 20-30 years and 
UC among patients aged 30-40 years. In the paediatric population, which represents 
about 7-20% of IBD patients, [5] IBD is diagnosed at 11.9 years on average [13] and the 
incidence of UC has remained stable over the years, while that of Crohn’s disease has 
been steadily increasing. [5] In Scotland the incidence of paediatric Crohn’s disease has 
increased from 2.86/100,000 per year in 1990 – 1995 to 4.75/100,000 per year in 2003 – 
2008. [14] In California, the annual incidence of Crohn’s disease increased between 1996 
and 2006 from 2.2 to 4.3 and that of UC from 1.8 to 4.9 new cases per 100,000 
population. [15] In France the reported incidence of paediatric Crohn’s disease increased 
between 1990 and 2007 by 71% from 6.5 to 11.1 new cases every year per 100,000 
persons. [16] Similarly, in Finland the mean annual incidence of IBD among the 
paediatric population almost doubled, increasing from 3.9 in 1987 to 7.0/100,000 in 
2003. [17]  
The rising trend in the incidence of IBD in populations of uniform and relatively steady 
genetic background over the years, and the increasing incidence in populations where 
IBD has been traditionally rare, is likely to reflect the influence of environmental factors 
rather than fundamental genetic alterations. This is strongly supported by studies in 
immigrant populations. In a population with traditionally high rates of abdominal 
tuberculosis and low incidence of IBD, the East London Bagladeshi community, IBD 
rates have been reported to rise over the course of time. [18] In a recent study from Spain, 
emigration was an independent risk factor for IBD, and emigration to European 
industrialized countries would be more strongly associated with a diagnosis of IBD 
compared to emigration to Asia or Latin America. [19]  
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1.2 The natural history of IBD 
1.2.1. The natural history of Crohn’s disease 
Crohn’s disease is characterized by transmural inflammation that can affect any point of 
the gastrointestinal tract from mouth to anus and can lead to strictures, fibrosis or 
penetrative complications. The primary lesion of Crohn’s disease, in the macroscopic / 
endoscopic level is the apthous ulcer and the evolution of this lesion is best described by 
studies of the post-operative recurrence of Crohn’s disease. A landmark study, following 
up 89 patients who underwent ileal resection for isolated ileal Crohn’s disease, proved 
that endoscopic lesions were present in 73% of patients 1 year after surgery and 85% of 
patients 3 years after surgery with a clinical recurrence rate of 20% and 34% respectively. 
[20] Similar results were obtained by others, proving that although endoscopic recurrence 
occurs within a year in the majority of patients, clinical symptoms take about 3 years to 
recur. [21]  
Crohn’s disease patients are best described by the Montreal classification according to 
their age of diagnosis, the disease location, the disease behaviour, and the presence of 
upper GI and perianal disease. [22] Recently this has been modified to improve the 
description and classification of paediatric Crohn’s disease according to the Paris 
modification. [23] However as most of the work presented in this thesis was undertaken 
prior to the Paris modification, Crohn’s disease will be classified according to the 
Montreal Classification. 
The disease location remains relatively stable over time, but still about 16% of patients 
will progress to a more extensive phenotype in the 10 years after diagnosis. 20% of 
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patients with predominantly ileal disease and 17% of patients with colonic disease had 
extension of location involvement with median time to extension 5.5 and 7.5 years 
respectively. 4.8% of patients with ileocolonic disease presented upper GI involvement in 
a median of 8.3 years. Perianal fistulas occur in about 43% of patients. [24] The median 
time from diagnosis to first perianal fistula presentation is about 4.8 years. Although the 
majority of patients with perianal fistulation will have only one fistulizing episode, 33% 
of the will have a second or a third episode during the course of their disease. [25]   
Crohn’s disease behaviour, changes and progresses during the course of time, as most 
patients will develop intestinal complications (figure 1.2). In a retrospective study from 
Minessota including 306 patients diagnosed with Crohn’s between 1970 and 2004, with a 
median follow up of 8.6 years, 81.4% of patients had inflammatory disease without 
stricturing or penetrative complications at baseline. The cumulative incidence of a 
stricturing or penetrative complication was 4.1% at 1 year, 18.5% at 5 years, 24.7% at 10 
years, 39.5% at 20 years and 43.9% at 30 years. 81.6% of patients with a progression in 
behavior of their disease would require surgery within the 6 months after the 
identification of the complication. Ileal involvement and 5-ASA utilization at diagnosis 
were associated with higher risk of complications in the follow up period. [26] Another 
study including 297 patients with Crohn’s disease confirmed the dynamics of behavioral 
evolution: 29.5% of patients initially diagnosed with inflammatory disease developed 
stricturing or penetration at 5 years after the diagnosis, 43% developed complications 
between 5 and 10 years from diagnosis and 33.3% between 20 and 25 years from 
diagnosis, proving that the change in behaviour can occur even decades after the 
diagnosis. The proportion of patients changing from an inflammatory to a stricturing 
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behavior was 27.1% with a median time to change 5.5 years and the proportion of change 
from an inflammatory to a penetrative phenotype was 29.4% with a median time to 
change of 6 years. New strictures or penetrative complications developed in 33% of 





Figure 1.2.: The natural history of Crohn’s disease phenotype. Taken from Cosnes et 
al, Gastroenterology 2011: 140: 1785 – 1794. Almost all Crohn’s disease patients with 
ileal involvement developed stricturing or penetrating complications during their disease 
course. Only 40-50% of patients diagnosed with colonic Crohn’s disease developed 
stricturing or penetrating complications during their disease course. 
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The natural history of Crohn’s disease is more aggressive among patients being 
diagnosed during their childhood: A landmark study, presenting the follow up of 276 
patients with CD diagnosed during their childhood and 596 adult onset CD patients in 
Scotland, showed that childhood onset CD is associated with panenteric involvement. 
Furthermore, disease extent progressed over time more rapidly among these patients with 
more than 30% of them presenting expansion of their disease location in 2 years. The rate 
of stricturing and penetrating complications over time was similar between adult and 
childhood onset Crohn’s disease. Although the time to surgery was longer among 
paediatric onset CD patients, this might reflect the more extensive disease phenotype in 
this group, which makes surgery a less attractive option compared to medical treatement. 
(Figure 1.3) [28] 
 
Figure 1.3.: Time to surgery in childhood and adult onset CD. (Van Limbergen et al, 
Gastroenterology, 2008. 135(4): p. 1114-22 [28]) Patients with childhood onset CD took 
longer to require surgery compared to patients with adult onset Crohn’s disease. 
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Crohn’s disease runs in a periodic remission – exacerbation pattern for most patients. 
However, there have been identified patients with very benign disease course and a 
minority of 10-15% of patients who will have chronic active and progressive disease. The 
relapse rate in the first 3 years after the diagnosis correlates with the relapse rates of the 5 
subsequent years, perhaps underlining the importance of early aggressive management 
and achievement of remission [29] in clinical and endoscopic level. The achievement of 
mucosal healing 1 year post diagnosis is associated with reduced requirement for 
corticosteroid treatment and reduced need for surgery in the 5 years post initial follow up. 
[30] The patterns of disease course for Crohn’s disease have been very elegantly 
elucidated by a Norwegian prospective follow up study of 237 new Crohn’s disease 
patients followed up for 10 years. 90% of patients had at least one episode of relapse and 
38% of them required surgery especially those diagnosed before the age of 40, those with 
ileal involvement or complicated behavior phenotype at diagnosis. Overall, 4 patterns 
were identified: i) patients with decrease in symptomatic severity over follow up, ii) 
patients with increase in the severity of symptoms over follow up, iii) patients with 
continuous symptoms of active disease, iv) patients with chronic relapsing bowel 




Figure 1.4.: Four predefined curves reflecting different patterns of CD activity from 
diagnosis to 10-year follow-up. Taken from Solberg et al, Clin Gastroenterol Hepatol, 






Chronic active inflammation may lead to treatment failure or intestinal complications that 
can not be managed solely by medical treatment. 5-15% of patients require surgery 
within the first 3 months of diagnosis and about 3.5% of patients per year require surgery 
for the management of strictures, perforation and active inflammation. In this cohort with 
a follow up of 25 years, a third of patients were operated on at least once, with patients 
having at least ileal disease and absence of rectal involvement being at greatest risk. The 
cumulative probability for surgery was not affected by the increasing use of 
immunosuppresants. [32] Similar results were obtained by others. [31, 33] 
Recurrent need for surgery can lead to short bowel syndrome and intestinal failure. 
Young age at first surgery and the presence of stricturing or penetrative disease have been 
shown to be independently associated with intestinal failure [34] pointing the need to 
maximize the benefits of the available treatments early in the disease course.  
 
1.2.2 The natural history of ulcerative colitis 
Ulcerative colitis involves the rectum and spreads in a retrograde fashion to the rest of the 
colon, however for some patients there may be rectal sparing and/or backwash ileitis. In a 
prospective evaluation of the disease extension involving 408 patients, at diagnosis 32% 
had proctitis, 33.5% had left sided disease and 34.5% had extensive disease. [35] In 
follow up colonoscopic investigation (median time 14 months), there was disease 
expansion in 14% of patients, extent regression in 22% and normal findings in 30% of 
patients. 22% of patients with initially diagnosed proctitis, 28% of patients with initially 
diagnosed left sided colitis or rectosigmoiditis presented expansion of the distribution of 
active inflammation in their follow up colonoscopy. [35]  
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The clinical course of ulcerative colitis is characterized by periods of remission and 
periods of symptomatic exacerbation. In a study from Denmark, 23% of the 1161 patients 
diagnosed with UC in Copenhagen between 1962 and 1987 had one episode of active 
disease during the observation period (median 3 years) and remained inactive thereafter, 
and 77% of patients presented a continuous relapsing course after the initial episode. [36] 
However the cumulative probability of a relapse free course decreased significantly over 
the course of time, reaching 18.4% after 5 years and 10% after 25 years. After the first 2 
years from diagnosis about 40% of patients will be in remission every year and this 
percentage increases to 50% at 20 years after diagnosis. [36] This improvement might be 
due to the disease becoming more inactive over the course of time, or simply reflect the 
number of patients who underwent “curative” colectomy (20% within the first 10 years 
and 30% within 25 years). Excluding patients who underwent a colectomy, a minority of 
5-10% presented chronic active inflammation and 40% of patients presented intermittent 
disease activity. [36]  
The course of UC can be more aggressive in children; In a study including 99 patients 
with childhood onset UC and 701 patients with adult onset UC, more children than adults 
had extensive disease at diagnosis (82% vs 48%) and this reflected on the time to 
colectomy which was significantly shortened among the childhood onset UC patients. 
(figure 1.5) [28] A retrospective longitudinal cohort study study shows that 28% of 
children with UC need to be hospitalized with acute severe colitis, 53% of them manage 




Figure 1.5.: Time from diagnosis to surgery in childhood and adult onset UC. Taken 
from Van Limbergen et al, Gastroenterology, 2008. 135(4): p. 1114-22. [28]  




The rate of mortality for both patients with Crohn’s and UC is not different to that of the 
general population, [5] however the impact of IBD on patient’s quality of life can be 
detrimental. 
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1.2.3 Paediatric and adult onset Inflammatory Bowel Disease 
 
It has been suggested that paediatric onset IBD may represent a different form of the 
disease and that it may also have a distinct aetiology. [38]. Given the increased 
prevalence of family history among those who are diagnosed with IBD early in life, the 
impact of environmental modifiers could be less prominent; and therefore IBD in this 
group may represent a more “pure” genetically derived form of disease with different 
phenotypic characteristics and natural history. [39] Two big studies have attempted to 
provide data on the natural history of IBD in the paediatric population and to compare it 
with the adults: one from Scotland [28] and one from France. [38] Both studies agree, 
that childhood onset Crohn’s disease is associated with more extensive, pan-enteric 
phenotype and less commonly isolated ileal or colonic disease. [28, 38] 50-70% of 
children had ileocolonic disease on diagnosis according to these two studies with 27% of 
children presenting with maximum disease extent according to their Montreal 
Classification (L3 + L4). [28, 38] The incidence of pan-entreric involvement was 
significantly higher among patients with childhood onset compared to those with adult 
onset Crohn’s disease, among whom the incidence of this phenotype on diagnosis is only 
3.2%.  
 
Disease progression was frequent among paediatric onset Crohn’s disease patients: 4 
years after diagnosis the incidence of stricturing and penetrative disease increased from 
4.4% to 12.9% and 11.4% respectively. [28] 60-90% of patients with paediatric onset CD 
required treatment with immunomodulators by the end of follow up. [28, 38] Surgery was 
more often required among patients with adult onset, compared to paediatric onset 
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Crohn’s disease (53% vs 17% respectively) and the time to first resection was 7.8 and 
13.7 years respectively. [28]  
Among patients with paediatric onset UC, 75% had extensive (E3) disease at diagnosis 
according to their Montreal Classification and from the remaining 25%, almost half 
patients had disease progression during follow up. [28] 10 years after diagnosis 40% of 
patients with childhood onset UC had undergone a colectomy compared to 20% of adult 
onset UC patients. [28] 
Within the paediatric population, a distinct phenotype has been described as well: those 
with very early onset disease (before their 8th birthday). [38] These children develop IBD 
with more frequent colonic involvement and less frequent ileal or panenteric 
involvement. [38, 40] Also, Crohn’s disease limited to the mouth or perianal area was 
more common in this sub-group of patients (13%) compared to patients diagnosed during 
their childhood, but after their 8th birthday (2.7%). [28] 
The above described phenotypic differences between paediatric and adult onset IBD have 
led to the hypothesis that the two phenotypes may stem from different genetic 
backgrounds. Recently, a GWAS study, including 3,426 patients and 11,963 controls 
from Europe and North America, identified five genomic regions that are associated with 
early onset IBD, one of which is relevant to the regulation of IL-27. [41] This was also 
confirmed at tissue level, were IL-27 mRNA was expressed at significantly lower levels 
in early onset CD and UC mucosa compared to normal controls. [41] A recent study 
using high density genotyping to evaluate genetic differences between paediatric and 
adult onset IBD suggested that the allelic architecture of common susceptibility variants 
for paediatric onset IBD is similar to the one of adult onset IBD. [42] However, this study 
 45 
did not focus on very early onset IBD. This is important because, while it is likely that 
paediatric and adult IBD are similar within their disease types (Crohn’s disease and 
ulcerative colitis), it has been known for over 25 years that IBD presenting in infancy is a 
distinct condition.  [40]   
Recenly, the composition of faecal microbiota among IBD patients has been the focus of 
a number or studies attempting to explore the pathophysiology and course of IBD. [43] 
Among adult patients with Crohn’s disease, the levels of Faecalibacterium Prausnitzii 
which has been shown to produce an anti-inflammatory 15 KDa protein [44] have been 
proved to be reduced in the intestinal mucosa. [45] Adult patients who undergo surgery 
are more likely to develop post surgical de novo inflammation if the proportion of 
Faecalibacterium Prausnitzii in the microbiota of the resected mucosa is low. [45] 
Interestingly, a Scottish study of the intestinal microbiota including 22 children with 
newly diagnosed IBD who were treatment naive and 12 controls observed an increase in 
Faecalibacterium Prausnitzii among children with Crohn’s disease compared to controls, 
challenging the outcomes of studies in adults and possibly suggesting that the microbiota 
of paediatric onset Crohn’s disease differs to the one of adult onset Crohn’s disease. [43] 
The above findings suggest that childhood onset IBD may have different phenotypic 
characteristics and natural history and distinct genetic background. However, this notion 
is not universally accepted, except in very early onset disease, which was always thought 
to be a distinct entity from Crohn’s disease and UC of adulthood. [40]
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1.3. Impact of IBD on the quality of life 
The symptomatology, hospitalizations, treatment and outpatient visits related to a 
diagnosis of IBD have a significant impact on patients’ quality of life. The study that 
developed the health related quality of life questionnaire, which is now widely used in 
clinical and research practice, included 150 patients and identified that IBD patients 
experience a moderate degree of functional impairment, mostly in the social and 
psychological rather than physical level. [46] Concerns about surgery, fatigue and body 
image issues were associated with social and psychological dysfunction, which are more 
prevalent among Crohn’s disease rather than UC patients. [46] In a recent study 
comparing quality of life between IBD and IBS patients, the psychological distress had a 
more significant impact on quality of life than the degree of gastrointestinal symptoms, 
and both were more severe in IBD than IBS patients. [47] Factors associated with poorer 
quality of life included the disease course, as defined by number of disease relapses, 
anxiety, level of social support and female gender. [48] Similar results were obtained in 
studies of the paediatric population; similar to the adult studies disease activity was 
associated with poorer quality of life scores. [49] Although a diagnosis of IBD has not 
been shown to be associated with poorer education and professional function – although 
absenteeism has been reported - [50] adolescents with IBD had significant impairment in 
their physical and psychosocial functioning. [51] 
The detrimental impact of IBD on patients’ lives is largely reversed by the successful 
management of IBD. Initiation on thiopurines on the correct clinical grounds was 
associated with a significant and long lasting positive effect on quality of life scores 
among IBD patients. [52] Similarly induction of clinical remission with infliximab 
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restored the quality of life of the majority of patients. [53] Achievement of clinical and 
endoscopic remission by any medical means has been associated with restoration of 
quality of life in IBD patients. [54] Therefore, successful treatment enhanced quality of 
life on validated assessment. Furtermore, the comprehension and elucidation of the 
pathophysiological mechanisms the lead to IBD is very important in order to optimize our 
current therapeutic tools and develop new treatments for the management of IBD.   
 
1.4. The pathogenesis of IBD 
The pathophysiology of IBD is largely unknown, however several aspects of it have been 
described. The clinical description of familial tendencies in IBD has led to the 
exploration of significant genetic aspects of its pathogenesis. A German study recruiting 
189 twin pairs in which at least one member had IBD confirmed a 35% and 16% 
concordance rate for Crohn’s disease and ulcerative colitis respectively in monozygotic 
pairs. [55] In dizigotic pairs, the concordance rate fell to 3% and 2% for Crohn’s disease 
and UC respectively. [55] In a British study of 250 twin pairs, the concordance rate was 
11% for any IBD. [56] In both UC and Crohn’s disease monozygoric concordant twins, 
there was good concordance for the Montreal classification of the disease and the need 
for medical treatments. This suggests that disease phenotype and course are to a certain 
extent genetically regulated. [56] In a study of the concordance rate following up 421 
patients with UC and 197 with Crohn’s disease for 10 years described a 26 and 9 fold risk 
for Crohn’s disease among siblings and parents respectively. The same study confirmed a 
8.6 and 1.5 fold risk for UC among siblings and parents respectively. [57]  
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The role of genetics in the pathogenesis of IBD has been further supported by genome 
wide association studies (GWAS); In a recent meta- analysis of 15 GWAS studies, 163 
genetic regions were identified to be related to the risk of IBD. [58] Of these 163 regions, 
110 were common for Crohn’s disease and UC, while from the remaining 53 loci, 30 
were associated with Crohn’s disease and 23 with UC. The loci implicated imply an 
interaction between the immune system and microbes both at the intestinal mucosal level 
and in the gut lumen [58] Another meta analysis of 6 GWAS including a total of 6333 
cases and 15056 controls confirmed the identification of 71 loci associated with Crohn’s 
disease, most of them being associated with loci relevant to the inate immune response. 
[59] One of the best described mutations that is associated with risk of developing 
Crohn’s disease and with the risk of more aggressive disease phenotype is NOD2. NOD2 
is involved with the recognition of muramyl dipeptide, a component of bacterial 
peptidoglycan and leads to NF-kB activation, priming of pro-inflammatory cytokine 
transcription and T cell activation. It is located on chromosome 16 and although more 
than 30 single nucleotide polymorphisms have been identified in association with 
Crohn’s disease, 3 of these are most commonly involved. [60] 
Similarly, in ulcerative colitis, a meta-analysis of 6 GWAS including 6687 cases and 
19718 controls describes 99 loci associated with the pathogenesis of the disease. Again 
these were in genomic regions associated with the regulation of the inate immune 
response and T cell activation, such as IL1R2, IL8 and JAK2.  
The genomically described affected pathways mostly lead to immunological dysfunction 
and inappropriate T cell activation. Luminal antigen sensing starts at the intestinal 
epithelium, where this interaction occurs through cell surface or intracellular structures 
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called pattern recognition molecules, such as Toll like receptors (TLR) and NODs, [61] 
and it is now widely accepted that IBD represents an inappropriate and dysregulated 
immunological response to luminal antigens. 
A key event in the pahogenesis of IBD is the breakdown of the intestinal epithelial 
barrier, which gives direct access for the luminal antigens to the mucosal immune cells 
and leads to T cell activation through innate and adaptive immune processes. [1] 
Epithelial tight junctions, a key component of the epithelial barrier are less resistant and 
more permeable among Crohn’s disease patients. [61] Apart from a leaky epithelium, the 
expression of TLRs is different in IBD patients compared to controls; TLR4, which is 
stimulated by lipopolysacharide, is minimally expressed in colonic and small bowel 
biopsies of healthy controls but significantly upregulated among IBD patients. [62] TLR3 
which is constitutively expressed in normal mucosa is significantly down-regulated in 
Crohn’s disease patients. [62] TLR5, which is expressed on the basolateral surface of the 
colonic epithelium, becomes accessible to luminal antigens after the primary epithelial 
injury and its activation through bacterial flagellin leads to IL-6 and IL-8 production. [63] 
These data clearly suggest a defect in the innate immune processes of the mucosal 





Figure 1.6. : The mucosal immune system in the pathogenesis of Crohn’s disease 
Taken from Baumgart et al, Lancet 2012, 380: 1593 [1] 
 
In the lamina propria, the dendritic cells, a subset of antigen presenting cells that express 
TLRs and NODs control the immunological response as they distinguish between 
commensals and pathogens. Dendritic cells present antigens to T cells and can lead to T 
cell activation, however the same cells educate the immune system at the very early 
stages of development on the tolerance towards self antigens (figure 1.6). [64] IBD 
patients have been shown to have significantly reduced numbers of immature and 
possibly tolerogenic dendritic cells during periods of flare up. [65] They also have high 
numbers of plasmocytoid dendritic cells both in the lamina propria and the mesenteric 
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lymph nodes, express higher levels of co-stimulatory molecules (CD86 and CD40), 
secrete higher concentrations of pro-inflammatory cytokines such as IL-6, IL-8 and TNF-
α than in controls [66] and express higher levels of TLR-2 and TLR-4. [67] Hence IBD 
patients have a distinct phenotype of dendritic cells populating their peripheral blood and 
mucosal immune system.  
This particular phenotype of innate immunity in IBD shifts the adaptive immune response 
towards a pro-inflammatory behaviour. Migration of naïve T cells to the secondary 
lymphoid tissues occurs through the high endothelial venules. The rolling and homing of 
the lymphocytes is promoted by the L selectin and α4β7 integrin on the surface of T cells 
with MAdCAM on the high endothelial venules. When naïve CD4 T cells enter the 
mesenteric lymph nodes and Peyer patches they interact with antigens presented through 
MHC II molecules on the surface of dendritic cells. Binding of the T cell receptor to the 
MHC II – antigen complex leads to T cell activation and eventually proliferation, 
enhancement of gut homing adhesion molecules and differentiation towards a colitogenic 
phenotype. [68] Following this initial priming event, T cells re-enter the systemic 
circulation and subsequently home to the gut, where they encounter their specific antigen 
presented on a variety of antigen presenting cells (macrophages, B cells, dendritic cells). 
This leads to a more vigorous response of activated T cells with increased production of 
IL-17, IFN-γ, TNF-α and IL-2. IL-2 enhances the proliferation of T helper cells. 
Following T cell activation, IFN-γ, TNF-α and IL-17 further enhance endothelial cell 
adhesion molecules expression and macrophage derived proinflammatory cytokines. This 
results in an uncontrolled secretion of Th1, Th17 and macrophage derived 
proinflammatory mediators and chronic active inflammation. [68] IBD is characterized 
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by an imbalance in the lamina propria level between pro-inflammatory cytotoxic T cells 
such as Th1 and Th17 and the natural peacekeepers, the regulatory T cells that suppress 
inflammation through the production of IL-10, TGF-β and IL-35 (figure 1.7). [1] It has 
been long established that Crohn’s disease is characterized by Th1 cell activation and 
production of IL-12, IFN-γ and TNF-α. UC on the other hand is associated with Th2 
response and increased production of IL-4, IL-5 and IL-13 and this has been supported by 












Figure 1.7: The imbalance of pro- and anti-inflammatory cytokines in Crohn’s 
disease. Taken from Brand S, Gut, 2009, 58(8): p. 1152-67. [70].  
Proinflammatory cytokines secreted by antigen presenting cells (APC) after they come in 
contact with antigens, promote the differentiation of pro-inflammatory T cell lineages 
(Th17 and Th1). The proinflammatory cytokines released by pro-inflammatory T cells, 







1.5 CD58 (LFA – 3) 
1.5.1 T cell activation 
Because of the importance described above of the antigen presenting cells, it is clear that 
T cell activation is a central event in the pathogenesis of IBD. The main stimulus for T 
cell activation is the interaction between the T cell receptor (CD3) with the antigen which 
is held by the MHC complex on the surface of antigen presenting cells.[71] As the 
affinity of the T cell receptor for the antigens is low, a number of co-stimulatory 
molecules are involved in the activation process. [71] T cell receptor stimulation results 
in either clonal expansion or anergy, depending on whether co-stimulatory molecules are 
involved in the process (figure 1.8). [72] There are a number of molecules that may 
provide a co-stimulatory signal for T cell activation such as B7.1 (CD80), B7.2 (CD86), 
and CD58. The best characterized co-stimulatory molecules are those of the B7 family. 
They are members of the immunoglobulin gene superfamily and have 25% amino-acid 
identity. Their cytoplasmic domains are remarkably different with that of B7.2 being 
considerably longer and containing potential phosphorylation sites. The genes coding for 
B7.1 and B7.2 are located at 3q13.3-3q21. [73] B7.1 and B7.2 are expressed on the 
antigen presenting cells and ligate to CD28 or CTLA-4 on the surface of T cells. B7-
CD28 co-stimulation in the presence of TCR signaling results in upregulation of IL-2 
receptor, cytokine transcription and T cell proliferation. In contrast B7-CTLA4 co-
stimulation down regulates T cell responses, [72] and CTLA-4 has a greater affinity for 
B7.1 and B7.2 than CD28. [74]  
The role of B7 molecules on antigen presenting cells such as dendric cells, leucocytes and 
macrophages in the pathogenesis of IBD is vital. In patients with active IBD the number 
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of CD86 positive dendritic cells in the peripheral blood is significantly higher compared 
to healthy controls. [65] In DSS colitis it has been proven that the number of B7 positive 
leukocytes increase 20 fold compared to normal mice by day 7 of colitis. [75] Similar 
results were obtained from human studies. In both UC and Crohn’s patients the 
population of B7.1 and B7.2 positive macrophages is markedly increased compared to 
controls in colonic mucosa biopsies. [76] Similar results, confirming the importance of 
co-stimulatory molecules have been reported by others. [77]  
 
Figure 1.8: The two signal model of T cell activation. Taken from Harris et al, [72] 
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These data led to the exploration of therapeutic strategies blocking the B7-CD28 
interaction. Abatacept, a recombinant fusion protein comprising a fragment of the Fc 
domain of human IgG1 and the extra-cellular domain of human CTLA-4, has proven 
clinical efficacy in the treatment of auto-immune disorders as rheumatoid arthritis and 
juvenile arthritis. [74] In animal studies using immunocompromised mice injected with 
CD4+CD45RBhigh T cells in order to induce colitis, abatacept treatment resulted in body 
weight preservation at 1 week, as opposed to untreated or cyclosporine treated mice that 
lost about 20% of their body weight by that time. Similarly, colonic length was preserved 
in the abatacept treated mice compared to controls. These clinical observations were in 
line with the understanding of the underlying mucosal immunology; Abatacept treatment 
significantly prevented the secretion of TNF-α, IFN-γ, IL-1 and IL-4 from the lamina 
propria lymphocytes in this model of IBD. [78] The application of these encouraging 
results was attempted in human IBD patients with moderate, or moderate to severe 
Crohn’s disease and UC. 451 Crohn’s disease and 490 UC patients were recruited and 
treated with 3 different doses of abatacept or placebo. In contrast to the results in studies 
using mice, abatacept did not prove effective in inducing clinical remission or achieving a 
clinical response in either Crohn’s disease or UC. [74]  
Although the results of this trial in IBD patients contrast to the results of the experiments 
in mouse models of IBD discussed above, they do not necessarily refute the targeting of 
co-stimulatory molecules as a treatment strategy for IBD. In fact, in CD28 deficient mice, 
T cells activate and proliferate with certain stimulants and these mice mount a normal 
cytotoxic T cell response in vivo when infected with the lymphocytic choriomeningitis 
virus. [79] These facts imply that in the complex immunological milieu of IBD, including 
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perhaps other co-stimulatory molecules should be taken into account in attempting to 
control mucosal inflammation. Therefore a part of this thesis will analyse a possible role 
for CD58-CD2 interactions.  
 
1.5.2 CD2 – CD58 
CD58 on antigen presenting cells is the ligand for CD2 on T cells (figure 1.9): CD2 is a 
50kD glycoprotein expressed in all peripheral T cells. It was initially described as the 
sheep red cell receptor. [80] It consists of an extra-cellular domain made up of 185 
aminoacids, a transmembrane domain of 24 aminoacids and an intra-cellular one of 117 
aminoacids. [81] The extra-cellular domain binds to its ligands, the transmembrane is 
used to anchor the receptor to the cell and the intracellular presumably for signal 
transduction and interaction with intra cellular structures. [82, 83] Initially, CD2 was 
perceived as an adhesion molecule, as experiments showed that blocking it with 
antibodies results in a significant reduction in the T cell binding (rosette formation) 
ability; [84] however subsequent experiments showed that CD2 stimulation caused T cell 
proliferation, IL–2 secretion and IL–2 receptor expansion. [85] Blocking CD2 caused 




Figure 1.9: The crystal structure of CD58 – CD2 complex. (Taken from Jining et al, 
European Journal of Biochemistry. 2004; 271: 2873 – 2886 [86]) 
 
Competition experiments with antibodies against several epitopes, demonstrated that 
CD58 (LFA – 3) [but not other adhesion molecules such as LFA – 1, complement 
receptor – 1 (CR1) and HLA – A, B] is the specific natural ligand to CD2. [85] This was 
reconfirmed with experiments using artificial target cells (ATC) reconstituted with 
purified CD58 and Jurkat T cells. Antibodies against CD58 and CD – 2, [but not against 
LFA – 1 or HLA] blocked the ATC – T cell conjugate formation. [87] The role of this 
interaction in T cell activation was initially studied by incorporating CD58 to murine L 
cells; CD58 positive, but not negative L cells promoted T cell proliferation in the 
presence anti – CD3 antibodies or low concentrations of PMA. The results could not be 
reproduced in the presence of an anti – CD5 antibody or medium suggesting an 
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indispensable role for CD58 in the T cells activation process. [88] The presence of pro-
inflammatory cytokines as IL-1 and IL-6 did not abrogate the need for CD2 – CD58 
mediation for T cell activation. [89] The same interaction in a different experimental 
setting using murine T cell hybridomas expressing the CD2 cDNA and liposomes 
expressing CD58 and HLA – DR, promoted IL-2 production by T cells. This was 
inhibited by blocking CD2 or CD58. [90] Moreover CD2 – CD58 interaction increased T 
cell intracellular cAMP, implying a role for the initiation of intracellular biochemical 
changes or a functional regulatory role. [91] 
This interaction is a dynamic process; CD3 stimulation up-regulates CD2 expression 
through an intracellular inside-out signaling pathway, while the avidity of CD2 to CD58 
is regulated by a number of biochemical molecules such as tyrosine kinases, protein 
kinase C and cAMP. [92]  
CD58 is a 40 – 70 kDa glycosylated protein made up of six distinct epitopes and is 
expressed in haematopoetic and non haematopoetic cells. [93] It is encoded by a 65 kbp 
gene that has six exons and is located at the human chromosome locus 1p13. [94] 
It is expressed on a mumber of immune molecules that play a central role in the 
pathogenesis of IBD, such as the dendritic cells. In an allogeneic mixed lymphocyte 
reaction model using blood dendritic cells as the antigen presenting cells, antibodies 
against CD58 blocked T cell activation. [95] In another model of T cell activation using 
dendritic cells and T cells, it was shown that when dendritic cells overexpressed a triad of 
co-stimulatory molecules (CD58, B7-1, ICAM-1) they had increased antigen presenting 
potency and could achieve increased T cell proliferation which produced 60% more IL-2 
and 66% more IFN-γ. [96]  
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1.5.3 The expression of CD58 in the GI tract 
CD58 was initially shown to be expressed in intestinal epithelial cells. It was not affected 
by cytokine stimulation (TNF-a, IL-1, IL-6, IFN – gamma). [97] Its expression was 
highly polarized and restricted to the basolateral membrane and its inhibition blocked the 
stimulation of CD4 T cell proliferation. [98] The functional role of CD58 on intestinal 
epithelial cells (IECs) has not been extensively studied, but in vitro experiments using co-
cultures of HT – 29 cells and intraepithelial lymphocytes obtained by the jejunum of 
otherwise healthy patients undergoing gastric bypass showed a  synergistic increase in the 
production of IL – 8, which was cell contact dependent and abrogated by the addition of 
antibodies blocking CD58. [99] CD58 is also expressed in the lamina propria 
mononuclear cells. In LPMC cultures blocking CD2 or CD58 resulted in decreased cell 
proliferation. When exposed to APCs, CD2 or CD58 again caused inhibition of 
proliferation and IFN-gamma production. [100] 
 
1.5.4 CD58 in the gastrointestinal diseases. 
Very limited data are available concerning the role of CD58 in inflammatory bowel 
disease. A soluble form of CD58 that can block the CD2 – CD58 interaction was 
decreased in the serum of UC and Crohn’s disease patients; this reduction was correlated 
to inflammatory markers and clinical disease activity. [101] When compared to healthy 
controls, the mucosal expression of CD58 in the ileum of Crohn’s disease patients was 
reduced and this reduction was reversed after treatment with infliximab. [102]  
In mice the molecule CD48 is the ligand to CD2, hence acts as the CD58 analogue. When 
wt naïve CD4 T cells are transferred into wt or CD48 -/- mice, they result in clinical and 
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histological features of colitis. [103] This does not occur when CD48 -/- CD4 T cells are 
transferred to CD48 knock out mice. Additionally, treating mice with established colitis 
with anti-CD48 antibodies decreased the clinical activity of the colonic inflammation. 
(figure 1.10) These results suggest a critical role for CD48 – CD2 interaction in the 




Figure 1.10: CD48 (the murine analogue of CD58) as a target for the treatment of 
intestinal inflammation. Treating mice with anti-CD48 (the murine analogue of CD58) 
antibodies improves established colitis and prevents development of colonic 
inflammation in animal models of IBD. Taken from Abadia – Molina et al. 
Gastroenterology; 2006; 130: 424 – 434. [103] 
 
The role of CD58 has been studied in colorectal cancer patients. It was shown that about 
50% of colorectal cancer patients had reduced expression of CD58, without this having 
an impact on the natural history of cancer. [104-106] The role of CD58/CD48 in the 
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development of colorectal cancer was also studied in mice; When a recombinant vaccinia 
virus containing CD48 was inoculated in colonic cancer cells these did not grow into a 
tumour when injected to immunocopmetent mice. [107]  
The importance of CD58 in the development of chronic active inflammation was 
examined in hepatocytes and PBMCs of hepatitis B patients where the levels of CD58 
correlated with HBV DNA levels and biochemical disease severity [108, 109] Similar 
results were obtained in a small study with hepatitis C patients. [110] The expression of 
CD58 was reduced after treatment with interferon – alpha among the responder hepatitis 
B and C patients. [111]  
  
1.5.5 CD58 in chronic inflammation outside the GI tract  
CD58 has been studied in a number of immune mediated disorders outside the GI tract.  
Rheumatoid arthritis 
CD58 expression is increased in the synovial fluid lymphocytes of patients diagnosed 
with rheumatoid arthritis (RA) compared to its expression in the PBMCs of RA patients 
or healthy controls. [112] CD58 has been shown to play a fundamental role in the 
pathogenesis of rheumatoid arthritis rather than just being a part of the disregulated 
immune response involved, as the SNP rs11586238 that is located near the CD2 – CD58 
region is strongly associated with the disease in a large GWAS study. [113] In a mouse 
model of arthritis (collagen induced arthritis), a CD2 derived peptide that can bind to 
CD58, when administered intravenously suppressed the clinical and histopathological 




Activated autoreactive T cells play a central role in the pathogenesis of multiple sclerosis 
and a SNP within the first intron of the CD58 gene has been identified in a GWAS of 
multiple sclerosis as a significant genetic protective factor for susceptibility to the 
disease. RNA studies confirmed that this allele is associated with an increase in RNA 
expression of CD58. [115] However, T cells in multiple sclerosis patients express higher 
levels of CD2. [116]  
 
Psoriasis 
Psoriasis is characterized by skin CD4 and CD8 memory T cell infiltration. CD58 is not 
expressed in normal skin, but is expressed in the keratinocytes, the blood vessels and the 
mononuclear cells of psoriasic lesions. The molecular expression on the mononuclear 
cells is downregulated after treatment with ciclosporine. [117] Additionally, in cultures of 
mixed epidermal T cells from psoriasic lesional biopsies, cell proliferation was 
significantly inhibited by the action of anti-CD2 and anti-CD58 mAbs. [118] Psoriasis 
was the first systemic immune mediated disorder where the CD2 – CD58 interaction has 
been investigated as a potential therapeutic target; Alefacept is a recombinant protein 
(CD58 IGG1 fusion protein) that binds to the CD2 on lymphocytes in order to block the 
CD2 – CD58 interaction (figure 1.11). [119] In vitro it has been shown to inhibit T cell 
responses. [120] In a placebo controlled trial including 229 patients with psoriasis (59 on 
placebo and 170 in 3 different doses of alefacept administered once weekly intravenously 
for 12 weeks) it showed increased efficacy in terms of psoriasis area and severity index. 
Clinical remission that was sustained for at least 10 weeks after the end of treatment and 
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was associated with a reduction in the number of peripheral CD4 cells and 
CD4+CD45RO+ T cells. [119] The efficacy of the drug was reconfirmed in a larger 
phase III trial. [121]  
 
Figure 1.11: Blocking CD2 – CD58 interaction as a way to immunomodulation. 
Reproduced with permission from Ellis et al, NEJM 2001; 345 (4): 286 [119] 
 
Graft versus host disease (GVHD) 
Apart from its use in dermatology, there is some evidence that alefacept can be an 
efficient treatment option in more challenging immunological cases as graft versus host 
disease which is a rare potentially lethal T cell mediated condiation that occurs post 
transplantation. [122] 3 small studies involving a total of 22 patient who developed 
steroid refractory GVHD after bone marrow transplantation, show an efficacy of about 
50% for alefacept. [123-125] A recent case report suggests durable effectiveness for 
GVHD post liver transplantation [122]  
These results show that blocking the CD2 – CD58 interaction can be a treatment option 
for the successful management of refractory T cell mediated disorders. In this thesis we 
will examine if this interaction maybe important in the immune modulation of IBD. 
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1.6 Environmental factors that influence IBD 
The previous chapter elucidated important aspect of the immuno-pathogenesis of IBD. 
This is largely defined by genetics, but it is also widely recognized that environmental 
factors play a significant role in concert with genetic susceptibility.  
1.6.1 Smoking 
Smoking has been reported as one of the most consistent risk factors for the pathogenesis 
of Crohn’s disease in western countries, associated with a two-fold risk. [4] Tobacco 
exposure can influence the phenotype and disease course; In a study comparing 81 never 
smokers with 92 smokers with Crohn’s disease, heavy smoking was associated with more 
small bowel involvement, more aggressive penetrative and perianal disease and higher 
risk for surgery. Smokers were 14% more likely to have an operation within 10 years 
from diagnosis, while the risk of re-operation was significantly higher among heavy 
smokers (OR 1.79 [95% CI 1.12, 2.55] p=0.015). [126] This is consistent with another 
study proving a significantly higher risk of post operative recurrence among smokers (OR 
2.96 [95% CI 1.5, 5.6]), [127] while post operative smoking cessation remains an 
important therapeutic intervention reducing the risk of recurrence and re-operation. [128] 
Interestingly, the impact of smoking in ulcerative colitis is protective (OR 0.58). The 
cause of the different impact of tobacco use in Crohn’s and UC is largely unknown; The 
impact of smoking on faecal microbiota and the immunological function have been 
quoted as possible biological mechanisms. [4] 
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1.6.2 Appendicectomy  
Appendicectomy has been extensively studied as an environmental factor influencing the 
pathogenesis of IBD. A number of studies associate appendicectomy with a reduced risk 
of developing ulcerative colitis; A landmark study of 212,963 patients and the same 
number of controls showed that appendicectomy for acute appendicitis or mesenteric 
lymphadenitis reduces the risk of UC occurrence by 27% and 52% respectively. This 
association was not proved when appendicectomy was done for non specific abdominal 
pain. [129] This was further confirmed in a meta-analysis of 13 case control study, 
showing that appendicectomy reduces the risk of UC by 62-65%. [130] Further studies 
investigated the role of appendicectomy on the course of UC: In a case control study 
6.5% of UC patients and 16.3% of the controls had undergone appendicectomy; Patients 
having undergone appendicectomy had less extensive disease and milder disease course 
with fewer relapses, less requirements for immunosuppressive therapy [131] and a lower 
risk of colectomy. [132]  
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1.6.3 Antibiotics 
As the intestinal microbiota plays an important role in the pathogenesis of IBD, the use of 
antibiotics has been investigated as a possible factor in the pathogenesis of IBD. In a 
recent nationwide prospective study from Denmark, following up 577,627 children, 
antibiotic users had an almost 2-fold risk to develop IBD (OR 1.84) and every course of 
antibiotics prescribed increased the risk of IBD by 12%. Antibiotic users were 3.41 times 
more likely to develop Crohn’s disease and children having been prescribed at least 7 
courses of antibiotics were 7.32 times more likely to develop Crohn’s disease. No 
significant association was shown between antibiotics and ulcerative colitis. [133] 
Another case control study from Canada, proved that individuals having been prescribed 
antibiotics were 50% more likely to develop Crohn’s disease or UC within the next 2-5 
years. [134] Similarly a large scale study using data from general practices in UK 
involving more than 1 million children and more than 6 million person years of follow 
up, confirmed that exposure to anti-anaerobic antibiotics in childhood is linked with an 
almost 2 fold risk of developing IBD by the age of 19. The risk was higher among those 
who were prescribed antibiotics earlier in life: Exposure before the first year was related 
with a 5.5 fold risk, exposure before the 5th year was related with a 2.6 fold risk and 
before 15 years with a 1.5 fold risk. [135] Of course this trend might be explained by the 
possibility that children prescribed antibiotics after the 15th year of age would have 
shorter follow up period than those exposed earlier as patients were followed up to their 
19th year of age.    
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1.6.4 Diet 
Diet has been investigated extensively as a possible factor related to the development of 
IBD. Most studies have focused on particular dietary patterns or nutrients. Increased 
sugar intake has been reported as a possible risk factor for the development of Crohn’s 
disease in questionnaire based studies. [136, 137] In a prospective study of 67,581 female 
healthy individuals in France, high intake of animal protein was associated with a 3 fold 
risk of developing IBD. [138] A similar multi-ethnic European study following up more 
than 200,000 healthy individuals suggested that increased intake of linoleic acid, an n-6 
polyunsaturated fatty acid that is present in red meat, cooking oils and margarines is 
associated with developing UC. Patients at the highest quartile of intake had a 2.5 fold 
risk of developing UC. [139] This constitutes an epidemiological rather than a direct 
aetiological relationship in all studies, however the authors of the last study suggest that 
linoleic acid, through its incorporation in the colonic cell membrane might cause the 
release of proinflammatory molecules, such as prostagladines and leukotrienes leading to 
the aggregation of immune cells. [139] Similarly a study from Japan concluded that there 
is a strong correlation between animal fat and n-6 polyunsaturated fatty acids with a new 
diagnosis of Crohn’s disease and [140] the administration of n-3 polyunsaturated fatty 
acids had a therapeutic benefit in TNBS induced colitis in mice, as opposed to n-6 
polyunsaturated fatty acids. [141] A recent longitudinal study assessing the risk of IBD in 
170,776 women followed up for 26 years, concluded that higher dietary intake of fiber is 
associated with significantly associated with reduced risk of developing Crohn’s disease 
and especially of ileal or ileocolonic distribution but did not impact on the risk of 
developing UC. [142] In practice it is difficult to interpret these data given that perhaps 
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patients with undiagnosed small bowel Crohn’s disease would avoid eating large amounts 
of fiber to avoid symptoms of diarrhea and abdominal pain. 
In one of the few studies of the impact of dietary components in IBD investigating the 
underlying pathophysiology as well, it was proven that the administration of fructo-
oligosaccharides in patients with active Crohn’s disease achieved a significant reduction 
in the IL-6 positive and a significant increase in the IL-10 positive dendritic cells in the 
lamina propria; [143] However, within the 4 week period of the intervention, this 
biological turnover failed to be translated in a clinical benefit. [143]  
In summary, diet seems to be another risk factor for IBD, at least epidemiologically. 
However more pathophysiological studies are required.   
 
1.6.5 The epigenetics of IBD 
In the previous sections of this thesis a number of genetic and environmental factors that 
influence the pathogenesis and course of IBD have been analysed. The genetic factors 
account for a fraction of the disease variance (13.6% for CD and 7.5% for UC). [144] 
However the evidence for the environmental factors and their impact on the disease 
variance has been mostly observational and the large variability in patients’ duration, 
intensity and frequency of exposure to different environmental factors make the study of 
these even more difficult to conduct and interpret. [144]  
The evolution of epigenetics has led to a new pathway of thinking when considering the 
impact of environemental factors in disease pathogenesis and outcome. Epigenetics can 
be defined as mitotically inherited changes in gene function that do not involve a change 
in DNA sequence like SNPs, but DNA methylation, histone modification, RNA 
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interference and positioning of nucleosomes. [144] The role of epigenetics in the 
pathogenesis of IBD has been studied to a certain extent mostly by identifying epigenetic 
changes around genes identified in previous GWAS studies but has not in a way specific 
to environmental factors.  
However, the epigenetic changes mediated by different environmental factors that have 
been epidemiologically linked to IBD have been studied by other disciplines of medicine 
and on the general population. For example, the impact of smoking on the epigenome has 
mainly been studied in the context of Chronic Obstructive Airway disease: DNA 
methylation has been shown to be relevant to ever-smoking status, the age of smoking 
initiation and CRP levels [145] and smokers’ macrophages have been shown to have 
downregulation of many miRNAs, [146] implying a possible link between the epigenetic 
changes related to smoking to the regulation of the inflammatory process.  
Dietary components during pregnancy (folic acid, poly-unsaturated fatty acids) have been 
shown to cause epigenetic changes relevant to the transcription of NF-kB, influencing the 
immune function [147] and the complex relationship of nutrients and the intestinal 
microbiota with the intestinal epigenetic programming is the target interest of an up and 
coming research discipline, the nutrigenomics. [148] Both gut microbiota and nutrients 
are increasingly considered as epigenetic regulators of the intestinal gene expression. 
[149, 150] The bacteria that reside the gut lumen, through the secretion of low molecular 
weight molecules (eg buyrate) can activate or inhibit the epigenomic regulation by 
affecting the activity of relevant enzymes. [150] Studies on Vitamins A, D and fatty acids 
have shown that they can directly activate nuclear receptors and induce gene 
transcription. [151] 
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1.6.5.1 Epigenetic changes specific to IBD mechanism according to mechanism 
involved: 
 
1.6.5.1.1 DNA methylation 
An epigenome wide association study using an Illumina Methylation assay and including 
16 paediatric patients with crohn’s disease, 21 adult patients with CD and 19 controls, 
identified significant differences in DNA methylation between patients and controls in 50 
sites.  [152] These included sites of the genome that are implicated with the immune 
system processes, the immune response and defense response to bacteria. [152] Another 
study assessing DNA methylation in B cells from 18 IBD patients (9 UC and 9 CD) and 
18 non-IBD siblings, identified 11 CpG sites with IBD, 14 with CD specific and 24 with 
UC specific associated methylation. [153] Again, genes implicated with differential 
methylation included genes relevant to the immune response such as IL-6, IL-10, IL-12B, 
PPAR-γ and MUC1. [153] The epigenetic changes in IBD have been also studied 
specifically on intestinal tissue: A study of 20 monozygotic twin pairs that were 
disconcordant for UC using colonic biopsies taken during colonoscopy 61 sites of 
differential DNA methylation were identified between cases and controls, the majority of 
which is implicated in the immune process. These loci were subsequently validated in an 
independent cohort. [154] Another study using rectal biopsies from UC, CD patients and 
healthy controls showed differential methylation of several genes that are involved in 




1.6.5.1.2 Histone modification 
The role of histone modification has not been extensively studied in IBD and most of the 
evidence about it is indirect. Histones can undergo a range of modifications including the 
acetylation, phosphorilation, methylation and ubiquitination of their N-terminal 
aminoacid tails. [144] These processes are regulated by enzymes such as the histone 
acetyl-transferase (HAC) and the histone deacetylase (HDAC). HDAC inhibitors, such as 
sodium butyrate and valproate have been shown to have anti-inflammatory properties 
[144] and oral administration of HDAC inhibitors in animal models of colitis resulted in 
clinical and histological improvement with a corresponding shift of tissue cytokine 
profile towards a more anti-inflammatory phenotype. [156]  TLR-4 regulates mucosal 
tolerance via mechanisms that could be at least partially regulated by histone acetylation 
and DNA methylation; Experiments undertaken in HT-29 cells showed a link between 
the responsiveness to LPS and the degree of histone deacetylation of the 5’ region of the 
TLR-4 gene. [157] 
 
1.6.5.1.3 RNA interference 
Micro-RNAs (miRNA) are single stranded non coding RNAs that regulate gene 
expression by inhibiting mRNA translation or causing mRNA degradation. [144] Studies 
in animals have shown that miRNAs play a role in gut homeostasis and studies in patients 
with IBD have shown a differential expression of miRNA that are involved in the 




1.7 IBD and nutrition 
1.7.1 Nutritional aspects of IBD 
The role of diet as a risk factor for the development of ulcerative colitis was first 
described during the 1960s when a questionnaire based study of cases vs controls showed 
that established breast feeding in infancy was less frequent among UC patients than 
healthy controls. [158] Around the same time, malnutrition in Crohn’s disease patients, 
and its implications due to poor intake, malabsorption, short gut, fistulation and 
micronutrient loss through the GI tract were increasingly identified. [159, 160] Now it is 
recognized that malnutrition affects 30-80% of Crohn’s disease patients. [161] In an 
anthropometric study taking into account muscle and subcutaneous fat, malnutrition was 
confirmed among IBD patients. 20% of patients are below the 90% of their ideal body 
weight. Malnutrition was linked with extensive small bowel Crohn’s disease and post 
surgical recurrence of Crohn’s disease. [162] Mid arm circumference was identified as a 
useful malnutrition screening tool for these patients. [163] Malnutrition would also be an 
issue among Crohn’s disease patients in remission or with mildly active disease with 
about 50% of them having a substandard body weight and fat stores despite adequate 








1.7.2 Mechanisms of malnutrition 
1.7.2.1 Decreased oral intake:  
The symptoms of diarrhea, abdominal pain and nausea that are linked with food intake 
result in reduced oral intake from IBD patients. [165] In a prospective study assessing the 
nutritional status and food intake in paediatric patients with Crohn’s disease, the weight, 
height and BMI of patients with active Crohn’s disease is significantly lower that that of 
patients with inactive Crohn’s disease. The total caloric intake was significantly lower 
than controls in both children with active (29% less) and inactive (6% less) Crohn’s 
disease compared to healthy controls. [166] In a cross - sectional questionnaire based 
study in Canada, adult patients with active Crohn’s disease, ingested similar amount of 
calories and micronutrients as patients with inactive Crohn’s disease. Despite this 
similarity both groups ingested substandard quantities of vitamins and minerals. Patients 
with penetrative or obstructive Crohn’s disease were excluded from this study and it 
would be risky to extrapolate the equality in intake for the general Crohn’s disease 
population. [167] Energy intake, appetite and pleasure from eating are lower among 
patients with colonic Crohn’s disease presenting with weight loss in another study. [161]  
 
1.7.2.2 Loss of nutrients:  
Loss of nutrient energy is another factor in the pathogenesis of malnutrition among IBD 
patients. Loss of nutrients is more prevalent in active Crohn’s disease and among patients 
that have undergone bowel resections or have stomas. [168] In a recent study of adult 
patients with Crohn’s disease in remission, measuring BMI, food intake and faecal gross 
energy, despite the fact that patients with a BMI < 18.5 had no difference in the caloric 
 75 
intake compared to patients with BMI > 18.5, energy malabsoprtion was significantly 
higher among the patients with the lower BMI. [169] Additionally it is documented that 
energy requirements are higher among IBD patients; Although there is increased resting 
energy expenditure among patients with active disease the total energy expenditure 
remains stable despite the possibly lower levels of physical activity. [170] This adds to 
the nutritional imbalance already caused by reduced oral intake. 
 
1.7.2.3. Short bowel syndrome:  
50% of Crohn’s disease patients will require surgery witin 10 years from diagnosis and 
the disease will recur to as many as 45-55% of them. [1] Hence, Crohn’s disease is the 
most common cause of short bowel syndrome. Patients with a short bowel are divided in 
two categories: Those with an ileostomy and those with a jejuno – colonic anastomosis; 
the former group needs at least 100cm of jejunum and the latter at least 50cm of jejunum 
left in order to avoid parenteral supplementation. [171] The main mechanism of 
malabsorption in these patients is the loss of intestinal surface; in addition to this, patients 
with an end – jejunostomy have a significantly higher gastric output than patients whose 
colon is preserved and in continuity with the remaining jejunum. [172] Patients who 
develop short bowel syndrome will require regular electrolyte supplementation [173] or 






1.7.3 Micronutrient deficiency:  
1.7.3.1 Iron deficiency:  
About 48% of Crohn’s disease patients and 20% of UC patients are anemic at diagnosis,  
making anaemia the commonest extra-intestinal manifestation of IBD. [175] In a study 
undertaken by the candidate but not a part of this thesis as iron does not have an 
immunomodulatory role in IBD, 70% of the children, 42% of the adolescents and 40% of 
the adults were anaemic and aneamia was accounted for by iron deficiency in 88%, 83% 
and 55% respectively. [176] Anaemia has been linked with IBD to the point of 
haemoglobin levels being part of the Crohn’s disease activity index. [177]  In up to 90% 
of cases, the cause of anaemia is iron deficiency, [178] and the pathophysiology of iron 
deficiency is multifactorial.  
The dietary intake of iron in IBD patients is low: In a study of 23 male and 24 female 
Crohn’s disease patients, 50% of the female patients had inadequate iron intake. [179] In 
a multicenter questionnaire based study of 91 Crohn’s disease patients and 91 controls in 
London, the mean dietary intake was significantly lower among cases by 2.3 mg/day 
compared to controls. This was mostly accounted for by lower intake of non-haem iron 
which is contained in fiber rich dietary products which could possibly cause symptom 
deterioratrion. [180] In UC patients iron intake is significantly lower in periods of disease 
relapse. [181] The impact of low dietary intake is further accentuated by the loss of iron 
rich erythrocytes from intestinal ulceration and bleeding. [177]  
In active inflammation the absorption of iron from enterocytes is impaired. [182] This is 
mainly mediated by hepcidin. 
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The role of hepcidin: Hepcidin is a peptide secreted by the hepatocytes that was initially 
shown to have anti-microbial properties, [183] and its role in iron homeostasis in human 
has been initially studied among patients with hereditary hemochromatosis where 
decreased expression of the gene coding for hepcidin compared to controls was shown. 
[184] Its synthesis is dependent on the amount of dietary iron entering the blood and the 
amount of iron in iron stores. Hepcidin regulates the absorption of iron (figure 1.12). 
Blocking the expression of hepcidin in mice resulted in increased iron absorption and iron 
overload in most tissues, while transgenic mice overexpressing hepcidin-1 transplacental 
and intestinal iron transport was blocked causing death at birth unless iron was 
administered parenterally.  [185] Hepcidin expression is linked to inflammation. 
Treatment of murine hepatocytes with IL-6 induced the mRNA expression of hepcidin. 
[186] Hepcidin mRNA was not induced during inflammation (terpentine abscess 
induction) in IL-6 KO mice as compared to WT mice, proving that IL-6, a central 
cytokine in the pathogenesis of IBD is an indispensable mediator of its synthesis. 
Similarly, iron levels decreased in WT but not IL-6 KO mice. In the same study, infusion 
of IL-6 to healthy human individuals caused remarkable increase in hepcidin levels and 
decreased serum iron and transferrin saturation levels by 34% and 33% respectively. 
[185] Moreover, in experiments using Caco-2 cells grown in transwell inserts, exposure 
to hepcidin decreased the iron transport from Caco-2 cells proving a direct relationship 
between hepcidin and iron malabsorption. [187] Serum levels of hepcidin are higher in 
UC and Crohn’s disease patients compared to controls making hepcidin a key factor of 
iron malabsorption among them. [188] This in turn has implications in oral iron 
replacement therapy administration. In a study of 19 Crohn’s disease patients, ferrous 
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sulphate absorption was significantly lower among patients with active disease and 
inversely correlated with IL-6 and CRP levels. [182] However, this is in contradiction 
with our series of patients where oral iron, when administered, led to an increase in 
corresponding Hb levels. [176] Effective treatment of iron deficiency is very important as 
if left untreated leads to chronic fatigue, physical and psychological dysfunction, 




Figure 1.12 : Iron metabolism and the role of hepcidin  
This figure was originally published in The Biochemical Journal, Wang et al, 2011 Mar 
15; 434(3): 365–381 [189]  
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1.7.3.2 Trace elements:  
Trace elements deficiencies have been widely described in inflammatory bowel disease 
and especially in Crohn’s disease. A large number of studies examine trace elements and 
as these are not central to the current thesis a brief summary follows 
 
1.7.3.2.1 Magnesium:  
Magnesium deficiency in Crohn’s disease was initially described in 4 patients in1970. 
[190]  In later study of Crohn’s patients requiring parenteral nutrition 88% (15/17) were 
deficient in magnesium and 12% of them were symptomatic. [191]  
 
1.7.3.2.2 Zinc:  
In a study comparing zinc levels between paediatric IBD patients, normal controls and 
controls of short stature and reduced weight (primordial short status and anorexia nervosa 
respectively) hypozincaemia was more prevalent among IBD patients compared to 
healthy controls. The mean serum zinc level was significantly lower among the IBD 
patients in comparison to the healthy controls and the controls for weight and height. In a 
univariate analysis, zinc levels were lower among those with moderate or severely active 
IBD and those with growth retardation, but not significantly different between Crohn’s 
and ulcerative colitis patients. The poor response to oral zinc supplementation among 
IBD patients with moderately or severely active IBD provides evidence for a decreased 




1.7.3.3 Vitamins:  
Vitamin deficiencies are common in IBD. A full description of all vitamin deficiencies is 
beyond the scope of the present work. In this chapter a brief description of vitamin 
deficiencies and their role in IBD will follow, including of more extensive details on the 
role of vitamin D, whose importance has been increasingly appreciated in recent years.  
 In a prospective study involving children with IBD, 14.4% of the patients were Vitamin 
A deficient and 6.2% were vitamin E deficient. Hypovitaminosis was not observed in the 
control population. In Crohn’s disease vitamin A and E deficiency could be predicted by 
disease activity either in the form of PCDAI or ESR. [193] Similar results were obtained 
in a study of vitamin A levels in adults. [194] In another study, serum levels of vitamin A 
would normalize after induction of remission without supplementation and 
hypovitaminosis A was linked with decreased serum levels of retinol binding protein 
rather than malabsorption. [195] Vitamin A supplementation has been tried as a means of 
remission induction in patients with Crohn’s disease, but without a favorable outcome. 
[196] More recently in an animal model study, all trans retinoic acid administered in mice 
with TNBS colitis resulted in decreased inflammation, an increase in anti-inflammatory 
cytokines (IL-4 and IL-10) and a decrease in pro-inflammatory cytokines  (IFN-gamma, 
TNF-alpha and IL-12). [197]  
Vitamin C levels are lower among patients with IBD compared to healthy controls 
irrespective of their disease activity status. [198] The mucosal levels of ascorbic acid are 
also decreased in active Crohn’s disease and ulcerative colitis [199] but a small pilot 
study in eleven patients failed to show any benefit for ascorbic acid. [200] 
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1.8 Vitamin D:  
Vitamin D exists in mainly 2 forms: Vitamin D3 (cholecalciferol) which is mainly 
synthetised through exposure to sunlight, and vitamin D2 (ergocalciferol) which is 
obtained from plant sources. [201] Vitamin D is synthetised when UVB radiation 
photolyses 7-dihydroxycholesterol at the skin to pre-vitamin D3 which is then processed 
into vitamin D3, which is converted in the liver to 25(OH)vitamin D3 (the main 
circulating form) before it undergoes the final hydroxylation in the kidneys to form 
1,25(OH)vitamin D, the main biologically active form of vitamin D. [202] 
Severe vitamin D deficiency leading to osteomalacia was reported for the first time over 
30 years ago in a prospective study of a cohort of 25 patients who had undergone a small 
bowel resection; 36% of them suffered from osteomalacia. [203] In a larger study of 82 
patients with Crohn’s disease, 65% of them had low vitamin D levels with the lowest 
levels observed among those who had undergone ileal resections. [204] In a study of 504 
IBD patients (403 CD and 101 UC), the prevalence of vitamin D deficiency was almost 
50% and among Crohn’s disease patients, vitamin D deficiency was associated with 
increased disease activity and poorer quality of life scores. [205] Factors apart from 
surgical resection and malabsorption that contribute to this are active inflammation, 
reduced oral intake and reduced sunlight exposure. [201] 
In addition to its well known impact on calcium metabolism, vitamin D has 
immunoregulatory properties; Vitamin D can suppress the proliferation of B and T cells 
as well as the mRNA production of cytokines as IL-2 and IFN – gamma and the 
production of IL-12 from monocytes and B cells. [206] Experiments using leukocytes 
from peripheral blood, proved that preincubation with Vitamin D inhibited the expression 
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of HLA-DR even when this was attempted to be induced by IFN – gamma hence 
impairing their antigen presenting properties. [207] Addition of Vitamin D to LPS 
stimulated dendritic cells inhibits their maturation by inhibiting the induction of co-
stimulatory molecules as CD40, CD86 and CD80 and induce the apoptosis of mature 
dendritic cells. [208] Vitamin D could reduce the expression of TLR2 and TLR4 among 
the monocytes of healthy individuals as well as individuals suffering from immune 
mediated disorders where the baseline TLR expression is higher. [202] This was 
accompanied by reduced translocation of NF-kB to the nucleus in Vitamin D treated 
monocytes. [209] The effect of Vitamin D to NF-kB activity is achieved by significantly 
increasing the mRNA levels and the half – life of IkB-alpha (Inhibitor of kB alpha) and 
decreasing its phosphorylation. [210] This is further supported by a study on mice 
embryonic fibroblasts showing that deletion of the vitamin D receptor gene resulted in a 
reduction of IkB-alpha protein levels by 40% [211] The vitamin D receptor (VDR) is 
expressed by monocytes and activated B and T cells. [212]  
Dendritic cells pre-incubated with Vitamin D attempting to stimulate CD4+ T cells shift 
their differentiation towards a Foxp3 positive phenotype that is known for its 
immunosuppressive and anti-inflammatory properties. [213] Foxp3 positive Tregs that 
are treated with vitamin D express higher levels of Foxp3 protein and are significantly 
more potent at suppression than the not treated ones even when a fixed number of Tregs 
interacts with an increased number of CD4+CD25- T cells. [214] The impact of Vitamin 
D on Foxp3 expression is mediated by direct binding of the VDR in the intronic (non-
coding) region of the Foxp3 gene. [215] The regulatory effect of Vitamin D on Foxp3 
expression is further supported by a study on 15 healthy volunteers whose Foxp3 levels 
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in the peripheral blood Tregs would be higher during the summer months when Vitamin 
D levels increase. [216]  







Figure 1.13: The immune regulatory properties of vitamin D.  
Taken from Mora et al. Nature Reviews Immunology, 2008. 8: 685 – 698.  [217] 
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TH17 cells have been shown to play a significant role in the mediation of inflammation in 
IBD. In an in vitro system of antigen presentation and T cell differentiation, the presence 
of vitamin D leads to an inhibition of TH17 differentiation and reduced IL-17 mRNA 
levels. This effect is mediated through the vitamin D receptor but was not observed in 
VDR -/- T cells and is independent of IL-10. [218] It is mediated through a reduction in 
RORγ and IL23 mRNA levels. [218]  
Additionally, the inhibitory role of vitamin D on the TH17 population has been shown in 
animal models and patients with immune mediated disorders. The number of TH17 cells 
in the spleen and the CNS of mice injected with myelin oligodendrocyte glycoprotein in a 
model of experimental autoimmune encephalomyelitis were significantly less among 
mice treated with oral vitamin D and the vitamin D treated mice had reduced disease 
activity scores (and very close to zero) during the 18 day follow up. [219] In peripheral 
blood T cells of treatment naïve patients with rheumatoid arthritis (RA), vitamin D 
suppressed the levels of IL-17 and IFN-gamma and increased the levels of IL-4. [220] In 
another RA study, vitamin D reduced the levels of IL17 in synovial biopsy cultures and 
this was enhanced by TNF blockage, but not achieved by blocking TNF in the absence of 
vitamin D. [221]  In a small study of patients with undifferentiated connective tissue 
disease who were deficient in vitamin D, vitamin D supplementation decreased the 
number of TH17 and Th1 cells. [222] Simirarly, in patients with SLE and 
hypovitaminosis D, vitamin D supplementation and restoration to normal levels results in 
decreased numbers of TH17 cells. [223]  
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Vitamin D might play a role in the pathogenesis and treatment of IBD. In an animal 
model of IBD (DSS colitis) administration of a vitamin D analogue could attenuate the 
clinical and histological disease activity of the chemically induced colitis. [224]  
 
1.8.1 The role of Vitamin D in the pathogenesis of IBD 
1.8.1.1 Epidimiological observation 
Evidence from epidemiological data suggests that the incidence and prevalence of IBD is 
higher in countries, where exposure to sunlight is low, such as Northern Europe, 
America, Australia and New Zealand in comparison to sunnier countries as those of 
South Asia. [201] Within Finland, a North – South gradient in the prevalence of UC has 
been shown; interestingly vitamin D levels were lower in the population of north Finland. 
[225] Additionally, a prospective study with a 3 year follow up among the second 
generation residents of Leicester of South Asian descent showed that they are in fact at 
higher risk to develop ulcerative colitis than the European residents. [226] A very recent 
well designed prospective study done among USA nurses with no previous history of 
IBD, showed that even in populations with great genetic variation (such as the USA), 
living in a southern state at the age of 30 reduced significantly the incidence of UC and 
Crohn’s (HR 0.62 and 0.48 respectively). [227] This gradient remained significant after 
adjusting for family history and smoking; unfortunately data on the disease course and 
vitamin D levels between different latitudes were not collected, however the authors 
extensively discuss the likelihood of a difference between vitamin D levels between the 
different latitudes as the possible explanation for their findings. [227] Moreover, a study 
of 72,719 women, using vitamin D levels as these were predicted by a linear regression 
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model according to age, sunlight exposure, dietary intake, race and BMI, showed that 
those who were vitamin D sufficient according to their predicted levels, the risk of 
developing Crohn’s disease was significantly lower [HR 0.38 (95% CI 0.15 – 0.97) 
p<0.05] and there was also a trend towards a reduced risk for developing ulcerative 
colitis [HR 0.57 (95% CI 0.19 – 1.70) p=0.2]. [228] Every 100 IU of vitamin D in this 
population’s diet resulted in a 10% reduction in UC risk and 7% reduction in Crohn’s 
disease risk. [228]  
 
 
1.8.1.2. Vitamin D genetics 
Recently, genetic polymorphisms relevant to vitamin D have been shown to be related to 
the risk of developing IBD. In a case control study of 158 UC patients, 245 CD patients 
and 164 controls, 3 different VDR polymorphisms were studied: TaqI genotype was 
significantly related to Crohn’s disease [OR 1.99, 95% CI: 1.14 – 3.47, p=0.02] [212] 
This result was not reproduced in a smaller study from Iran, which showed an association 
between Fok I polymorphism of the VDR gene and UC [OR 1.57, 95% CI: 1.11 – 2.22, 
p=0.01], [229] and similar results were obtained in a more extensive Irish study enrolling 
1359 patients. [230] However, in another study from New Zealand where 897 IBD 
patients and 482 controls were genotyped for three VDR SNPs (rs11568820, rs2228570 
and rs731236) there was no association between the studied genetic variations and the 
risk of IBD for the overall population but only an association between rs731236 (TaqI) in 
males with UC and CD. [231] In a study of Jewish IBD patients, the Bmsl vitamin D 
receptor polymorphism was associated with UC [OR 2.21, 95%CI (1.06 – 4.9), p=0.04]. 
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[232] A study genotyping 636 IBD cases and 248 non-IBD controls for two common 
SNPs of the vitamin D binding protein, showed that DBP 420 variant Lys is less common 
in IBD patients than controls, adding evidence for a role of vitamin D in the pathogenesis 
of IBD. [233]  
In a recent meta-analysis of 15 GWAS studies, a SNP on the VDR was proved to be 
associated with the risk of IBD. [58] A recent meta-analysis of 9 studies, confirmed an 
association between the tt genotype of TaqI genotype and the risk of developing Crohn’s 
disease in Europeans and that the ff genotype of the FokI polymorphism is associated 
with UC in Asians, pointing a role for ethnicity in the susceptibility to IBD perhaps due 
to under-defined specific gene-sets. The same study suggests that the Aa and aa 
genotypes of the ApaI polymorphism reduce the susceptibility to Crohn’s disease. [234] 
 
1.8.1.3 Vitamin D in animal models of IBD 
In two animal models of IBD, the VDR status played a crucial role in the development 
and severity of intestinal inflammation: in the CD45RB transfer model, transferring T 
cells from VDR knock-out mice to Rag KO mice resulted in more severe colonic 
inflammation compared to transferring equal numbers of T cells from VDR wild-type 
mice. Similarly, in the IL-10 knock-out model, knocking out the VDR resulted in more 
severe inflammation and 100% mortality in 8 weeks compared to IL-10KO/VDR-wild 
type mice. [235] In another study, it was documented that high levels of human VDR 
expression on the intestinal epithelium of mice (transgenic model) had a protective effect 
when colitis was attempted to be induced with TNBS, DSS or activated T cell transfer. 
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VDR signalling blocked the activation of NF-kB and was associated with reduced IEC 
apoptosis. [236]  
Another proposed mechanism for the beneficial role of vitamin D in IBD is its role on the 
intestinal microbiota. VDR KO mice and mice lacking the ability to produce 1,25 (OH)2 
vitamin D were shown to have greater numbers of Bacteroides and Proteobacteria and 
fewer Firmicutes and Defferibacters. [237] A similar modification of the intestinal 
microbiome was shown in another study comparing mice raised on a vitamin D deficient 
or sufficient diet: mice that were raised on vitamin D deficient diets had increased 
population of Bacteroides, Actinobacteria and Gammaproteobacteria compared to thosed 
raised on a vitamin D sufficient diet. Interestingly and in contrast with the previously 
described study, the vitamin D deficient mice also had increased population of 
Firmicutes. [238] However, both these studies suggest that vitamin D status is a regulator 
of the intestinal microbiota in mice, which plays a role in the development of IBD.  
IL-10 KO mice expressed higher levels of TNF-α in the ileum and ascending colon and 
when treated with a high calcium, vitamin D sufficient diet the degree of inflammation 
was less, compared to mice kept vitamin D deficient through dietary and light restriction. 
[239] In another model of IBD, DSS induced colitis, when mice were raised with a 
vitamin D deficient diet had lower levels of serum vitamin D, more significant weight 
loss and higher colitis histology scores when compared to mice raised on a vitamin D 
sufficient diet. [240] Moreover, micro array experiments proved that 27 genes were 
expressed at a lower level in mice raised on a vitamin D deficient diet, including 
angiogenin-4 which is a protein with bactericidal activity. [240] In another study using 
DSS induced colitis as a model for IBD, treatment with a vitamin D analogue 
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significantly decreased the histologic score of colonic inflammation compared to 
controls. This was related with a reduction in cytokine production by colonic DCs and 
downregulation of their co-stimulatory molecules. [241]  
A proposed mechanism for the beneficial role of vitamin D in IBD was the enhancement 
of the epithelial integrity, whose loss is a key event in the pathogenesis of the disease: 
treatment of Caco-2 monolayers with 1,25(OH)2 vitamin D enhanced the expression of 
ZO-1 and E-cadherin and when the cells were incubated with DSS, the tight junction on 
the monolayer was significantly disrupted when vitamin D was not presen. [242] This 
result was replicated in another study that also proved that mice fed with a vitamin D 
deficient diet had lower serum vitamin D levels and increased intestinal epithelial 
permeability both at baseline and after C. Rodentium infection when this was assessed in 
vivo by measuring the serum levels of a FITC-dextran probe that was administered 
orally. [238] 
 
1.8.2 Therapeutic potential of vitamin D  
The emerging evidence about the role of vitamin D in the pathogenesis of IBD and about 
the prevalence of vitamin D deficiency in IBD has triggered clinical studies about the 
therapeutic potential of vitamin D. In a double blinded placebo controlled trial of Vitamin 
D (1200 IU per day) vs placebo in 94 Crohn’s disease patients who were in clinical and 
biochemical remission, those randomised to vitamin D would take longer to relapse 
compared to those randomised to placebo and according to cox regression analysis there 
was a statistical trend [HR 0.42, 95% CI 0.16 – 1.10, p=0.06]. [243] However, subgroup 
analysis from the same study of 10 patients receiving vitamin D supplementation, that 
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have been selected based on the largest vitamin D increase from week 0 to week 26, and 
10 patients receiving placebo (seasonally matched) showed that the PBMCs of those 
receiving vitamin D, would produce more IL-6 than those receiving placebo. [244] This 
would advocate against a possibly immunosuppressive role of vitamin D but it could 
represent bias relevant to the fact that the patients receiving vitamin D supplementation 
could possibly have subclinical inflammation that was not identified by the CRP or the 
CDAI. A smaller clinical trial in Crohn’s disease patients comparing two different doses 
of vitamin D administration (10000 IU vs 1000 IU daily) showed superiority of the 10000 
IU dose in clinical score improvement, implying that optimizing the dosing regime of 
vitamin D makes a difference in the clinical outcome. [201] In a recent publication on 
quality improvement interventions for paediatric IBD, among 505 paediatric patients 
those who had their vitamin D levels optimized through ergocalciferol administration had 
significantly better chance of having inactive disease than those who had not; similarly 
vitamin D levels were significantly higher among IBD patients with inactive disease. 
[245]  
Data from in vitro experiments suggest a potential role for vitamin D in the treatment of 
intestinal fibrosis; CARD – 024, a vitamin D analogue could repress fibrotic changes 
induced on human colonic myofirbroblasts by TGF-β stimulation or culture on high 
stiffness substrates. [246] Given the fact that intestinal fibrosis leads to surgery and 
morbidity associated with its complications and the relevant loss of intestinal surface this 
novel role of vitamin D may be promising. 
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1.8.3 Vitamin D in cancer prevention in IBD:  
As patients with IBD are at increased risk of colorectal cancer and vitamin D has been 
shown to prevent cancer growth and proliferation by inhibiting growth factors and 
inducing apoptosis, its role as a possibly chemopreventive agent for colorectal cancer has 
been investigated. [201] In mice, colonic tumour development was inhibited by 
increasing the dietary intake of vitamin D. [247] Additionally, cyclin D1 levels – a 
protein linked with early colorectal tumours -  have been documented to be higher in the 
descending colon of the VDR KO mice in comparison to the heterozygote and wild type 
mice. [248]  
In a large prospective case control study, the serum levels of vitamin D were inversely 
related to the incidence of colorectal cancer. In fact, patients whose levels were at the 
highest quartile, were 40% less likely to develop colorectal cancer in comparison to those 
of the lowest quartile. Although serum levels were related with the risk of colorectal 
cancer, this was not related to the dietary intake of vitamin D and calcium. [249] 
Additionally, higher vitamin D levels were associated with reduced colorectal cancer 
specific [HR 0.69, (95% CI 0.50 – 0.93), p=0.04] and overall mortality [HR 0.67 (95% CI 
0.50 – 0.88), p=0.01]. [250] However, these results were not reproduced in a cohort of 
Finnish male smokers. [251] Furthermore, a prospective trial of oral supplementation 
with small dose (400 IU) of vitamin D per day in 36282 post menopausal women, 
showed no difference in the incidence of colorectal cancer between the two groups. [252]  
However published studies on vitamin D in IBD do not fully explore important aspects of 
its possible role on the response to the already applied treatments and the potential role of 
ethnicity.  
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1.9 The medical management of IBD  
The medical management of IBD traditionally includes strategies of induction to 
remission and maintenance of clinical remission. This can be achieved with a variety of 
medication. In this section I will summarize the most important aspects of the evidence 
base for the current use of medical treatments. As this represents a large volume of 
literature, I will mostly concentrate on EEN.  
 
1.9.1 5-ASAs 
Treatment with sulphasalazine or 5-ASAs represents the most common current treatment 
for induction to remission in patients newly diagnosed with ulcerative colitis. These can 
be delivered orally or rectally according to the extent of the disease and can be successful 
in  inducing clinical remission. [3] The ASCEND 3 trial proved that among patients with 
moderately active disease, 4.8 g of mesalamine per day can improve disease activity in up 
to 70% of patients and induce clinical remission in 43% of them. [253] A recent study 
evaluating the usefulness of prolonged release mesalazine in patients with mildly to 
moderately active UC proved that remission can be induced in up to 60% of patients with 
the rate of complete endoscopic remission being 47% among those who received 4g once 
daily and a favorable safety profile. [254] Reassuringly a meta-analysis of the mucosal 
healing rates of UC patients treated with 5-ASAs, showed a cumulative rate of 44%. 
[255] 
Mesalamine has been proved to be more efficacious than placebo in maintaining 
remission in ulcerative colitis patients with a success rate of 59% vs 40% for placebo. 
[256] This is in agreement with previously published results that show a maintenance of 
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remission rate of 64% for mesalazine vs 38% for placebo [257] and confirmed by a 
Cochrane analysis. [258] 
The outcomes of the use of 5-ASA compounds for the induction and maintenance of 
remission in Crohn’s disease have been extensively studied and are more controversial. 
Some studies have proved that 5-ASAs are not superior to placebo in improving the 
disease activity. [259, 260] Others proved that a high dose of oral aminosalicylates [261] 
can be more efficacious than placebo (placebo response 18%) in inducing remission to 
43% of patients with mild or mild to moderately active ileal or ileocolonic disease. 
However, a later meta-analysis of three trials of high dose oral mesalamine (4g/day) 
showed that in comparison to placebo, mesalamine reduces the CDAI by a net of 18 
points, proving that the evidence for the use of mesalamine in inducing remission among 
Crohn’s disease patients is at best equivocal. [262]  
Similarly, the data on the use of 5-ASAs in maintaining remission in Crohn’s disease 
patients are conflicting. In a multicenter randomized control study, sulfasalazine was of 
no benefit when compared to steroids, combination of steroids and sulfasalazine and 
placebo. [263] Another study comparing high dose mesalamine with placebo for the 
maintenance of remission in Crohn’s disease patients who were induced to remission 
with steroids showed that the mesalamine group did not gain any benefit in terms of 
numbers of patients in successfully maintained in remission and time to first relapse. 
Contrary to the previous study, a trial including 125 Crohn’s disease patients in remission 
proved that 2.4g of 5-ASA per day are superior to placebo in maintaining remission for at 
least 12 months. However, a Cochrane review analyzing the results of 8 placebo 
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controlled studies concluded that there is no evidence to suggest a benefit for 5-ASAs 
over placebo for the maintenance of remission in Crohn’s disease. [264]  
 
1.9.2 Corticosteroids 
The usefulness of steroids for the treatment of ulcerative colitis was first described in a 
landmark randomized controlled trial in 1954, [265] and further validated by others. 
[266] Their success in managing active inflammation is achieved by the modulation of 
genes involved in the regulation of the innate immune response, the suppression of Th1 
and Th2 responses, [267] the inhibition of white cell migration and adhesion through the 
down regulation of L-selectin, chemokine release and pro-inflammatory cytokine release. 
Additionally steroids block the maturation of dendritic cells to a mature phenotype 
expressing MHC II molecules and co-stimulatory molecules such as B7.1, B7.2 and 
ICAM-1 blocking T cell activation. [268] Despite the high success rate of steroids in 
managing active ulcerative colitis, their role in maintenance of remission is limited to the 
point of being considered as a not acceptable strategy by their dose and duration 
dependent adverse events as osteoporosis, osteonecrosis, hyperglycaemia, glaucoma, 
cataracts, cushingoid appearance and the increased risk of infections. [269]  
Steroids have been proved more effective than placebo in inducing remission in Crohn’s 
disease patients, [270] and the addition of sulphasalazine did not provide a therapeutic 
benefit, [271] hence they have been the mainstay of treatment for Crohn’s disease for 
decades. Their efficacy in treating active inflammation was confirmed on a meta-analysis 
that quotes a benefit of up to 30% more than placebo in inducing remission. [272] 
However, when penetrative complications are present (perianal fistulas, Crohn’s mass) 
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steroids can be associated with increased risk of sepsis, perioperative complications and 
death. [273]  
Apart from the risks associated with the use of steroids in Crohn’s disease, there are other 
issues that limit their use as a maintenance treatment. About 70% of patients who achieve 
remission with corticosteroids do not achieve mucosal healing, perhaps because of the 
inability of steroids to control submucosal inflammation. Hence about 50% of patients 
who entered remission with steroids will clinically relapse within a year. [274] In clinical 
trials, both prednisolone [270] and budesonide [275] have failed as maintenance 
strategies, although budesonide was better than placebo, but with a median time to 
relapse of 179 days.  
 
 
1.9.3 Exclusive enteral nutrition 
The use of steroids is a particular challenge among paediatric Crohn’s disease patients. 
Almost 30% of paediatric patients experience growth retardation [276] which has been 
proved to be relevant to chronic active inflammation. [277] Given the proven negative 
impact of steroids in children’s bone mineral density [278] and growth [279], managing 
Crohn’s disease with minimal or no use of steroids at all would be beneficial.  
 
1.9.3.1 The use of enteral nutrition as primary therapy for Crohn’s disease 
The use of enteral diets was initially described as a means of support, rather than 
treatment among patients hospitalized post small bowel resections, acute pancreatitis and 
acute flares of IBD. [280] The first report of the use of elemental diet in IBD patients was 
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in 1973: 13 IBD patients were treated with an elemental diet for an average of 22 days 
achieving a significant nutritional benefit with very good tolerability. [281] 
Subesequently, in 1980, it was used for the management of growth retardation in 4 
children with ileal or ileocolonic disease. The growth velocity achieved during the 6 
weeks of enteral nutrition was impressive and the disease activity reduced, although 
according to the presented data, 2 of the patients had inactive disease and 2 had mild to 
moderate active disease. [282] In a study of the effect of exclusive elemental diet in 
gastrointestinal protein loss, exclusive elemental diet was trialed open label on 7 patients 
with extensive jejunoileal Crohn’s disease. There was a 47% reduction in plasma protein 
loss with a corresponding increase in plasma protein levels and although clinical response 
was not formally assessed, all patients reported increased energy levels and improvement 
of their overall well-being. [283]  At the same time, a French publication reported that 
exclusive enteral nutrition was effective in treating active inflammation and bypassing 
steroid dependency in 17 children with active Crohn’s disease based on clinical and 
laboratory criteria. [284] The results were repeatable in a further cohort of 10 children 
treated with enteral nutrition for three weeks by the same group; all children went into 
clinical remission from a moderate or moderate to severe disease activity on baseline. 
[285] The results of these trials were put in context when exclusive elemental diet as a 
means of induction to remission in paediatric and adolescent patients with Crohn’s 
disease was compared to high dose steroids in a randomized controlled trial. 17 patients 
were recruited and treated with either high dose steroids or exclusive enteral nutrition for 
6 weeks and the outcome in achieving clinical remission as measured by the Lloyd – Still 
disease activity index, biochemical markers and body weight was similar between the 2 
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groups. Interestingly, although the weight gain was similar between groups, the height 
velocity was significantly higher among the nutritionally treated patients, after six months 
of starting treatment. [286] The results of this trial were replicated in two metachronous 
randomized trials: One including 19 paediatric patients with Crohn’s disease that were 
randomized to an exclusive whole protein enteral diet (n=10) or prednisolone  [287] and 
one including 20 adult patients with mild to moderate active Crohn’s disease thay were 
randomized to receive corticosteroids or exclusive enteral nutrition for 2 weeks. [288] In 
both trials, EEN was proved to be at least as efficacious as treatement with corticosteroids 
in inducing clinical remission. Similar results were produced by a more recent 
retrospective study of 105 paediatric Crohn’s disease patients (36 having received EEN 
and 69 corticosteroids) showing a remission rate of about 90% for both groups. [289] 
 
The studies described above provide enough evidence to support the use of EEN in 
Crohn’s disease patients. However, there is heterogeneity in the disease phenotype of 
patients included and the type of feed used making it difficult to extract safe conclusions 
regarding the best patient selection and practice in EEN in order to achieve optimal 
results.  
 
1.9.3.1.1 Response to EEN and disease location 
A prospective open label study of the effect of EEN in 65 children with Crohn’s disease 
suggested that EEN is less efficient in inducing remission to patients with colonic disease 
compared to those with ileal or ileocolonic (50% vs 91% and 82% respectively). It is 
noteworthy that post treatment improvement in endoscopic scores of disease activity was 
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not observed in patients with colonic Crohn’s disease. [290] However, a different study 
using EEN in 110 children with Crohn’s disease for 8 weeks suggested that remission 
rates in patients with colonic disease are about 80% and not different to the rest of 
patients included in the study and therefore that disease location does not influence the 
achievement of remission with EEN. [291]  
 
1.9.3.1.2 Are all formulas similarly efficient? 
The composition of the feed administered has been a significant point of interest in 
research attempting to optimize the results of nutritional therapy for Crohn’s disease. The 
favorable result of enteral nutrition in achieving clinical remission was achieved with 
elemental but not necessarily with polymeric diets in a randomized control study of 30 
patients (75% vs 36% respectively). [292] However, this result was not reproducible in 
other studies. In a randomized trial including 32 patients, Gonzalez-Huix et al report 
similar efficacy of a polymeric diet that was administered through a naso-gastric tube 
with high dose corticosteroids in achieving clinical remission (80% vs 88%, p=0.4). Of 
note, one of the two patients that failed treatment with corticoteroids during the first week 
of treatment, was treated with a polymeric diet and went into remission. [293] Similarly, 
a trial comparing an amino-acid based low fat diet to a peptide based high fat diet in 
adults with Crohn’s disease reported similar efficiency in inducing remission between the 
two treatment arms. [294] The same result was reproduced in a study comparing an 
amino-acid with whole protein enteral feeding. [295] Further trials confirmed the equal 
efficiency of polymeric and elemental diets in treating active Crohn’s disease in children: 
Ludvigsson et al performed a trial of elemental vs polymeric diet for active Crohn’s 
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disease in 33 children showed similar efficiency between the two formulas in achieving 
remission and favored the polymeric diet in terms of nutritional benefit. [296] Grogan et 
al compared elemental with polymeric diet in 34 children with newly diagnosed Crohn’s 
disease. Elemental and polymeric diet achieved similar rates of clinical remission (90% 
and 80% respectively, p = ns) and within a two year follow up the time to clinical relapse 
was also similar between groups. [297] Rigaud et al reported equal and high rates of 
remission in difficult to treat adult patients with Crohn’s (n=30) who had failed treatment 
with corticosteroids and were randomized to receive an exclusive diet with either an 
elemental or a polymeric formula. 53% of patients were in clinical remission after two 
weeks of treatment and 70% after four weeks of treatment with no difference in remission 
rates between the two groups. Interestingly, most of the patients taking part in this study 
suffered from colonic Crohn’s disease. [298] The equality in efficiency between 
elemental and polymeric diets has been confirmed by a Cochrane review in 2007. [299]  
 
1.9.3.2 EEN in adults with Crohn’s disease 
Traditionally, enteral nutrition has been a treatment reserved for the paediatric patients. 
More recently its role has been investigated for the management of active mucosal 
inflammation among adult patients; In 1984 O’Morrain et al reported comparable disease 
activity improvement with corticosteroids or exclusive elemental diet among adult 
patients with Crohn’s disease. [300] In a study of exclusive polymeric diet among adult 
Crohn’s disease patients that required hospitalization in 3 centers in UK, steroids and 
enteral nutrition had similar efficiency in inducing remission in the per protocol 
population. However, 40% of the patients that were initially randomized to receive EEN 
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did not tolerate enteral nutrition due to either its poor palatability or due to the discomfort 
associated with a nasogastric tube. [301] A multi-center controlled trial from East Anglia 
involving 124 patients showed that in the intention to treat population, elemental diet was 
shown to be efficient at inducing remission in 84% of patients who tolerated it. However 
30% of patients initially enrolled in the study did not tolerate it. [302]   
 
At a higher level of evidence, several meta-analyses attempted to confirm the benefit of 
EEN in inducing remission in children with Crohn’s disease with variable results. A 
meta-analysis of 8 trials comparing EEN with corticosteroids showed that on an intention 
to treat basis, corticosteroids are more efficient than EEN in inducing clinical remission. 
However, this was influenced to a certain degree by a 21% intolerance / non-adherence 
rate of the population receiving EEN. [303] A later mata-analysis including 571 patients 
that were treated with EEN reported a cumulative remission rate of 70% which is similar 
to that of corticosteroid treatment. [304] This was confimed by another meta-analysis of 5 
trials [305] and a meta-analysis of 11 clinical trials proving similar efficacy of 
corticosteroids with EEN in inducing clinical remission in Crohn’s disease patients. [306] 
However, a Cochrane review concluded that corticosteroids are more effective than EEN 
in inducing clinical remission in Crohn’s disease patients. This was according to the 
authors possibly influenced by the significant variability between the trials included in 
the reported remission rates, likely secondary to the differences between the included 
populations, the disease activity measures, the interventions employed to administer EEN 
and the trial methodology. [299]  
 
 101 
1.9.3.3 Enteral nutrition for maintenance of remission 
Having been proven that exclusive enteral nutrition is an excellent option for the 
induction of remission in patients with Crohn’s disease the possibility of using enteral 
nutrition for the maintenance of remission has attracted analogous interest. When 
children that received EEN achieved clinical remission, the probability of maintaining 
remission was significantly higher for those who continued receiving enteral nutrition 
supplementary to their normal diet. At 12 months 79% (15/19) of children who received 
supplementary enteral nutrition were in clinical remission compared to 43% (12/28) of 
those who didn’t and this was statistically significant. [307] In the same study, patients 
who carried on with partial enteral nutrition achieved better height velocities within the 
12 months of follow up. [307] In a study of partial EN in steroid dependent patients who 
were in remission, administration of supplementary EN helped to wean off steroids and 
43% of patients ramained in steroid free remission at 12 months. [308] In a trial of “half 
enteral nutrition” in adults, patients were randomized to receive either unrestricted diet or 
50% of their daily requirements through an enteral feed. Remission had been induced 
with steroids, EEN, TPN, Infliximab and/or surgery and within the two years of follow 
up 64% of the patients having an unrestricted diet presented with a relapse compared to 
35% of patients who received “half enteral nutrition”. [309] These two studies were 
included in a Cochrane review suggesting that supplementary enteral nutrition may be 
effective in maintaining remission. [310] In another study among adult Crohn’s disease 
patients that required hospitalization for the management of their Crohn’s, administration 
of at least 900 Kcal daily in the form of enteral nutrition was an independent factor 
predicting non-hospitalisation, especially for those with ileal involvement. [311] 
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Similarly, among 145 patients that were treated with total parenteral nutrition to achieve 
remission, the recurrence rate was significantly lower among those that continued to 
receive partial enteral nutrition during the maintenance period.  [312] 
In the era of biologic therapies for Crohn’s disease, partial EN has been investigated as a 
possible factor that could enhance or maintain for longer the effect of anti-TNF therapy 
and the data are mostly conflicting. The first published prospective clinical trial of enteral 
nutrition during maintenance treatment with Infliximab in patients who had been induced 
to remission with Infliximab included 56 patients who were randomized to receive a night 
EN infusion with a day low fat diet, or carry on their usual dietary pattern. Although the 
percentage of patients who were still in remission was higher in the EN group that result 
did not reach statistical significance. [313] However, a retrospective study from the same 
country (Japan) included 102 patients with a mean follow up of 18 months and reported 
significantly higher cumulative remission rates among patients who received concomitant 
EN compared to those who didn’t. 31% of patients on concomitant EN had their 
inflammatory markers raised or required IFX treatment intensification as compared to 
58% of patients who didn’t receive concomitant EN (p<0.01) and multivariate analysis 
confirmed that partial EN was the only factor associated with maintenance of remission. 
[314] Similar results were obtained from another retrospective Japanese study including 
85 patients. Sustained remission was associated with the amount of EN used 
concomitantly to IFX and patients receiving at least 600 Kcal of EN per day were more 
likely to sustain remission. [315]  
The studies described above provide very encouraging results on the usefulness of partial 
EN on the maintenance of remission in Crohn’s disease with or without the concomitant 
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use of biologics. However, they are heterogeneous in their definition of relapse and lack 
of endoscopic data. In this context the studies of EN in the prevention of post operative 
recurrence become even more meaningful. Yamamoto et al conducted a randomized 
control study of post operative partial EN in patients who had undergone ileal resection 
or right hemicolectomy due to obstructive or penetrative complications of Crohn’s 
disease and had clear margins post-operatively: patients who were randomized to receive 
about 50% of their daily calorific needs through EN had significantly lower rates of 
clinical (5% vs 35%, p<0.05) and endoscopic (30% vs 70%, p<0.05) recurrence 12 
months post surgery. [316] When the follow up of this study was extended to 5 years, the 
EN group presented significantly reduced recurrence requiring treatment with biologics, 
however the cumulative recurrence and reoperation rates, although lower in the EN 
group, did not reach statistical significance. [317] Similarly, Esaki et al reported 
significantly less cumulative post – operative recurrence rates in patients receiving at 
least 1200 Kcal of enteral nutrition after surgery. [318] 
 
1.9.3.4 Enteral nutrition and mucosal healing 
Exclusive enteral nutrition significantly improves patients’ nutritional status. Following 
treatment with EN, the weight z scores of paediatric patients normalize and this is related 
to an improvement in body water, fat and protein composition. Similarly, an increase in 
height velocity and the normalization of insulin like growth factor – 1 (IGF – 1) has been 
described. [319] However, it is proved that the clinical benefits achieved with enteral 
nutrition are beyond nutritional improvement. Clinical remission in Crohn’s disease 
patients is associated with mucosa healing and a decrease in the mucosal expression of 
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pro-inflammatory cytokines mRNA such as IL-1, IL-8 and IFN-γ and an increase in 
mucosal anti-inflammatory cytokines such as TGF-β [320] The effect of mucosal healing 
was not observed in patients receiving steroids when compared to enteral nutrition. [321] 
In an excellent study of 37 children randomized to enteral nutrition or oral corticosteroids 
for 10 weeks, which was followed by endoscopic re-evaluation, it was demonstrated that 
although the rates of clinical remission were similar, only 33% of steroid treated patients 
achieved mucosal healing as compared to 74% of patients treated with exclusive enteral 
nutrition. (figure 1.14) Similarly the histological activity scores were lower among the 
EEN treated patients. [322] The effect of EEN in achieving endoscopic improvement in 
patients with Crohn’s disease was reconfirmed by another study of 34 paediatric patients 
reporting a 60% rate of early endoscopic response with a 42% rate of complete mucosal 
healing among patients who tolerated treatment. [323] These results imply an interaction 






Figure 1.14: Crohn’s disease endoscopic severity index scores in two groups of 
patients pre and post treatment with exclusive enteral nutrition (open squares) or 
oral corticosteroids (filled squares). (Borrelli O et al, Clinical Gastroenterology and 
Hepatology, 2006. 4(6): p. 744-53) [322] 
  
 
In ulcerative colitis, although an improvement in the degree of diarrhea has been 
observed, it was not linked with any mucosal improvement. [324]   
 
1.9.3.5 Long term outcomes of exclusive enteral nutrition 
Given its efficiency in inducing remission, achieving mucosal healing and improving 
nutrition, the favorable long term outcomes with EN come as a natural consequence. In a 
retrospective British study of 44 paediatric patients it was shown that in a median follow 
up of 3 years 38% of patients did not relapse and the median time to relapse was 54 
months (and almost double if the large bowel is not involved). The use of steroids was 
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avoided in almost 50% of cases and when required their use would be postponed by 68 
weeks. [325] Similar results were obtained in a randomized controlled study of elemental 
versus polymeric diet in paediatric Crohn’s disease where a third of the patients remained 
in remission at the end of a two-year follow up, [297] and a retrospective study reporting 
a 40% relapse free survival at two years for paediatric patients treated with EEN. [326] 
Another study attempted to elucidate any differences in the outcome of EEN when this 
was used more than once in order to treat active Crohn’s disease. [327] In this study of 52 
paediatric patients (of whom 40 were newly diagnosed) 92% achieved clinical remission 
at the end of the first course of EEN and the remission rates were similar between newly 
diagnosed and previously treated patients. Of those, 67% relapsed within the subsequent 
12 months and when a second course of EEN was used to treat their relapsing disease, 
remission was achieved in 62% of cases. [327]  
These results show a very promising outcome in the long term, however the follow up 
period was not even for all patients and some of the patients included would be followed 
up for just 1 year. Additionally important aspects of the disease evolution as the need for 
treatment escalation and surgery were not described.  
The long term outcomes of induction to remission with EEN have not been extensively 
described in adult patients. A prospective study from 3 London hospitals suggests that 
more than 90% of adult patients induced to remission with EEN will remain in remission 





1.9.3.6 The therapeutic mechanisms of enteral nutrition 
Although the use of enteral nutrition as an induction strategy is established knowledge 
and in many institutions practice, it is still not well known how enteral nutrition delivers 
its therapeutic benefit. Possible mechanisms apart from bowel rest and nutritional 
improvement include the modulation of the intestinal microflora and the modulation of 
the patient’s immune response. 
 
1.9.3.6.1 The effect of enteral nutrition on the intestinal microbiota  
The role of the composition of intestinal microflora in the pathogenesis of IBD, is well 
established given the role of antibiotics in treating Crohn’s disease, the improvement of 
colonic inflammation with faecal diversion and the data from germ free animal studies 
suggesting the necessity of the microbiota for the occurrence of IBD. A study of 6 newly 
diagnosed paediatric Crohn’s disease patients treated with EN, using the faecal 16s DNA 
to describe the faecal microbiota proved that the diversity of the Eubacteria, Bacteroides 
and coccoides of patients is significantly changing on the course of time with treatment 
administration compared to controls. The change in microbiota composition remains after 
discontinuation of treatment and is related to the decrease in the disease activity index. 
[328] Similar results were obtained by others. [329] The correlation of change in 
microbiota with the disease improvement with EN poses the question on whether the 
alteration in the microbiota is the outcome of EN through which EN exerts its anti-
inflammatory action, or whether the shift in microbiota pattern is the result of the 
improvement of mucosal inflammation. In fact a study of 15 patients who were on enteral 
nutrition with a polymeric diet due to upper GI obstructive lesions or dysphagia 
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secondary to neurological deficit proved that the composition of the microbiota did not 
change over time with EN, however the concentration of acetate, butyrate and total short 
chain fatty acids significantly increased with EN. [330] This positive effect of EN on the 
short chain fatty acids is opposite to the results obtained from other studies that have 
proved a negative or neutral effect. [331]   These results imply that possibly EN does not 
achieve its therapeutic benefit through the modification of the microbiota, although it 
must be noted that these studies characterize the luminal microbiota which could be 
different to the mucosal microbiota.  
However there is a possibility that at least a part of the anti-inflammatory effect of EN 
occurs through its impact on the metabonomic profile of the intraluminal bacteria: In a 
study using faecal samples of 18 paediatric patients having undergone treatment with 
EEN, there was a significant decrease in the pro-inflammatory acetic acid and an increase 
in the anti-inflammatory butyrate. [332] 
 
1.9.3.6.2 Enteral nutrition and the intestinal epithelium 
Given the limitations of the “microbiota” hypothesis, taking into account the direct and 
inevitable interaction of EN with the intestinal epithelium and the fact that intraluminal 
contents as butyrate have been proved to alter the expression of genes that co-ordinate the 
mucosal immune response, such as IL-8 and MCP-1, [333] the action of EN through a 
direct interaction with the intestinal epithelium is a very attractive hypothesis and the data 
supporting it are so far are encouraging but very limited. Incubation of Caco2 cells with a 
polymeric formula has been proved to protect the tight junction integrity from the adverse 
effect of TNF-α. [334] The protective effect of a polymeric formula in this experimental 
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setting was equally effective to that of Infliximab and more effective to that of 
hydrocortisone. [334] Incubation of colonic biopsies from Crohn’s disease patients with 
elemental diet resulted in a significant increase in the ratio of IL-1 receptor antagonist to 
IL-1β when compared to controls. This increase in the anti-inflammatory cytokines did 
not occur when tissue from UC patients or non-IBD patients was incubated with 
elemental diet proving a direct link between enteral nutrition and the treatment of active 
Crohn’s inflammation. [335] Another study using a variety of epithelial cell lines proved 
that the incubation of epithelial cells with a polymeric formula feed significantly 
decreased the inflammatory response (as measured through supernatant IL-8 levels) when 
these were stimulated with IL-1 or TNF-α. Pre-treatment with EN reduced the subsequent 
inflammatory response of the intestinal epithelial cells and treatment with EN after 
exposure to pro-inflammatory stimuli “treated” the inflammatory response successfully. 
This was mediated by the potentiation or inhibition of degradation of IκB and possibly 
the subsequent inhibition of NF-κB translocation. [336] Consistent with the in vitro data, 
a preceding study of patients with Crohn’s disease pre and post treatment proved that the 
reduction in IL-2 producing cells was best achieved with enteral nutrition. [337] These 
data suggest that EN has a direct effect on the immunological function of the intestinal 
epithelium which may mediate its short and long term benefits. Additionally, given the 
role of IL-2 in T cell activation they imply a possible link between enteral nutrition and 






It is clear that recurrent use of steroids should not be the treatment plan for either UC or 
Crohn’s disease and that although they are effective in induction of remission a 
substantial number of patients will relapse. Hence in patients who require repeated 
courses of steroids or who become steroid dependent the development of an escalated 
maintenance strategy is the appropriate next step. The drugs of choice in this situation 
belong to the group of thiopurines and are azathioprine and 6-mercaptopurine. There is 
strong evidence that they can result in successful weaning of steroids and endoscopic 
improvement in previously steroid dependent UC patients for almost 60% of those who 
tolerate it. [338] Maintenance with thiopurines resulted in decreased need for further 
steroids and decreased requirements for hospital admissions and surgery. [339] In 
Crohn’s disease patients, thiopurines constitute excellent options for the maintenance of 
remission. A Cochrane analysis confirmed that using thiopurines patients with Crohn’s 
disease are 2-3 times more likely to be in steroid free remission. [340] However, non-
adherence to thiopurines has been highlighted as a particular problem, especially in 
adolescents and young adults; among our patients at Barts and The London NHS Trust, 
29% of adolescents/young adults were non adherent as compared to 8% of the adults. 
[341] 
Thiopurines exert their cytotoxic activity by being incorporated into the DNA duplex, 
halting the cell cycle and blocking the action of some restriction enzymes and finally cell 
proliferation. [342] Their immune modulatory effect in IBD is also supported by the 
induction of apoptosis and the selective inhibition of inflammatory gene expression in 
activated T cells such as the α4 integrin. [343] At least a part of its apoptotic effect is 
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mediated through the diversion of a co-stimulatory pathway – that of CD28 – in to a pro-
apoptotic pathway. [344] These data apart from confirming the role of T cell activation in 
the pathogenesis of IBD show that its inhibition directly or through the co-stimulatory 
pathways can be treatment strategies.  
 
1.9.5 Anti-TNF-α inhibitors 
The most recently developed and utilized drugs for IBD are the monoclonal antibodies 
against TNF-α which in literature are often described as biologics. The ones most 
commonly used are infliximab (which was the first to be discovered) and its fully 
humanized version, adalimumab. The efficiency of infliximab as a treatment option for 
immune mediated inflammatory disorders was initially described in rheumatoid arthritis 
patients [345] and soon after in Crohn’s disease. [346] Infliximab as means of induction 
to remission can achieve remission or response for about 70% of patients reducing the 
need for steroid administration. [347, 348] In a landmark study, the ACCENT I trial, 
infliximab was proven to be efficacious as means of maintenance for Crohn’s disease. 
Patients on infliximab were about 2-3 times more likely to be in remission at week 30 and 
54 compared to those on placebo with remission rates reaching 40%. This was 
accompanied by weaning of steroids and improvement in quality of life scores. [349] The 
ACCENT II trial proved that infliximab is very effective in inducing and maintaining 
remission in fistulizing Crohn’s disease. 70% of the 282 patients with perianal, 
enterocutaneous or rectovaginal fistulas achieved improvement of their fistulating disease 
on induction treatment with 3 doses of infliximab at weeks 0, 2 and 6. From those who 
achieved an initial response concerning their fistulas, 36% would be in complete response 
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and 46% in response from the perspective of fistulation if they were randomized to carry 
on treatment with infliximab as compared to 19% and 23% respectively for placebo. 
[350]  
Similar encouraging results were obtained for adalimumab in Crohn’s disease. The 
CLASSIC I  trial showed that after 2 doses of infliximab 36% of patients with moderate 
to severe Crohn’s disease according to CDAI who were anti-TNF inexperienced achieved 
clinical remission and 50% a reduction of at least 100 points in their disease activity 
score. [351] The superiority of adalimumab to placebo in inducing clinical remission 
remained in the more challenging to treat patients who had been previously intolerant to 
infliximab or had a secondary loss of response, with a 21% remission rate on induction 
compared to only 7% for placebo. [352] In another study including primary non 
responders to infliximab, the rate of remission on induction with adalimumab was 
reported to be 38% for the overall population and 29% for the primary non responders, a 
very encouraging result. [353] Adalimumab has been shown to be an effective treatment 
strategy for refractory paediatric CD as well; in a recent study 61% of paediatric patients 
achieved remission with adalimumab. [354] 
As well as infliximab, adalimumab was proved to be an effective maintenance strategy. 
The CLASSIC II trial proved that about 80% of patients who achieved remission on 
induction would still be in remission after a year of treatment compared to 44% of 
patients randomized to placebo. From the patients not achieving remission with the 
induction regime of the CLASSIC I trial and were enrolled for open label administration 
of adalimumab, 35% discontinued treatment (25% of them for lack of efficacy) and 46% 
of the intention to treat population was in remission at week 54. [355] Another study, the 
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CHARM trial showed similar good results irrespectable of previous exposure to anti-
TNFs. [356] 
Infliximab is now licensed for use in the treatment of active ulcerative colitis as well. 
According to the results of the ACT-1 trial 39% of patients can achieve remission and 
69% a clinical response after 3 doses of infliximab compared to 15% and 37% 
respectively for placebo. At the end of one year of treatment the remission and response 
rates fell to 20% and 37% respectively but still achieved statistical significance when 
compared to placebo. [357] Less encouraging were the results for adalimumab in UC. On 
induction treatment, adalimumab failed to achieve a statistical significance for remission 
compared to placebo. At the end of year 1, 22% of adalimumab treated patients were in 
remission compared to 12% of the placebo treated patients. The corresponding 
percentages were 10% and 3% respectively for patients having previously failed 
infliximab. [358] 
Infliximab was developed as an anti-cytokine agent and its success in Crohn’s disease 
came as no surprise given that the number of TNF-α secreting molecules are increased in 
active Crohn’s disease.  [352] Interestingly another anti-TNF drug, etanercept which is a 
soluble receptor to TNF-α rather than a monoclonal antibody such as infliximab is not 
effective in treating active mucosal inflammation when compared to placebo. [359] This 
shows that the healing action of infliximab is not mediated solely by cytokine blockage. 
In a study of 10 patients who underwent lower GI endoscopy immediately before and 24 
hours after infliximab infusion it was proved, that although the number of peripheral 
blood lymphocytes was not influenced by treatment, in the lamina propria infliximab 
induced T cell apoptosis. Studies in Jurkat cells proved that incubation with infliximab 
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decreases their ability to produce IFN-γ and makes them prone to apoptosis by increasing 
the Bax/Bcl-2 ratio. [360] Although both infliximab and etanercept neutralize TNF-α 
effectively only infliximab induces lamina propria T cell apoptosis. [361] Similarly the 
population of the highly inflammatory Th17 lineage in the lamina propria of Crohn’s 
disease patients, is significantly reduced after treatment with infliximab, [362] while the 
population of regulatory T cells is increased in the peripheral blood. [363] These results 
suggest that targeting the mucosal activated T cells can be an effective way to treat 
chronic active inflammation.  
The mucosal immune modulation achieved with anti-TNFs influences other immune 
molecules as well. Recently it has been proved that MAdCAM-1, which is essential for 
the recruitment of lymphocytes in the colonic mucosa, is down-regulated in patients who 
respond to treatment with infliximab or adalimumab. This down-regulation is not the 
result of mucosal healing and management of mucosal inflammation but a direct 
pharmacological effect as it occurs when inflamed colonic biopsies are cultured in the 
presence of infliximab. [364] Another study of the effect of Infliximab on 69 Cell 
Adhesion Molecules in 61 patients with colonic IBD proved that treatment with 
Infliximab restores to normal levels most of the molecules that are overexpressed prior to 







1.10 Questions to be examined 
In this thesis, we will attempt to explore the nutrient effects in inflammatory bowel 
disease from the angle of enteral nutrition and vitamin D. We study the role of enteral 
nutrition in the long term outcome of Crohn’s disease. We use the real life criteria of 
clinical relapse and treatment escalation as markers of disease progression as our data 
stem from real life experience. In an attempt to examine the possibility of enteral 
nutrition directly affecting the T cell activation and possible ways of achieving this, we 
investigate the effect of enteral nutrition on the expression of CD58 in the intestinal 
epithelium.  
We elect to study both adult and paediatric populations. I am an adult physician - 
gastroenterologist; however, the long term influence of EEN can be best described in 
children. EEN is the standard clinical practice of our Trust and therefore, selection bias 
which could be a limitation in the adult population – given that not all adults diagnosed 
with Crohn’s disease receive EEN as primary treatment – is eliminated by studying a 
more uniform population such as our paediatric cohort. However, we also describe the 
course of Crohn’s disease in a group of adult patients in an attempt to discuss its 
outcomes and the intolerance rate that has been described as a major limitation for the use 
of EEN among adults in the so far published literature.  
Finally, given the link between ethnicity and vitamin D levels and taking into advantage 
the fact that our local population includes immigrants of a specific area of South Asia 
(Bangladesh) we aim to compare the disease course and phenotype between patients of 










Chapter II: The long term outcomes of exclusive enteral 
nutrition when used as the primary treatment for 
children with newly diagnosed Crohn’s disease 
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2.1 Background 
Enteral nutrition has been proved to be at least as effective as corticosteroids in inducing 
remission in children with Crohn’s disease [286] and in our paediatric gastroenterology 
unit it is used as first line treatment for children diagnosed with Crohn’s disease. The data 
available regarding the long term outcomes when using enteral nutrition as induction 
treatment are limited. There is only one study including 44 patients with a median follow 
up of 3 years. The range of follow up was heterogeneous, between 1 and 7 years and the 
study analyses the data in a solely descriptive way. [325] One recently published 
prospective study of 34 paediatric patients that were newly diagnosed with Crohn’s 
disease, suggested that EEN improved clinical, endoscopic and radiological disease 
activity. Of the 26 children that completed the course of EEN, 22 achieved clinical 
remission and of those, 15 achieved mucosal healing at 6 weeks. Mucosal healing at 6 
weeks predicts a better outcome at 1 year in terms of endoscopic relapse, need for anti-
TNF use and hospitalization. [323]  
We therefore devised a retrospective study to describe the long term outcome of enteral 
nutrition in children diagnosed with Crohn’s disease for the 5 years after their diagnosis. 
We sought to define the time to clinical relapse and time to and need for treatment 
escalation as well as time to progression of disease phenotype according to the Montreal 




All the patients diagnosed with Crohn’s disease during their childhood under the care of 
paediatric IBD clinic at Barts and The London NHS Trust between 2003 and 2006 were 
included (incident cohort). Patients who did not remain under our department and for 
whom data were not available for a follow up of 5 years at the time of the study were 
excluded. All patients underwent bi-directional endoscopy and multiple biopsies and 
small bowel studies (MRI small bowel or small bowel follow through) in order to 
confirm the diagnosis of Crohn’s disease according to the PORTO criteria. [366] We did 
not collect data for patients diagnosed with Crohn’s disease prior to 2003 as Infoflex, our 
prospective database was introduced in 2003. We included only patients diagnosed with 
Crohn’s disease at the Royal London Hopsital. The catchment area of the Royal London 
Hospital includes East London, Kent, Essex and East Hertfordshire..  
 
2.2.2 Data collection 
This was a retrospective study examining the first five years after the diagnosis of 
Crohn’s disease in children receiving EEN for induction to remission. The patients to be 
included for the study were collected through the gastroenterology unit database 
(Infoflex). Infoflex was established by Dr NM Croft for the needs of the paediatric IBD 
team of the Royal London Hospital and is now expanding in the transition and adult IBD 
clinics. A number of variables are collected and saved prospectively in the database. 
These include date and source of referral, date, type of diagnosis and Montreal 
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classification, surgery, past medical history and family history, medication at each visit 
and disease activity.  
Additional clinical data were collected through the outpatient clinics letters that were 
electronically available at the electronic patients records (EPR). Biochemistry and 
haematology data were collected through the electronic databases of EPR, Winpath and 
Clinical records system (CRS). All data were collected by two medically qualified 
investigators who were both working as clinical research fellows at Barts and The 
London to ensure the validity of the data (NK and AR). A list of all the collected 
variables is available in Appendix II.  




All patients were treated with exclusive enteral nutrition (Modulen IBD Nestle) as 
induction strategy under the joint care of a paediatric gastroenterology consultant and the 
paediatric dietician. Treatment was administered orally, but in a minority who did not 
tolerate it, or when concerns regarding inadequate intake existed a small bore NG tube 
was used. The volume of the feed was initially 1 litre per day and would gradually 
increase to cover the patients’ needs according to dietician review. Enteral nutrition was 
administered as an exclusive diet; no other food apart from water and flavouring powder 
for the feed (made from the feed manufacturer) was allowed. Treatment duration was 6 
weeks for all patients according to the British Society of Paediatric Gastroenterology, 
Hepatology and Nutrition Guidelines. [367] Patients were assessed about their response 
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to treatment and subsequently a normal diet was re-introduced under dietician follow up 
within the next 1-2 weeks. Gradual food re-introduction allowed for any food 
intolerances to be identified. The exact protocol of EEN and food re-introduction is 
shown in Appendix III. 
Subsequent medical treatments included further courses of enteral nutrition, 5-ASAs, 
corticosteroids, antibiotics, thiopurines and anti-TNFs and were prescribed according to 
local and national guidelines by paediatric gastroenterologists of our unit.     
 
2.2.4 Definitions of remission and relapse 
Clinical remission was defined according to physician’s global assessment as described in 
clinic letters provided that the patient was not on corticosteroids. Clinical relapse was 
defined according to physician’s global assessment from clinic letters and / or need for 
treatment with corticosteroids or escalation of treatment to azathioprine, need for surgery 
or need for escalation to anti-TNF. We elected to use physician’s global assessment in 
our definition for remission/relapse and not an arithmetic measure such as the paediatric 
Crohn’s disease activity index (PCDAI) [368] mainly for two reasons: Due to the 
retrospective data collection from clinic letters, a number of the variables included in the 
PCAI would be missing. Additionally the clinical decision making regarding our patients 
in the clinic setting is based on the global assessment of an experienced paediatric 
gastroenterologist; the use of a numerical activity index such as the PCAI is more 
relevant in a clinical trial setting, where patients are not necessarily seen by an 
experienced specialty physician in order to ensure uniformity rather than our clinical 
setting.   
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Patients who achieved complete remission with exclusive enteral nutrition are 
characterized as responders and patients who did not achieve that are characterized as non 
responders. 
 
2.2.5 IBD phenotype and disease course 
 Crohn’s disease was phenotyped according to the Montreal Classification [369] and was 
recorded at diagnosis and at 5 years post diagnosis. The Montreal classification has now 
been superseded by the Paris classification, [23] however this work has been undertaken 
prior to the development of the later.  The natural history of Crohn’s disease was assessed 
by comparing the time to change in Montreal Classification; the treatments used 
including numbers of courses of steroids, and use of and time to use of 
immunosuppressant treatments and surgeries. 
 
2.2.6 Vitamin D levels 
Vitamin D status was estimated through the measurement of serum 25(OH)vitamin D 
levels. The optimal vitamin D levels are a matter of debate in literature as there is no 
clear consensus of opinions and a recent systematic review of the relevant literature 
suggests different cut off values for every functional endpoint of vitamin D. [370] In our 
study, vitamin D insufficiency was defined as 25 (OH) vitamin D levels of less than 50 
ng/L as this has been described as the threshold of pharmacological intervention and 
deficiency as levels of less than 25 ng/L as this threshold is reportedly associated with 
osteomalacia. [371]  
Our endpoint of disease course was analysed twice: First, according to vitamin D 
deficiency against non deficient patients and second, according to vitamin D 
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insufficiency against sufficient patients. For this part of the study only patients who had 
their 25-hydroxy-vitamin D levels checked during the course of follow up were included.  
 
2.2.7 Data analysis 
Data were analysed to provide results describing the time to first clinical relapse, to first 
use of steroids, thiopurines or anti-TNFs and the time to first surgery. Our population was 
divided in those who achieved clinical remission with exclusive enteral nutrition on 
induction and those who did not. Further analysis according to vitamin D deficiency was 
undertaken. The statistical tests used for univariate analysis of baseline demographic and 
disease specific variables were student’s t-test (for continuous variables) and the chi-
square test (for categorical variables). Kaplan Mayer analysis with log rank test was 
conducted to determine the time to clinical relapse or treatment escalation in the two 
groups. All analyses were 2 tailed and p-values of less than 0.05 were considered as 
statistically significant. All statistical tests were performed electronically with the use of 
statistical package for social sciences (SPSS version 16.0). Prism – GraphPad (GraphPad 
Prism 6) software was used for the generation of graphs.  
 
2.2.8 Ethical approval 
The data for this component of the thesis were collected as part of an audit for Barts and 
The London NHS Trust (Clinical Effectiveness Unit, audit number 992) and therefore did 
not require formal ethical approval according to the UK National Research Ethics Service 
(NRES) guidelines.  
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2.3 Results: 
2.3.1 Demographics – disease characteristics at diagnosis 
64 patients were diagnosed with Crohn’s disease between 2003 and 2006. 6 did not have 
EEN as induction treatment and there were minimal data recorded for 2 other patients as 
follow up was not carried on with our Trust after diagnosis due to patient relocation. (Fig 
2.1)  
 
Figure 2.1: Patients included in the study 
 
56 patients were included in the study and 71% (40/56) were male. The duration of 
follow up was 5 years for all patients as established by the study criteria. The mean [SD] 
age and CRP at diagnosis were 12.2 [2.6] years and 46.1 mg/dl [39.7] respectively. 64% 
(36/56) of patients were Caucasian, 21% (12/56) Asian, 9% (5/56) Afro-Caribbean and 
5% (3/56) of other or mixed ethnic decent. 25% (14/56) of patients had ileal disease, 
12.5% (7/56) colonic and 62.5% (33/56) ileocolonic disease. Upper GI involvement was 
64 children diagnosed 2003-
2006 
56 children included in the 
study 
8 children excluded: 
- 3 had antibiotics 
- 3 had 5-ASAs 
- 2 were lost to follow up 




present in 48% (27/56) of our patients. 84% (47/56) of patients had inflammatory disease 
phenotype at diagnosis, 5% (3/56) stricturing and 11% (6/56) penetrative. Perianal 
disease was present in 30% (17/56) of our patients. The baseline demographic and 
disease specific characterisitics of the patients included are summarized in table 2.1. EEN 
was administered to all the patients included. Only 20% (11/56) of the patients required 
administration of the feed through NG tube and 5% (3/56) did not tolerate EEN. No 
patient with Crohn’s disease received corticosteroids as primary treatment.  
 
2.3.2 Disease course 
After six weeks of treatment, 57% (32/56) of patients were in clinical remission, 25% 
(14/56) experienced a clinical response and 18% (10/56) failed to improve on exclusive 
enteral nutrition. Among patients who achieved clinical remission, 28% (9/32) had EEN 
administered via NG tube compared to 8% (2/24) of those who didn’t (p=0.06) The mean 
[SD] CRP at 6 weeks was 12.9 mg/dl [20.4] and was significantly lower when compared 
to the CRP at diagnosis pairwise. Other inflammatory markers also descreased in concert; 
ESR from 34.4 [31.3] on diagnosis to 18.1 [20.3] after treatment (p<0.01) and platelet 
count from 564*10³/µ/L [183] to 486*10³/µ/L [140] post treatment (p<0.01). Serum 
albumin increased at the same interval from 31.4 [8.0] to 39.1 [5.0] (p<0.01). 
By the end of year 1 and 5, 45% and 80% of patients had clinically relapsed respectively. 
The mean [SD] time to clinical relapse was 23.7 [20.8] months. 62.5% of our patients 
required treatment with corticosteroids over the 5 years of follow up. The median [range] 
number of courses of corticosteroids required overall was 2 [0 – 6] and the mean [SD] 
time to first course of steroids was 29.9 [25.3] months. 79% of patients required treatment 
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with thiopurines, 19% required treatment with anti-TNFs and 32% required surgical 
management with mean [SEM] time to treatment escalation 30.7 [20.0], 51.8 [16.0] and 
51.1 [16.1] months respectively. The data described above are summarized on Table 2.1 
 
Characteristics All patients 
Gender male, n (%) 40 (71.4) 
Ethnicity 
Caucasian, n (%) 36 (64.3) 
Asian, n (%) 12 (21.4) 
Afrocaribbean, n (%) 5 (8.9) 
Other, n (%) 3 (5.4) 
CRP at diagnosis, mg/dl 46.1 (39.7) 
Alb at diagnosis, mg/dl 31.4 (8.0) 
Age at diagnosis, years 12.2 (2.6) 
Vitamin D checked ever, n (%) 42 (75) 
Vitamin D levels, ng/L 36.6 (25.2) 
Vitamin D insuficiency, n (%) 33 (78.6) 
Vitamin D deficiency, n(%) 19 (45.2) 
Location 
Ileal, n(%) 14 (25) 
Colonic, n(%) 7 (12.5) 
Ileocolonic, n(%) 35 (62.5) 
+ L4, n(%) 27 (48.2) 
+ perianal, n(%) 17 (30.4) 
Behaviour 
Inflammatory, n(%) 47 (83.9) 
Strictuting, n(%)  3 (5.4) 
Penetrating, n(%) 6 (10.7) 
Clinical relapse in 1 year, n (%) 25 (44.4) 
Clinical relapse in 5 years, n (%) 45 (80.4) 
Time to relapse, months 23.7 (20.8) 
Need for corticosteroids, n (%) 35 (62.5) 
Time to corticosteroids, months 29.9 (25.3) 
Number of corticosteroid courses in 5 
years, median (range) 
2 (0-6) 
Need for thiopurines, n (%) 44 (78.6) 
Time to thiopurines, months 30.7 (20.0) 
Need for anti-TNFs, n (%) 16 (28.6) 
Time to anti-TNFs, months 51.8 (16.0) 
Need for surgery, n (%) 18 (32.1) 
Time to surgery, months 51.1 (16.1) 
 
 Table 2.1 The baseline demographics and disease specific characteristics and the 
disease course after primary treatment with EEN of our population 
All values express Mean [SD] unless otherwise indicated 
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2.3.3 What is the meaning of the initial response to enteral nutrition? 
The clinical course of Crohn’s disease differed significantly between the patients who 
achieved clinical remission at diagnosis when compared to those who did not. The 
baseline demographics and disease characteristics did not differ significantly between the 
two groups apart from that perianal disease was more prevalent among those who did not 
achieve remission with EEN. (Table 2.2) 58% (14/24) of the responders and 34% (11/32) 
of the non responders to EEN relapsed clinically within the first year of diagnosis 
(p=0.07). Within the five years follow up period more non-responders would relapse 
clinically and this would be sooner in comparison to patients who achieved clinical 
remission with EEN as primary treatment. (Figure 2.2) 
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Figure 2.2: Survival analysis of time to clinical relapse between responders and non 
responders to EEN. Within the five years follow up period more non-responders would 
relapse clinically and this would be sooner in comparison to patients who achieved 
clinical remission with EEN as primary treatment 
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Significantly less responders (50%, 16/32) required treatment with corticosteroids over 
the course of 5 years when compared to non responders (79%, 19/24) (p=0.03). 
Moreover, the time to first steroid use was significantly longer among the responders and 
the total number of steroid courses over 5 years was significantly lower in this group, 
confirming that achievement of remission with EEN as the primary treatment results in 
less frequent, less likely and later exposure to corticosteroids. (Table 2.2, figure 2.3) 
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Figure 2.3: Survival analysis of time to first use of corticosteroids among responders 
and non responders to EEN. The need for use of corticosteroids was less among 
responders to EEN as primary treatment for Crohn’s disease. The time to first use of 
corticosteroids was longer in that group. 
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The proportion of patients who required treatment with thiopurines, anti-TNFs or surgical 
intervention did not differ significantly between groups (Table 2.2), neither did the time 
required for the patients to be escalated to these treatments. However, there was a trend 
towards earlier use of thiopurines among patients who did not achieve clinical remission 
with EEN (25.3 months [20.0] for non responders vs 34.7 months [19.2] for responders, 
p=0.06) (figure 2.4), showing the need for early aggressive medical management in those 
who fail to achieve remission with EEN. 
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Figure 2.4: Survival analysis of time to first use of thiopurines among responders 
















Gender male, n (%) 22 (69) 18 (75) 0.61 
Ethnicity 
Caucasian, n (%) 17 (53.1) 19 (79.2) 0.06 
Asian, n (%) 9 (28.1) 3 (12.5) 
Afrocaribbean, n (%) 2 (15.6) 0 (0) 
Other, n (%) 2 (8.3) 1 (3.1) 
CRP at diagnosis, mg/dl 49.8 [45.7] 41.0 [29.5] 0.47 
Alb at diagnosis, mg/dl 30.5 [9.6] 32.5 [5.3] 0.39 
Age at diagnosis, years 12.0 [2.7] 12.4 [2.6] 0.53 
Vitamin D checked, n (%) 25 (78.1) 17 (70.8) 0.53 
Vitamin D levels, ng/L 33.4 [4.6] 41.4 [6.9] 0.32 
Vitamin D insuficiency, n (%) 20 (80) 13 (76.5) 0.78 
Vitamin D deficiency, n(%) 13 (52) 6 (35.3) 0.29 
Location 
Ileal, n(%) 9 (28.1) 5 (20.8) 0.65 
Colonic, n(%) 3 (9.4) 4 (16.7) 
Ileocolonic, n(%) 20 (62.5) 15 (62.5) 
+ L4, n(%) 17 (53.1) 10 (41.7) 0.40 
+ perianal, n(%) 6 (18.8) 11 (45.8) 0.03 
Behaviour 
Inflammatory, n(%) 27 (84.4) 20 (83.3) 0.89 
Strictuting, n(%)  2 (6.2) 1 (4.2) 
Penetrating, n(%) 3 (9.4) 3 (12.5) 
Clinical relapse in 1 year, n (%) 11 (34.4) 14 (58.3) 0.07 
Clinical relapse in 5 years, n (%) 24 (75) 21 (87.5) 0.24 
Time to relapse, months 28.2 [21.0] 17.8 [19.2] 0.04† 
Need for corticosteroids, n (%) 16 (50) 19 (79) 0.03 
Time to corticosteroids, months 21.7 [15.9] 6.8 [7.9] 0.002† 
Number of corticosteroid courses in 5 
years, median [range] 
0.5 [0-4] 3 [0-6] 0.008 
Need for thiopurines, n (%) 23 (71.9) 21 (87.5) 0.16 
Time to thiopurines, months 34.7 [19.2] 25.3 [20.0] 0.06† 
Need for anti-TNFs, n (%) 7 (21.9) 9 (37.5) 0.2 
Time to anti-TNFs, months 53.1 [15.4] 50.2 [16.9] 0.23† 
Need for surgery, n (%) 9 (28.1) 9 (37.5) 0.46 
Time to surgery, months 53.0 [13.7] 48.5 [18.8] 0.42† 
 
Table 2.2: Demographic and disease specific characteristics of responders and non 
responders to EEN. † denotes Kaplan – Meier analysis, log rank test. All variables are 
expressed as mean [standard deviation], unless differently indicated. 
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2.3.4 Disease course among responders and non responders excluding patients who 
did not tolerate EEN 
We further analysed the data according to the viva comments, after excluding the three 
patients who did not tolerate EEN to eliminate any bias relevant to patients’ intolerance 
to EEN. Time to clinical relapse and time to first use of corticosteroids remained 
statistically significantly longer among responders to EEN. The results are shown on 
Appendix IV. 
 
2.3.5 Progression of disease phenotype among responders and non responders to 
EEN in 5 years 
We compared the two groups according to the progression of their disease location and 
behavior. Progression of phenotype is a major complication of Crohn’s disease [28] as 
this can lead to escalation of medical management, need for surgery and severe 
implications in patients’ quality of life. 
There was no difference in the disease phenotype as this was defined according to the 
Montreal classification between responders and non responders to EEN. There was a 
trend towards more frequent progression of disease location and behavior among the 
patients who did not respond to the initial induction with EEN (62.5%, 15/24) compared 
to those who did (37.5%, 12/32) (p=0.06) (table 2.3). This trend was mostly led by the 
development of new stricturing or penetrating complications which were more prevalent 
among the non responders (45.8%, 11/24), compared to responders (25%, 8/32) (p=0.10) 
and which can cause severe morbidity and disability in paediatric patients with Crohn’s 
disease. In fact, data sub-analysis confirmed that 6.2% (2/32) of responders to EEN 
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developed new stricturing over the course of follow up as compared to 29.2% (7/24) of 
the non responders (p=0.02). Given the fact that stricturing is associated with the 
development of intestinal failure, [34] this result may point the need for a more proactive 
management of children failing their primary treatment with EEN, but a randomized 
study of more aggressive therapy at an earlier point will be needed before safe 
recommendations on this can be made. There was no difference between groups in the 
proportion of patients who developed new penetrative complications over the course of 5 







not achieved  
n=24 
p - value 
Location Ileal, n (%) 8 (25.0) 5 (20.8) 
0.40 Colonic, n (%)  1 (3.1) 3 (12.5) 
Ileocolonic, n (%) 23 (71.9) 16 (66.7) 
+ L4, n (%) 18 (58.1) 12 (50.0) 0.55 
+ perianal, n (%) 9 (29.0) 11 (45.8) 0.20 
Behaviour Inflammatory, n (%) 19 (59.4) 9 (37.5) 0.13 
Stricturing, n (%) 4 (12.5) 8 (33.3) 
Penetrating, n (%) 9 (28.1) 7 (29.2) 
MC progress 12 (37.5) 15 (62.5) 0.06 
 Location progress, n (%) 5 (15.6) 2 (8.3) 0.41 
New L4, n (%) 4 (12.5) 2 (8.3) 0.62 
New perianal, n (%) 5 (15.6) 2 (8.3) 0.41 
Behaviour progress, n (%) 8 (25) 11 (45.8) 0.10 
 
Table 2.3: The final Montreal classification (MC) and the disease progression of 





2.3.6 Disease course comparison between Caucasian and South Asian patients. 
The phenotype of Crohn’s disease according to the Montral Classidication did not differ 
between Caucasian and South Asian patients. Similarly the need for and time to steroids 
and treatment escalation to thiopurines, anti-TNFs or surgery did not differ between the 
two ethnic groups. (Table 2.4) However, more South Asian patients presented new 
perianal disease during follow up [4 (33.3%) compared to 3 (8.3%) Caucasian patients 
(p=0.03)]. Also more South Asian patients presented expansion of their disease location 
during follow up compared to Caucasian patients. (Table 2.5) 
The vitamin D levels –when these were checked- did not differ between the two groups, 




















Gender male, n (%) 25 (69.4) 10 (83.3) 0.35 
CRP at diagnosis, mg/dl 43.1 (35.6) 34.1 (27.9) 0.51 
Alb at diagnosis, mg/dl 31.1 (9.2) 32.2 (6.8) 0.73 
Age at diagnosis, years 12.8 (2.4) 11.1 (2.7) 0.04 
Vitamin D checked, n (%) 16 (44.4) 6 (50) 0.74 
Vitamin D levels, ng/L 34.7 (18.3) 26.8 (22.7) 0.41 
Vitamin D insuficiency, n (%) 13 (81.2) 5 (83.3) 0.91 
Vitamin D deficiency, n(%) 8 (50) 4 (66.7) 0.48 
Location 
Ileal, n(%) 7 (19.4) 3 (25) 
0.4 Colonic, n(%) 4 (11.1) 3 (25) 
Ileocolonic, n(%) 25 (69.4) 6 (50) 
+ L4, n(%) 16 (44.4) 7 (58.3) 0.4 
+ perianal, n(%) 11 (30.6) 4 (33.3) 0.86 
Behaviour 
Inflammatory, n(%) 30 (83.3) 10 (83.3) 
0.64 Strictuting, n(%)  2 (5.6) 0 (0) 
Penetrating, n(%) 4 (11.1) 2 (16.7) 
Remission with EEN, n(%) 17 (47.2) 9 (75) 0.09 
Clinical relapse in 1 year, n (%) 19 (52.8) 6 (50) 0.87 
Clinical relapse in 5 years, n (%) 32 (88.9) 9 (75) 0.24 
Time to relapse, months 20.5 (18.6) 23.2 (2.7) 0.57 
Need for corticosteroids, n (%) 26 (72.2) 8 (66.7) 0.71 
Time to corticosteroids, months 24.9 (24.6) 28.4 (24.3) 0.62 
Number of corticosteroid courses in 5 
years, median [range] 
2 (0-6) 1.5 (0-3) 0.26 
Need for thiopurines, n (%) 32 (88.9) 8 (66.7) 0.07 
Time to thiopurines, months 26.3 (17.8) 34.6 (23.8) 0.16 
Need for anti-TNFs, n (%) 10 (27.8) 5 (41.7) 0.37 
Time to anti-TNFs, months 54.4 (12.4) 41.7 (23.5) 0.21 
Need for surgery, n (%) 14 (38.9) 3 (25) 0.38 
Time to surgery, months 48.9 (17.6) 52.5 (15.4) 0.42 
 
Table 2.4: Demographic and disease characteristics of Caucasian and South Asian 







p - value 
Location Ileal, n (%) 7 (19.4) 2 (16.7) 
0.45 Colonic, n (%)  4 (11.1) 0 (0) 
Ileocolonic, n (%) 25 (69.4) 10 (83.3) 
+ L4, n (%) 19 (54.3) 7 (58.3) 0.81 
+ perianal, n (%) 12 (34.3) 6 (50) 0.33 
Behaviour Inflammatory, n (%) 19 (52.8) 4 (33.3)  
0.27 Strictuting, n (%) 8 (22.2) 2 (16.7) 
Penetrating, n (%) 9 (25) 6 (50) 
MC progress    
 Location progress, n (%) 3 (8.3) 4 (33.3) 0.03 
New L4, n (%) 3 (8.3) 2 (16.7) 0.41 
New perianal, n (%) 3 (8.3) 4 (33.3) 0.03 
Behaviour progress, n (%) 11 (30.6) 6 (50) 0.22 
 
 
Table 2.5: Montreal classification and phenotype progression in Caucasian and 




2.3.7 Response to exclusive enteral nutrition and Vitamin D 
Vitamin D levels were checked in 41% (13/32) of the responders and 50% (12/24) of the 
non responders at some point during their follow up. There was no difference between the 
two groups in the mean vitamin D levels (mean [SD] ng/L 34.8 [21.1] for responders vs 
31.0 [15.6] for the non-responders, p=0.62) , neither in the percentage of patients who 
were insufficient (76.9% [10/13] of the responders vs 91.7% [11/12] of the non-
responders, p=0.32) or deficient in vitamin D (46.2% [6/13] of the responders vs 50% 
[6/12] of the non-responders, p=0.85).  
 135 
2.3.7.1 The phenotype and course of Crohn’s disease in vitamin D deficient vs vitamin D 
sufficient patients (vitamin D > 25ng/L) 
The phenotype of Crohn’s disease was similar in patients who were sufficient and 
deficient in vitamin D. Similar proportions of vitamin D sufficient and deficient patients 
presented clinical relapse and required treatment with corticosteroids within the follow up 
period (Table 2.6). However, there was a trend towards earlier need for treatment with 
corticosteroids among the vitamin D deficient patients who tended to require more 
courses of corticosteroids during their follow up. (Table 2.6) Our data suggest that more 
patients who were vitamin D deficient required earlier treatment with a thiopurine during 
their disease course, another indication of more aggressive disease progress, but there 
was no difference in the need and time to escalation of treatment to anti-TNFs and 













 Vitamin D 
deficient 
(n=12) 
Not Vitamin D 
deficient 
(n=13) 
p -  value 
Age at diagnosis, years 12.8 [2.5] 12.4 [2.2] 0.67 
Location Ileal, n (%) 3 (25.0) 5 (38.5) 
0.15 Colonic, n (%) 3 (25.0) 0 (0) 
Ileocolonic, n (%) 6 (50.0) 8 (61.5) 
+ L4, n (%) 6 (50.0) 6 (46.2) 0.85 
+ perianal, n (%) 6 (50.0) 5 (38.5) 0.56 
Behaviour Inflammatory, n (%) 11 (91.7) 9 (69.2) 
0.16 Stricturing, n (%) 0 (0) 0 (0) 
Penetrating, n (%) 1 (8.3) 4 (30.8) 
Clinical relapse in 1 year, n (%) 7 (58.3) 5 (38.5) 0.32 
Clinical relapse in 5 years, n (%) 11 (91.7) 10 (76.9) 0.32 
Time to relapse, months 16.9 [18.5] 27.8 [22.2] 0.12 
Need for corticosteroids, n (%) 10 (83.3) 8 (61.5) 0.10 † 
Time to corticosteroids, months 17.1 [21.2] 34.5 [25.6] 
Number of corticosteroid courses in 5 years,  
median [range] 3 [0 – 6] 1 [0 – 4] 0.07 † 
Need for thiopurines, n (%) 11 (91.7) 8 (61.5) 0.03 † Time to thiopurines, months 21.9 [18.0] 39.4 [20.6] 
Need for anti-TNFs, n (%) 2 (16.7) 4 (30.8) 0.38 † Time to anti-TNFs, months 56.0 [13.2] 47.0 [20.6] 
Need for surgery, n (%) 5 (41.7) 6 (46.2) 0.92 † Time to surgery, months 45.0 [20.1] 47.1 [20.9] 
 
Table 2.6: Disease course and phenotype of patients who were vitamin D deficient or 
not.  
† denotes Kaplan - Meier analysis, log rank test. All variables are expressed as mean 




2.3.7.2 The phenotype and course of Crohn’s disease in vitamin D insufficient vs vitamin 
D sufficient (vitamin D > 50 ng/L) patients 
The phenotype of Crohn’s disease according to their Montreal classification on diagnosis 
was similar between the two groups at diagnosis. Similar proportions of patients in both 
groups relapsed, required treatment with corticosteroids, thiopurines and biologics and 
there was no difference in the time required for treatment escalation. Similar proportions 
of patients required surgical intervention between the two groups. (Table 2.7) 
It is of note that most of the patients have been insufficient in vitamin D and only 4 of the 
25 patients in total who had their vitamin D levels checked during their follow up were 





















p - value 
Age at diagnosis, years 12.8 [2.4] 11.5 [1.8] 0.31 
Location Ileal, n (%) 8 (38) 0 (0) 
0.15 Colonic, n (%) 3 (14) 0 (0) 
Ileocolonic, n (%) 10 (48) 4 (100) 
+ L4, n (%) 10 (48) 2 (50) 0.93 
+ perianal, n (%) 8 (38) 3 (75) 0.17 
Behaviour Inflammatory, n (%) 18 (86) 2 (50) 
0.10 Stricturing, n (%) 0 (0) 0 (0) 
Penetrating, n (%) 3 (14) 2 (50) 
Clinical relapse in 1 year, n (%) 10 (48) 2 (50) 0.93 
Clinical relapse in 5 years, n (%) 18 (86) 3 (75) 0.59 
Time to relapse, months 20.6 [20.0] 33.0 [25.4] 0.38 † 
Need for corticosteroids, n (%) 15 (71) 3 (75) 0.76 † Time to corticosteroids, months 24.9 [24.9] 32.7 [26.4] 
Number of corticosteroid courses in 5 years,  
median [range] 2 [0-6] 1 [0-1] 0.17 † 
Need for thiopurines, n (%) 17 (81) 2 (50) 0.20 † Time to thiopurines, months 28.1 [20.0] 46.2 [21.9] 
Need for anti-TNFs, n (%) 4 (19) 2 (50) 0.15 † Time to anti-TNFs, months 53.6 [15.9] 39.4 [24.5] 
Need for surgery, n (%) 10 (48) 1 (25) 0.49 † Time to surgery, months 45.5 [20.3] 49.1 [21.8] 
 
Table 2.7: The Montreal classification and disease course of vitamin D sufficient and 
vitamin D insufficient patients.  
† denotes Kaplan - Meier analysis, log rank test. All variables are expressed as mean 





This is one of the few studies with long enough follow up (5 years) showing that EEN is 
overall well tolerated and that 57% (32/56) of paediatric patients with Crohn’s disease 
achieved clinical remission with EEN as primary treatment. These patients tended to have 
a better clinical outcome over the first five years from their diagnosis. 
The disease extent of our population according to the Montreal Classification is 
comparable to results of others: Similar to the patients of the Scottish cohort [28] most of 
our patients were diagnosed with ileocolonic disease and about half of them had upper GI 
involvement.   
 
2.4.1 The 5 year outcome of paediatric patients with CD treated with EEN as primary 
therapy 
In our paediatric population with newly diagnosed Crohn’s disease treated with exclusive 
enteral nutrition to induce remission, 57% of patients achieved clinical remission. Our 
result is in agreement to the results reported in another recent study from UK. [326] 
Knight et al in one of the first studies describing the long term outcomes of enteral 
nutrition quoted a 90% response rate, which is very close to our 82% rate of combined 
response or remission. [325] The mean time to clinical relapse in our patients has been 
28.7 months if we include in our calculation the patients who did not relapse during the 5 
year follow up. The mean [SEM] time to relapse for the patients that relapsed during the 
course of follow up was 14.9 [1.7] months which contrasts to the recently quoted 6.5 
months [326] but is closer to the 54.5 weeks reported by others in a group of patients with 
similar age of diagnosis and  Montreal classification to our patients. [325] This difference 
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could be possibly explained by the ethnic composition of our population. 22% of our 
patients are of Asian origin, mainly Bangladeshi – and they presented a more aggressive 
disease course, with a higher proportion of them developing new perianal disease and 
overall advancing their disease phenotype according to Montreal Classification over the 
course of follow up compared to white Caucasian patients. Also, we demonstrated in a 
study described in this thesis that patients of Bangladeshi descent with Crohn’s disease 
have a more aggressive disease course than White Caucasian patients. Although Cameron 
et al do not describe the ethnic diversity of their population, taking into account 
demographic data of the population of Glasgow suggesting that Asian ethnic minorities 
represent about 7% of the population [372], we can safely assume that our study includes 
a greater proportion of South Asian patients.  
 
2.4.2 Achievement of clinical remission with EEN is associated with better long term 
outcomes – interpretation and clinical implications 
Previous studies have raised the question about whether induction to remission with 
exclusive enteral nutrition delays the need for treatment with corticosteroids. [325] Our 
results give an answer to this question and confirms that achievement of remission with 
enteral nutrition reduces the need for and delays the time to treatment with 
corticosteroids. This is explained by the associated  prolonged time to clinical relapse. 
 Although responders to EEN who achieved remission were less likely to suffer from 
perianal disease, this is unlikely to account for the difference observed in the two groups 
in the need for and the time to first treatment with corticosteroids as in our clinical 
practice we avoid using steroids in patients with perianal disease. Cox regression analysis 
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reconfirmed that adjusting for patients with perianal disease, patients who achieve 
remission with exclusive enteral nutrition have less need for steroid treatment and if they 
do, take longer to require it (HR 0.31, [95% CI 0.15 – 0.64], p<0.01). In our patients 
there was a statistical trend towards less cumulative need for azathioprine for those who 
achieved clinical remission with EEN. This could possibly reflect the effect of perianal 
disease among the non responders which in clinical practice requires more often 
treatment with immunomodulators or anti-TNFs. However, adjusting for perianal disease, 
Cox regression analysis showed that achievement of remission with EEN is an 
independent predictor of less cumulative need for thiopurines over five years (OR 0.50, 
[95% CI 0.26 – 0.95], p=0.03) while perianal disease was an independent factor 
associated with more often and shorter interval time to the of use of anti-TNFs (HR 3.9, 
[95% CI 1.4 – 11.3], p=0.01).  
A likely explanation of the difference observed in the long term outcome in patients who 
achieve remission with EEN is the achievement of mucosal healing by this group of 
patients as has already been described by others, [322] although this was not directly 
assessed in our study. Additionally, taking into account our data (described in the 
following chapter) about the effect of EN to the expression of CD58, the effect of EN on 
the luminal microbiota [328] and the proven impact of the luminal microbiota on the 
mucosal immunology and specifically the cytokine profile of the dendritic cells, [373] we 
can speculate that the beneficial impact of EEN on the long term outcome of Crohn’s 
disease might be relevant to a direct downregulation of the pro-inflammatory response  
Our results could suggest that patients who do not achieve remission with EEN should be 
followed up and treated more aggressively; however the trial data to support this opinion 
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are not adequate. In a small study of early Infliximab vs conventional management in 
paediatric patients who had been diagnosed with Crohn’s disease for a year, there was an 
initial benefit from the group that received early Infliximab. However this was not 
evident by the end of 3 years of follow up. [374] In a larger study of paediatric Crohn’s 
disease patients, early use of azathioprine was associated with less exposure to 
corticosteroids and less hospitalizations, but the follow up period of 1 year in this study is 
not adequate to pre-define the long term outcome. [375] Moreover, neither of these 
clinical trials uses any kind of risk stratification of the patients included.  
 
2.4.3 Strengths 
Our study has several strengths. First of all, although retrospective in design, it includes a 
consecutive number of patients maintained in a prospectively collected database with 
equal follow up that were treated with EEN as primary therapy for Crohn’s disease. The 
total number of patients included is comparable to the sample of previous other studies, 
however the follow up period is significantly longer than what has been described by 
others [326] [325] investigating the long term follow up after EEN. Moreover, this is the 
first study attempting to investigate the impact of the response to induction treatment with 
EEN to the long term outcome of five years.  
 
2.4.4 Limitations 
Conversely, this work also has a number of limitations. Because of our retrospective data 
collection our results are potentially subject to interpretation bias and bias due to missing 
data. Therefore, outcome measures such as quality of life and social function, both very 
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important in paediatric Crohn’s disease were not collected. Similarly, information on 
adherence and feed volume are not available. Our data represent a population of children 
treated in a tertiary center and are possibly subject to tertiary center bias although taking 
account the complexity of paediatric IBD cases and the fact that local district general 
hospitals in most cases are not able to deliver a paediatric endoscopy and specialist IBD 
care this risk is probably overrated. We based our assessment of the response to enteral 
nutrition on the physician’s global assessment which is a relatively subjective measure 
and likely to be subject to inter-observer variability. Due to the retrospective data 
collection, an objective measure of response and relapse could not be assessed. However, 
we used steroid prescription, escalation of medical treatment, need for surgery and 
physician’s global assessment in order to describe the natural history of Crohn’s disease 
in our cohort of patients in an attempt to provide a detailed description of the disease 
course of our patients. Unfortunately data on mucosal healing and endoscopic scores 
were not available because children are not evaluated endoscopically in remission. 
Moreover, measurements of faecal calprotectin which could provide an objective 
measurement of clinical and endoscopic disease activity, [376] are not available as faecal 
calprotectin testing is not routinely available in our Trust. 
 
 
2.4.5 Vitamin D levels and their impact on the long term outcome of paediatric 
Crohn’s disease 
44% [25/56] of our patients had their vitamin D levels checked at least once at some 
point during the time of follow up. This is lower than the percentage of patients who had 
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their vitamin D level checked in other studies, [245] likely due to the fact that there is no 
strict protocol concerning the measurement of Vitamin D levels in adult or paediatric IBD 
patients in our clinical setting.  
Vitamin D levels and vitamin D insufficiency did not impact on the clinical course of 
Crohn’s disease in our paediatric patients. However, patients who had vitamin D levels of 
25ng/L or less tended to require corticosteroids more often and earlier in their disease 
course. They also required more often and earlier during their disease course treatment 
with a thiopurine.  It is difficult to precisely interpret this result given the fact that most of 
our patients had a single measurement of their vitamin D level, which is variable in time 
and dependent on external factors such as sunlight. Not having serial vitamin D levels for 
our patients it is difficult to establish their vitamin D status at the time of a disease flare. 
The results on the impact of vitamin D levels on the clinical course of Crohn’s disease are 
mixed in the studies published so far, with some reporting a reduced likelihood of disease 
flare for those who are sufficient in Vitamin D levels over a year’s follow up [245] and a 
direct direct effect of vitamin D levels in disease activity and surgery [377, 378] while 
others assessing the role of vitamin D in the paediatric setting, suggest that vitamin D 
levels are not related to disease activity. [379]  
Moreover, one should take into account the fact that these studies do not provide any 
pathophysiological link between vitamin D plasma levels and disease activity. Vitamin D 
deficiency in Crohn’s disease could possibly represent a surrogate marker of mucosal 
disease activity and associated malabsorption that would lead to the clinical manifestation 
of active disease in the future and not necessarily the primary regulator of the disease 
course. Also, one would expect that the exposure of patients’ to sunlight is limited during 
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periods of active disease due to their daily activities being compromised. In fact, a study 
on the effect of vitamin D supplementation in the immunological response of PBMCs 
proved that supplementation and normalization of vitamin D levels in Crohn’s disease 
patients resulted in increased production of IL-6, a proinflammatory cytokine from 
PBMCs and CD4+ T cell proliferation. [244]  
 
Overall, the data presented in this chapter, give useful insights on the long term outcomes 
of EEN when it is used among children with Crohn’s disease as primary therapy. 
However, the part of the study assessing the role of Vitamin D is limited by the lack of 
serial measurements and the data presented may be indicative but are not conclusive of 









Chapter III: The effect of enteral diet on the expression 
of CD58 in intestinal epithelial cell lines
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3.1 Background 
In the previous chapter we discussed the long term outcome of paediatric patients with 
Crohn’s disease receiving EEN as their induction treatment, proving the favorable 
outcomes of patients responding to EEN. Although EEN is – at least in the UK – the first 
line induction treatment for children with Crohn’s disease, the current mechanisms of its 
action are largely unknown. Apart from providing patients with a period of bowel rest 
and nutritional support, EEN impacts on the composition of the luminal microbiota and 
alters the host immunological response.  
The first point at which any direct interaction between EEN and the mucosal immune 
system could possibly lead to a down-regulation of T cell response is at the interface with 
intestinal epithelial cells. Enteral nutrition has been shown to have direct 
immunoregulatory activity on the intestinal epithelium: it down – regulates the IL-8 
response when added to the medium of Caco-2 cells, [336] as well as the MHC II 
expression on the intestinal epithelium in animal studies [380] possibly through the direct 
inhibition of the Class II transactivator gene mRNA. [381] The effect of enteral nutrition 
on the expression of MHC II molecules and secretion of IL-8 could possibly affect 
negatively the T cells activation.  
Given the fact the T cell activation depends on MHC II as well as on the signaling 
provided by co-stimulatory molecules and taking into account the evidence on the role of 
co-stimulatory molecules in the pathogenesis of IBD we sought to establish whether 
enteral nutrition can affect the expression of a co-stimulatory molecule: CD58. CD58 has 
been shown to be expressed on Caco-2 cells however its role in the pathogenesis and 
management of IBD has not been extensively studied. In this chapter we investigate if 
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CD58 is expressed on the intestinal epithelium of patients with Crohn’s disease and study 
the impact of EEN on the expression of CD58 on the intestinal epithelial cells. 
 
3.2 Methods: 
3.2.1 Intestinal epithelial cells (ex-vivo) 
Intestinal epithelial cells from areas with active and inactive inflammation of patients 
undergoing colonoscopy or colectomy as part of their standard management for Crohn’s 
disease and from healthy mucosa (patients undergoing colectomy for colorectal cancer) 
were isolated with standard treatment with 1mM EDTA [382] and have been a kind 
donation of Anna Vosenkamper and Neil McCarthy, post doctoral fellows.  
 
3.2.2 Intestinal epithelial cell lines and culture conditions 
Caco-2 cells and HT-29 cells obtained from the Jackson’s laboratory were cultured in 
culture medium at standard conditions (37˚ C and 5%CO2) at the Blizard Institute of cell 
and molecular science. Both lines used are cancer cell lines as there is lack of a good 
model in non cancer cell lines. The medium used was Dulbecco’s Modified Eagles 
Medium (DMEM) supplemented with Fetal Calf Serum (FCS) (10% per volume), 
penicillin and streptomycin mix (1% per volume), non essential amino acids (1% per 
volume) and HEPES buffer solution (1% per volume). The cells were split with trypsin 
and passages 20 – 35 were used for experiments. 
For experimentation, cells were seeded in 6 or 12 well plates and when they reached a 
confluence of 80-90% they were kept in serum free medium for 48h. Subsequently, half 
of the wells were cultured in serum free medium for further 48h or in enteral diet formula 
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(Modulen IBD®) diluted in serum free medium at the concentration recommended by the 
manufacturer for use in Crohn’s disease patients. After this incubation, the supernatants 
were removed and cells were washed with PBS three times before the protein was 
harvested. 
 
3.2.3 Protein extraction (for both cell lines and ex-vivo cells) 
Cells were inclubated with 150ul of lysing solution at 4˚ C for 30 mins. The lysing 
solution is made of cell-lytic reagent enriched with phosphatase inhibitors (1:1000) and 
phosphatase inhibitor. Subsequently, samples were sonicated for 15 secs each and then 
protein was qualtified. Protein quantification took place through spectophotometry 
against known standards with a standard curve. After protein quantification, PBS was 
added to each sample in different amounts to reach a final equal concentration. Laemli 
Buffer was added (10ul per sample) and samples were further incubated at 65˚C for 15 
mins before being stored at -80˚C. 
 
3.2.4 SDS PAGE and Western blot 
3.2.4.1 Materials 
SDS PAGE was used to separate proteins according to their molecular weights on 
polyacrilamide gels. Each gel was made of 1.65 ml 30% Acrylamide, 1.9 ml Tris HCl 1M 
pH 8.8, 50ul 10% SDS, 1.35 ml of water, 50 ul of 10% Ammonium persulphate and 3 ul 
TEMED. The running buffer was made of Glycine (192mM), 0.1% SDS and Tris base 
diluted in water and normalized to a pH of 8.3. Each of the stacking gels was made of 
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30% Acrylamide (335 ul), Tris – HCl 1M pH 6.8 (250 ul) water (1.35 ml), 10% SDS (20 
ul), ammonium persulphate (25ul) and TEMED (2.5 ul). 
The primary antibody was a mouse IgG2 anti-human CD58 antibody purchased from 
Sigma Aldrich matched with a secondary antibody. In order to normalize the CD58 blot 
and ensure that similar amounts of protein were loaded to each well, the CD58 antibody 
was removed with Restore Western Blot Stripping Buffer (Thermo Scientific) and the 
blots were re - stained with antibodies to GAPDH.  
 
3.2.4.2 Assay 
The gels were put into the gel tanks and sufficient running buffer was added to cover the 
wells. Samples were added and electrophoresed at 110 V until the gel front reached the 
bottom of the gel (approximately 1 hour).  
A semi – dry trans – blotter was used for the western blot. This involved making “a 
sandwich” of Whatman paper soaked in transfer buffer, the membrane (pre wet in 
methanol), the gel and more Whatman paper soaked in transfer buffer. The semi dry 
bloater was electrophoresed for 80 mins at 200 V. Membranes were subsequently 
removed and incubated in 5% albumin in washing buffer for 1h to block. Membranes 
were then incubated overnight in 3ml 1% albumin in washing buffer and the primary 
antibody in the concentration recommended by the manufacturer. The following morning, 
the blots were washed 6 times (10 mins each) in washing buffer and were then incubated 
with the secondary antibody in 1% albumin solution for 1 hour and then re-washed for 1 
hour as before. The blots were then incubated for 5 mins with ECL, wrapped in cling film 
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and exposed to film in the dark room. The film was developed using an automated 
developer. 
 
3.2.4.3 Western blot quantification 
We used Adobe Photoshop CS6 for western blot quantification. The colors were inverted 
and the bands were selected using the “lasso application” according to software 
instructions. Using the histogram analysis the quantification of the area surface and 
intensity were extracted.  
The quantification of CD58 was defined as :  
Intensity CD58 * Area CD58 / Intensity GAPDH * Area GAPDH 
The results of this formula were normalized for each blot in order to allow comparability. 
To achieve this, the results of each western blot gel were multiplied to a factor so as the 
sum of the qualntification results of each gel would be equivalent to 100. 
 
3.2.5 Statistics 
The data obtained from the quantitation study were tested for Gaussian distribution with 
the Kolmogorov-Smirnov test. Comparisons were made using 2-tailed student’s t-test. All 




3.3.1 CD58 expression in the human intestinal epithelium 
Intestinal epithelial cells from 2 healthy controls, 3 patients with inactive Crohn’s disease 
and 2 patients with active Crohn’s disease were obtained. CD58 protein was expressed on 
the intestinal epithelium in all cases. (Figure 3.1) Further to this result, we attempted to 






      HC                                  ACD                                    ICD 
 
    GAPDH 
 
Figure 3.1: Experiment 1: The CD58 expression on intestinal epithelial cells from 
healthy controls (HC), patients with active Crohn’s disease (ACD) and patients with 
inactive Crohn’s disease (ICD): CD58 is expressed in the intestinal epithelial cells of 
healthy volunteers as well as patients with active or inactive Crohn’s disease 
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3.3.2 CD58 expression in Caco-2 cells 
CD58 protein, was expressed in Caco-2 cells. Further to this result, we attempted to 
investigate whether when Caco-2 cells were cultured in the presence of Modulen, CD58 
expression was significantly down regulated. This result was reproduced in 3 independent 
experiments as these are shown to figures 3.2 – 3.4. Statistical analysis of the 
quantification of the western blot bands through Photoshop confirmed the statistical 
significance of the results. This is presented in figure 3.5. Similar results were obtained in 
an experiment using HT-29 instead of Caco-2 cells (figure 3.6). 
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Figure 3.2: Experiment 2: The CD58 expression in untreated (medium) and 
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Figure 3.3: Experiment 3: The CD58 expression in untreated (medium) and 
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Figure 3.4: Experiment 4: The CD58 expression in untreated (medium) and 
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Figure 3.5: The quantitative comparison of CD58 protein expression among Caco-2 
cells treated or not treated with Modulen. Modulen significantly reduces the 













Figure 3.6: Experiment 5: The CD58 expression in untreated (medium) and 
modulen treated (Modulen) HT29 cells. CD58 is expressed on HT29 cells and is 





3.3.3 Summary of findings: 
The co-stimulatory molecule CD58 was expressed in the epithelial cells of patients with 
active or inactive Crohn’s disease as well as in the intestinal epithelial cells of healthy 
controls. CD58 was expressed in intestinal epithelial cell lines, however incubation with 





This is the first study confirming the presence of the co-stimulatory molecule CD58 in 
the intestinal epithelium of patients with Crohns disease, UC and healthy volunteers as 
well. This extrapolates the findings of previous studies that proved the presence of CD58 
in intestinal epithelial cell lines to the human gut. [98] Our study was the first to attempt 
to and successfully downregulate the expression of CD58 on intestinal epithelial cell lines 
with the use of enteral nutrition. We propose that a mechanism by which enteral nutrition 
could possibly exert its beneficial impact, is on the intestinal inflammation through the 
down-regulation of CD58 on the intestinal epithelium. This mechanism is not the only 
means by which this happens as enteral diet could act in a number of ways. A recent 
study suggested that the expression of CD58 is decreased in the mucosa of patients with 
Crohn’s disease and is normalized after treatment of these patients with infliximab. [365] 
However, the results obtained from this study did not investigate the expression of this 
molecule on the intestinal epithelium but in whole biopsies. Given the previously shown 
pro-inflammatory interaction between intraepithelial lymphocytes and CD58 on intestinal 
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epithelial cells [99] which was inhibited upon blockage of CD58, we provide additional 
data regarding CD58 on the intestinal epithelium as a target for therapeutic intervention 
in IBD. This is further supported by the data on the successful management of psoriasis – 
another T cell mediated discorder – by alefacept, an antibody inhibiting the CD58-CD2 
interaction. [121] 
The idea of dietary treatment influencing the immunology of IBD is a very interesting 
aspect in IBD research. Apart from the immunomodulation achieved through EEN, a 
recent study has shown that VSL3, a probiotic mostly used for the management of 
pouchitis, is able to increase the production of IL-10 and decrease the expression of TLR-
2 in colonic dendritic cells. [383]  
Our study does not provide data on whether CD58 is up-regulated or not in the intestinal 
epithelium of patients with IBD. The main reason for this, is the fact that the experiments 
were designed to determine the presence or not of this molecule on the intestinal 
epithelium. The number of patients included were insufficient for quantitative analysis. 
Attempting to assess the expression of CD58 in IBD patients compared to healthy 
controls would be logistically difficult given the fact that most of our IBD patients who 
are undergoing colonoscopy are on treatments that could possibly affect the expression of 
CD58 in any direction. Hence only newly diagnosed patients should be included. 
Moreover, assessing the impact of enteral nutrition in the intestinal epithelium of IBD 
patients would mean the undertaking of a repeat colonoscopy in patients after the end of 
treatment. Given the risks and discomfort associated with colonoscopy and the fact that 
EEN is mainly used according to the current clinical practice in children and adolescents 
with Crohn’s disease it would be difficult to ethically justify such an undertaking for 
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research purposes. Therefore, it is technically difficult to assess and extrapolate our 
results as these are shown on cell lines to patients.  
In order to assess the effect of enteral nutrition on the CD58 expression on Caco-2 cells 
we elected to use western blot as it is a method that directly assesses protein expression. 
Although our blots clearly indicate the down-regulation of CD58 on Caco-2 cells after 
exposure to Modulen the only way to quantify our findings was through assessing the 
area and intensity of the bands by using Adobe Photoshop®. This technique confirmed 
our findings which were visually evident on the transfers, however we acknowledge that 
this is prone to selection and interpretation bias. In an attempt to minimize the relevant 
bias data were quantified and analysed with the method described according to area and 
intensity and also by comparing the mean intensities of preselected and equal areas (data 
not shown) with similar results. Another limitation of western blot is the fact that very 
small differences on time exposure of films to the blots can result in significant 
differences that are observed in the intensity of the blots making any comparison of 
proteins isolated in different blots technically challenging and difficult to interpret. In 
order to overcome this limitation we normalized our results against the expression of 









Chapter IV: Exclusive enteral nutrition among adult 
patients with Crohn’s disease 
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4.1 Background 
Exclusive enteral nutrition has been traditionally regarded as the treatment of choice for 
the management of paediatric Crohn’s disease. However, a growing body of evidence has 
suggested that it can also be a valid choice in the management of adults. A UK study 
suggested that EEN can be as efficient as the treatment with corticosteroids if tolerated. 
However, the same study reported a 40% intolerance rate suggesting that adherence to 
EEN among adults may be a challenge. [301] A landmark East Anglia study suggested 
that it can be effective in inducing remission in up to 85% of a patients, but reported 
similarly high rates of intolerance mounting to 30%. [302] The rates of intolerance and 
subsequent non adherence may be associated with the unfavorable outcomes of a meta-
analysis [303] and a Cochrane review [299].   
The evidence described above, highlights the issue of adherence and tolerance in the use 
of EEN among adult patients with Crohn’s disease. The intention-to-treat population in 
London is socially and ethnically diverse, making adherence a challenge. Our catchment 
area includes patients of mostly Caucasian or South Asian background. Ethnic diversity is 
associated with different socioeconomic and education backgrounds, different patient 
beliefs and possibly attitudes and different genetic backgrounds. These factors may 
influence the rates of tolerance/adherence and the short and the long term outcomes of 
EEN. 
Therefore we conducted a retrospective study in our adult patients with Crohn’s disease 
aiming to document the efficacy and long term outcomes of EEN among adults with 
Crohn’s disease. We also aimed to investigate whether ethnicity if a factor associated 





Adult patients with either established or newly diagnosed Crohn’s disease that received 
care from the department of dietetics of Barts and The London NHS Trust between 
February 2012 and May 2014 with a view to be established on exclusive enteral nutrition 
were identified with the support of Lydia Hill, dietician. Patients that did not receive 
further follow up by our department or who migrated or were lost to follow up for any 
reason were excluded from this study. All patients had been diagnosed with Crohn’s 
disease based on standard histopathological and radiological criteria. [384]  Patients with 
indeterminate colitis and patients who were diagnosed elsewhere with Crohn’s disease 
but the diagnosis had not been clearly confirmed were excluded from the study. The 
catchment area of the adult IBD service of the Royal London Hospital includes East 
London and London suburbs in Essex within the M25. 
 
4.2.2 Data collection 
This is a retrospective study examining the disease course among adult patients with 
Crohn’s disease after receiving EEN. The patients to be included for the study were 
identified by Lydia Hill, dietician at the Royal London Hospital through the dietetics 
department database.  
Clinical data on the disease phenotype, concurrent and previous treatments and disease 
course and need for further medical or surgical therapies were collected through the 
outpatient clinics letters that were electronically available at the electronic patients 
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records (EPR). Biochemistry and haematology data were collected through the electronic 
Clinical records system (CRS). All data were collected by the author of this thesis.  




All patients were treated with exclusive enteral nutrition in order to induce remission 
under the joint care of an adult gastroenterology consultant and a dietician. Treatment 
was administered orally, but in a minority who did not tolerate it, or when concerns 
regarding inadequate intake arose, a small bore NG tube was used. The volume of the 
feed was initially 1 litre per day and would gradually increase to cover the patients’ 
nutritional requirements, according to dietician review. Enteral nutrition was 
administered as an exclusive diet; no other food apart from water and flavouring powder 
for the feed (made from the feed manufacturer) was allowed. Treatment duration was 6 to 
8 weeks for all patients. Patients were assessed on their response to treatment and 
subsequently a normal diet was re-introduced with dietician’s advice follow up within the 
next 1-2 weeks.  
Medical treatments after the course of EEN included corticosteroids, antibiotics, 
thiopurines and anti-TNFs and were prescribed according to local and national guidelines 





4.2.4 Follow up 
The follow up period included the time from initiation of EEN up until the date of the last 
documented follow up appointment that was attended by the patient. 
 
4.2.5 Definitions of remission and relapse 
Clinical remission and clinical response was defined according to physician’s global 
assessment as described in clinic letters provided that the patient was not on 
corticosteroids. Clinical relapse was defined according to physician’s global assessment 
from clinic letters and / or need for treatment with corticosteroids or escalation of medical 
treatment or need for surgery. We elected to use physician’s global assessment in our 
definition for remission/relapse and not an arithmetic measure such as the Crohn’s 
disease activity index (CDAI) mainly for two reasons: Due to the retrospective data 
collection from clinic letters, a number of the variables included in the CDAI would be 
missing. Additionally the clinical decision making regarding our patients in the clinic 
setting is based on the global assessment of an experienced paediatric gastroenterologist; 
the use of a numerical activity index such as the CDAI is more relevant in a clinical trial 
setting, where patients are not necessarily seen by an experienced specialty physician in 
order to ensure uniformity rather than our clinical setting.   
 
4.2.6 Data analysis 
Data were analysed to provide results describing the time to clinical relapse, to use of 
steroids, thiopurines or anti-TNFs and the time to first surgery after administration of 
EEN. Our population was divided in those who achieved clinical remission with 
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exclusive enteral nutrition on induction and those who did not. The statistical tests used 
for univariate analysis were student’s t-test (for continuous variables) and the chi-square 
test (for categorical variables). Kaplan Mayer analysis with log rank test was conducted 
to determine the time to clinical relapse or treatment escalation in the two groups. All 
analyses were 2 tailed and p-values of less than 0.05 were considered as statistically 
significant. All statistical tests were performed electronically with the use of statistical 
package for social sciences (SPSS version 16.0). Prism – GraphPad (GraphPad Prism 6) 
software was used for the generation of graphs.  
 
4.2.7 Ethical considerations 
As we have been evaluating the disease course of patients using our IBD service, we did 





55 patients were identified in the dietetics department database and from them 33 were 
excluded. Among the excluded patients, 14 patients did not have a confirmed diagnosis of 
Crohn’s disease (disease diagnosed abroad but not confirmed in UK, diagnosis of 
Tuberculosis or Indeterminate colitis), 10 patients were lost to follow up very soon after 
administration of EEN, 4 patients received partial enteral nutritional support or advice on 
a low residue diet, 3 had EEN co-administered with oral or IV corticosteroids and 2 had 















Figure 4.1: Patient population included in the study 
 
 
4.3.2 Demographics – disease characteristics at the time of EEN 
73% (16/22) of the patients included were male. The mean [SD] age at diagnosis and age 
at the time of EEN administration and were 20.6 [7.3] and 30.8 [8.8] years respectively. 
The mean disease duration at the time of EEN was 7.5 [8.8] years.  The mean [SD] 
duration of follow up was 1.9 [0.8] years. 40.9 % (9/22) of the patients were Caucasian, 
54.5 % (12/22) South Asian and 4.5% (1/22) African – Caribbean.  
55 patients identified 
22 patients included 
33 patients excluded 
- 14 for unclear diagnosis 
- 10 lost to follow up 
- 4 had partial EN 
- 3 for steroid co-administration 
- 2 had a short course 
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31.8% (7/22) of patients were diagnosed with Crohn’s disease at age younger than 17 
years, 63.8% (14/22) between 17 and 39 years and 4.5% (1/22) at the age of 40 or older. 
31.8% (7/22) of patients had ileal disease, 4.5% (1/22) colonic and 63.6% (14/22) 
ileocolonic disease. Upper GI involvement was present in 22.7% (5/22) of our patients. 
31.8% (7/22) of patients had inflammatory disease phenotype, 36.4% (8/22) stricturing 
and 31.8% (7/22) penetrative. Perianal disease was present in 31.8% (7/22) of our 
patients. There was no significant difference in the baseline demographic and disease 
specific characteristics between Caucasian and South Asian patients. (see table 4.1) 
All patients received exclusive enteral nutrition. An NG tube was administered in only 
9.1% (2/22) of patients and 18.2% (4/22) did not tolerate the diet. There was no 
difference in the rates of intolerance and the need for NG placement between Caucasian 
and South Asian patients [22.2% (2/9) vs 16.7% (2/12), p=0.75 and 11.1% (1/9) vs 8.3% 
(1/12), p=0.83 respectively]. 27.3% (6/22) of patients had EEN administered in the past. 

















Gender male, n (%) 16 (72.8) 7 (77.8) 8 (66.7) 0.58 
Age 30.8 [8.8] 30.5 [6.6] 31.7 [8.7] 0.73 
Disease duration 7.5 [8.8] 8.4 [9.1] 7.2 [9.3] 0.77 
Age at dianosis, years 20.6 [7.3] 19.5 [6.1] 21.8 [8.2] 0.49 
Age at diagnosis 
(years) 
≤ 16, n (%) 7 (31.8) 3 (33.3) 3 (25)  
0.65 17-39, n (%) 14 (63.6) 6 (66.7) 8 (66.7) 
≥ 40, n (%) 1 (4.5) 0 (0) 1 (8.3) 
Location 
Ileal, n (%) 7 (31.8) 4 (44.4) 3 (25)  
0.49 Colonic, n (%) 1 (4.5) 0 (0) 1 (8.3) 
Ileocolonic, n (%) 14 (63.6) 5 (55.6) 8 (66.7) 
+ L4, n (%) 5 (22.7) 1 (11.1) 4 (33.3) 0.24 
+ perianal, n (%) 7 (31.8) 1 (11.1) 5 (41.7) 0.13 
Behaviour 
Inflammatory, n (%) 7 (31.8) 2 (22.2) 5 (41.7)  
0.65 Strictuting, n (%)  8 (36.4) 4 (44.4) 4 (33.3) 
Penetrating, n (%) 7 (31.8) 3 (33.3) 3 (25.0) 
Previous 
treatments 
EEN, n (%) 6 (27.3) 1 (11.1) 4 (33.3) 0.24 
Corticosteroids, n (%) 13 (59.1) 6 (66.7) 6 (50) 0.45 
Thiopurines, n (%) 15 (68.2) 6 (66.7) 8 (66.7) 1.0 
Methotrexate, n (%) 3 (13.6) 1 (11.1) 2 (16.7) 0.72 
Anti-TNF, n (%) 7 (31.8) 3 (37.5) 3 (25) 0.55 




4.3.3 Disease course 
After treatment, 22.7% (5/22) of patients went into remission, 77.3% (15/20) experienced 
a clinical response and 9.1% (2/22) did not have any benefit. There was no difference in 
the clinical response and remission rates between Caucasian and South Asian patients. 
(See table 4.2) The mean [SD] CRP after treatment was 17.6 mg/dl [22.5] and was 
significantly lower compared to the CRP prior to initiation of EEN 60.2 mg/dl [66.8] 
(p<0.01). In concert, the mean [SD] platelet count decreased from 363*10³/µ/L [117] to 
346*10³/µ/L [124] (p=0.38) and serum albumin levels increased from 36.4 g/L [7.3] to 
40.4 g/L [5.5] (p<0.01) 
Table 4.1 Baseline demographic and disease specific characteristics. All values 
express Mean [SD] unless otherwise specified. 
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By the end of follow up 63.6% (14/22) of patients had clinically relapsed, 55.6% (5/9) of 
the Caucasian and 66.7% (8/12) of the South Asian patients (p=0.60).  The mean [SD] 
time to clinical relapse was 11.1 [11.2] months and there was no significant difference in 
duration of remission between the two ethnic groups (see table 4.2). 31.8% (7/22) of 
patients required treatment with corticosteroids after EEN and the mean [SD] time to 
corticosteroids was 18.9 [11.1] months. 36.4% (8/22) of patients required de novo 
treatment with thiopurines after EEN and18.2% (4/22) continued with thiopurine 
treatment that was prescribed prior to EEN. The mean [SD] time to treatment with 
thiopurine was 16.2 [12.8] months. 50% (11/22) of patients required treatment with anti-
TNF after EEN and the mean [SD] time to treatment was 14.7 [10.5] months. 36.4% 
(8/22) of patients required surgical treatment after EEN and the mean [SD] time to 
surgery was 18.0 [10.0] months.  
There were no differences between the two ethnic groups in the disease outcomes during 
follow up between the two ethnic groups. Similar proportion of patients clinically 
relapsed, required steroids, treatment with thiopurine, anti-TNF or surgery. Also, the time 










Clinical course and need for treatment 








Remission after EEN, n (%) 5 (22.7) 1 (11.1) 4 (33.3) 0.24 
Response after EEN, n (%) 15 (77.3) 4 (44.4) 6 (50.0) 0.80 
Clinical relapse during follow up, n (%) 14 (63.6) 5 (55.6) 8 (66.7) 0.60 
Time to clinical relapse (months) 11.1 [11.2] 12.3 [13.1] 10.3 [10.8] 0.57† 
Need for corticosteroids, n (%) 7 (31.8) 2 (22.2) 5 (41.7) 0.35 
Time to corticosteroids (months) 18.9 [11.1] 20.4 [9.3] 18.2 [13.0] 0.37† 
Need to initiate thiopurines, n (%)* 8 (36.4) 3 (42.9) 5 (50.0) 0.77 
Time to thiopurines (months) 16.2 [12.8] 16.3 [11.8] 16.2 [14.5] 0.77† 
Need to initiate anti-TNF, n (%) 11 (50) 6 (66.7) 5 (41.7) 0.26 
Time to anti-TNF (months) 14.7 [10.5] 9.7 [8.6] 18.6 [11.1] 0.07† 
Need for abdominal surgery, n (%) 8 (36.4) 5 (55.6) 3 (25.0) 0.15 
Time to abdominal surgery (months) 18.0 [10.0] 14.7 [11.2] 20.9 [8.9] 0.13† 
 
Table 4.2: Response to EEN and need for treatment escalation during follow up. All 
values express Mean [SD] unless otherwise stated 
*4 patients already on azathioprine exluded 
† denotes Kaplan-Meier, log rank test 
 
4.4 Discussion 
This study attempts to record the outcomes to EEN in adult patients with Crohn’s disease. 
Also, this is the first study to our knowledge attempting to compare the response to EEN 
and the need for treatment escalation after EEN between Caucasian and South Asian 
adult patients with Crohn’s disease.  
 
The rate of remission after treatment of EEN in our adult patients was only 22.7% (5/22) 
and is significantly lower than that of our paediatric patients of whom 57.1% (32/56) 
went into clinical remission after treatment with EEN (p<0.01). Comparing patients of 
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South Asian descent to Caucasian patients did not identify any significant differences in 
the clinical outcome of EEN or the need for treatment escalation after EEN. 
An important factor that may explain the lack of difference between the two ethnic and 
age groups is the fact that these patients represented adults with advanced disease 
phenotypes and not treatment naïve newly diagnosed patients, as was the case in our 
previous study (Chapter 2) on paediatric patients. Many of them had received treatment 
with corticosteroids or anti-TNF in the past and the majority of them had been on 
previous treatment with thiopurines. Also 1 in 3 of the patients included had undergone 
previous surgery. The advanced disease phenotype and failure of previous medical 
therapies could explain the fact that the rate of intolerance to EEN in our study is lower 
than the rates reported by others [301] as these patients had been exposed to 
corticosteroids in the past and possibly had ongoing penetrative complications that would 
preclude the use of corticosteroids. Their advanced disease phenotype could also set the 
grounds for the treating physicians to pro-actively escalate medical management rapidly 
in order to avoid further disease complications. Therefore, one could question whether 
the description of the treatments that were initiated after EEN are representative of the 
actual disease course. While in the paediatric setting treatment with immunomodulators 
would be initiated if absolutely clinically indicated as part of the long term risk 
management of these patients, in our adult patients with complicated disease it would be 
undertaken more promptly in order to prevent further complications. However, escalation 
to anti-TNF therapy, according to the NICE guidelines requires the presence of clinically 
active disease. The proportion of Caucasian patients that required treatment with anti-
TNF or escalation to a new anti-TNF after EEN numerically exceeded the proportion of 
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South Asian patients and there was a trend for earlier administration of anti-TNF to 
Caucasian patients. Similar were the trends in the requirement for and time to abdominal 
surgery after EEN, however the numerical difference observed did not reach statistical 
significance.  
This study has a number of limitations. The patients included where identified through 
the database of the dietetics department. The data input in the database is relying on the 
dieticians’ meticulousness and it is possible that a number of patients has not been 
recorded posing a degree of selection bias. Additionally, the total number of patients 
included is small, making the study underpowered. We did not do preliminary sample 
size calculations as the final sample size would be entirely dependent on the number of 
patients that we could identify from the database of the department of dietetics. However 
a post hoc calculation of the statistical power using a simple online calculator 
(http://clincalc.com/Stats/Power.aspx) suggests that the statistical power of this study to 
detect the observed difference in the remission rates, need for anti-TNF and surgery is 
12%, 20% and 13% respectively. Therefore our sample can be useful to describe the 
response to EEN and need for treatment escalation in the overall population. However, 
the numbers of patients included in each ethnic group is too small to allow for any safe 
conclusions to be drawn. This may explain the fact that the trends described in the need 
for anti-TNF and surgery in between patients of South Asian and Caucasian descent 
contrast the clinical impression from our practice, that overall the South Asian patients 
have a more aggressive disease course. Therefore we designed a retrospective study 
aiming to investigate the disease phenotype and course between the two populations that 









Chapter V: Is there a difference in the clinical course of 
IBD in adult Bangladeshis and Caucasian patients 







The data presented so far are based on patients who are being followed up in the 
paediatric, adolescent and adult IBD clinics at the Royal London and St Bartholomew 
hospitals which are both based in East London. One of the particularities the local 
population served by Barts Health is the presence of a significant number of Asian 
immigrants the majority of whom come from Bangladesh, which is reflected in our 
patient population and poses a question regarding whether conclusions drawn from our 
patients can be applicable to the general population. According to census data, in our 
borough, the Tower Hamlets, individuals of Bangladeshi descent represent 33.2% 
(67,200 out of a total population of 202,100) and individuals of Indian or Pakistani 
descent represent 2.2% of the population. [386] 
The incidence of IBD in Asian ethnic minorities in the UK has risen. [18]. Data from 
patients of South Asian descent living in the UK suggest that, compared with Northern 
Europeans, South Asians are more frequently diagnosed with extensive ulcerative colitis 
(UC) than with Crohn’s disease and that the latter is characterized by a more benign 
inflammatory non-stricturing non-penetrating phenotype [387]. Moreover, there is 
evidence to suggest that hypovitaminosis D is more prevalent among patients of South 
Asian descent. [388]  
Our impression when discussing patients in weekly MDTs has been that Bagladeshi 
patients with IBD in East London have a more aggressive course of disease, compared to 
white Caucasian patients, but this has not so far been scrutinized scientifically. Therefore 
in this chapter we investigate the differences in disease course between Bagladeshi and 
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5.2.1 Study design & clinical setting  
We conducted a retrospective case-controlled study to evaluate the phenotype and disease 
course of IBD patients of Bangladeshi descent, comparing it to that in white Caucasian 
patients, matched for age at diagnosis and disease duration and investigating the possible 
role of vitamin D in any differences noted. Barts and the London NHS Trust is a tertiary 
referral centre in East London, UK, that serves approximately 2000 paediatric, adolescent 
and adult patients with IBD from the local catchment area and beyond. Only patients of 
Bangladeshi descent and white Caucasian patients were included. Mixed race patients of 




The self-reported ethnicity, age at diagnosis, disease duration and postcode of each 
consecutive patient attending our specialist IBD outpatient clinics between March and 
August 2010 was recorded. Only patients living in postcodes from the inner East London 
area (boroughs of Tower Hamlets, City, Hackney ane Newham) were included in an 




5.2.3 Defining age at diagnosis 
In order to investigate if Bangladeshi patients develop IBD at an earlier age than white 
Caucasian patients, we assessed age at diagnosis in all patients of inner East London, 
including those who were not subsequently matched. Because the age distribution in our 
local Bangladeshi patients was skewed towards a younger age compared to that of white 
Caucasians, for this part of the study we studied the comparison of age at diagnosis in 




For the remainder of the study, all patients of Bangladeshi descent who were formally 
diagnosed with IBD based on standard endoscopic, histological and radiological criteria 
attending our specialist IBD outpatient clinics were included. These were subsequently 
matched to a Caucasian IBD patient of English, Scotish or Welsh descent attending our 
clinics in terms of disease duration (± 5 years) and age at diagnosis (± 3 years) in order to 
compare the natural history of the disease. When more than one match was available, the 
individual with the closest disease duration was included.  
 
5.2.5 Demographic and socio-economic data  
Demographic data, including place of birth and year of migration were collected from our 
Electronic patient records online system (EPR) and our IBD database. Socio-economic 
data was obtained from the ACORN database. [389] The ACORN database provides 
information on the socioeconomic status based on an individual’s postcode, by analyzing 
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demographic data, social factors, population and consumer behaviour. This online 
database segments the UK population into 56 ordinal socioeconomic types: where 1 is 
categorized as “affluent mature professionals, living in large houses” and 56 as “multi-
ethnic populations living in crowded flats” and is postcode specific. The area of inner 
East London is characterized by a significant demographic diversity concerning the 
socioeconomic status of its residents and the postcode specificity provided by the 
ACORN database ensures that differences will be identified even within the same 
geographic area. 						
	
5.2.6 IBD phenotype and disease course 
IBD was phenotyped according to the Montreal Classification [369] and was recorded at 
diagnosis and the last follow up. The natural history of UC and Crohn’s disease were 
assessed by assessing and comparing the time to change in Montreal Classification; the 
treatments used including numbers of courses of corticosteroids, and use of and time to 
use of immunosuppressant treatments and surgeries. In an attempt to minimize bias in 
data collection, we prospectively decided that the relevant data will be collected by 4 
researchers: 2 for the data of the Bangladeshi patients and 2 for the data of the white 
Caucasian patients; The ones collecting data on the Bangladeshi patients (JRG and NMJ) 







5.2.7 Extra-intestinal manifestations and complications 
We recorded the incidence of organ specific extra-intestinal manifestations such as 
arthropathy, skin or ocular involvement and primary sclerosing cholangitis. We also 
recorded the prevalence of anaemia and vitamin D deficiency at the last outpatient 
attendance.  
Anaemia was defined according to WHO criteria [390]: in men as Hb <13.0 g/dL, in non 
pregnant women as Hb <12 g/dL, in pregnant women as Hb <11.0 g/dL, in children of 12 
- 13 years old as Hb < 12 g/dL and in children of 5-12 years old as Hb<11.5 g/dL. Iron 
deficiency was defined as a ferritin <30ug/L when the corresponding CRP was <10 mg/L, 
or a ferritin <100ug/L when C-reactive protein (CRP) was >10 mg/L and/or transferrin 
saturation (TNSat) <16% [391]. Anaemia of chronic disease was defined as anaemia in 
the presence of a CRP-adjusted, normal or increased serum ferritin and/or a low plasma 
iron and iron binding capacity [176]. B12 deficiency was defined as <191 ng/L and folate 
deficiency as serum folate <3.8 mcg/L. Blood test results were obtained from the 
electronic patient record.  
Vitamin D status was estimated through the measurement of serum 25 – hydroxyl – 
vitamin D levels. The optimal vitamin D levels have been a matter of debate as there is 
no clear consensus of opinions and a recent systematic review of the relevant literature 
suggests different cut off values for every functional endpoint of vitamin D. [370] In our 
study, vitamin D insufficiency was defined as 25 (OH) vitamin D levels of less than 50 
ng/L as this has been described as the threshold of pharmacological intervention and 
deficiency as levels of less than 25 ng/L as this threshold is reportedly associated with 
osteomalacia. [371]  
 178 
5.2.8 Statistical analysis 
Statistical analyses were conducted using the Statistical Package for the Social Sciences 
(SPSS) (version 16, San Diego, California, USA) and Prism (version 4, Chicago, Illinois, 
USA) software. All analyses were two tailed and p values <0.05 were considered 
significant. Univariate analysis of baseline demographic data comparing patients of 
Bangladeshi descent and white Caucasians was carried out using chi-squared test for 
categorical data, Student’s t-test for continuous normally distributed variables and Mann-
Whitney U tests for discrete or nonparametric data. Univariate survival analyses using 
Kaplan-Meier curves and the log-rank test were used to identify differences in the 
proportions of patients and the time to change in Montreal Classification, escalation in 
therapy and need for surgery between the ethnic groups. Where ethnicity was found to 
influence disease progression, multivariate Cox regression analyses, taking into account 
factors that are known to be linked with a worse prognosis was undertaken. 
 
5.2.9 Ethical considerations 
As we have been evaluating the disease course of patients using our IBD service, we did 










We screened 2449 appointments of 1247 patients (figure 5.2). 192 patients were excluded 
because they did not have a confirmed diagnosis of IBD according to standard criteria. 
13% [ 132/1055] and 59% [623/1055] patients reported that they are of Bangladeshi and 
Caucasian descent respectively and of these significantly more Caucasian than 
Bangladeshi lived outside the inner East London boroughs (62% [389/623] vs 8% 
[11/132], p<0.0001).   
 
5.3.2 Age at diagnosis 
In the population available for matching, only 7% (9/121) Bangladeshis compared with 
26% (60/234) Caucasians had IBD diagnosed at age >40 years (P<0.001). However, after 
adjusting for the age distributions in the Bangladeshi compared with the local white 








Figure 5.1: Age at diagnosis of the Bangladeshis and white Caucasians in the 
screening population. There was no difference in the age distribution of IBD incidence 




We were unable to match 2% [2/121] of the Bangladeshi patients because their disease 
durations were less than 4 months and a similar white Caucasian match was unavailable 
(see Figure 5.2). As a consequence of our matching there was no difference in the mean 
[SD] age at diagnosis (23.4 [11.2] vs 24.0 [11.5] yrs, p=0.7) or disease duration (6.1 [4.7] 
vs 6.9 [4.8] yrs, p=0.43) between the Bangladeshi and white Caucasian groups 





Figure 5.2: Diagram outlining the screening, matching and inclusion of Bangladeshi 
and white Caucasians. Each index case was then matched on the grounds of age at 
diagnosis (to within 3 years) and then disease duration (to within 5 years) to a white 
Caucasian patient of English, Scottish or Welsh descent. Where more than one potential 
match on the grounds of age at diagnosis was available, the individual with the closest 
disease duration was included.			 
 
5.3.4 Baseline demographics 
There was no difference in the mean age between groups (Table 5.1). Overall, more 
patients of Bangladeshi descent were male than female (p=0.05) (Table 5.1). There were 
no differences in the proportions of patients who were ex- or current smokers or in the 
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duration of smoking, between groups. However, and allowing for missing data, more 
Bangladeshi men (41% [26/63]) than women (10% [4/40], p<0.01) were, or had been 
smokers; in contrast, there was no difference in smoking status of patients according to 
gender in the white Caucasians (53% [17/32] men vs 48% [16/33] women, p=1.0) (Table 
5.1). Based on their postcodes and according to the ACORN classification type (median 
[range]), patients of Bangladeshi (55 [9-56]) descent lived in more socioeconomically 
deprived areas of East London than patients of white Caucasian (21 [1-56]) descent 






Characteristic Bangladeshi  n = 119 
White 
Caucasian  
n = 119 
p-value 
Sex  Male, n (%) 72 (61) 57 (48) 0.05 
Age Mean [SD] age (years)  29.6 [11.6] 30.9 [11.8] 0.37 
Cigarette  
Smoking  
Lifelong non-smoker, n(%) 73/103 (71) 65/98 (66) 
0.55 Smoker, n (%) 15/103 (15) 13/98 (11) 
Ex-smoker, n (%) 15/103 (15) 20/98 (20) 
Pack years  3.1 [0.7-15.0] 4.5 [0.3-42] 0.18 
ACORN 
type  ACORN type  55 [9-56] 21 [1-56] <0.001 
Duration Mean [SD] age at diagnosis 
(years)  
23.4 [11.2] 24 [11.5] 0.69 
Mean [SD] disease duration 
(years)  
6.1 [4.7] 6.9 [4.8] 0.16 
Time to diagnosis (months)  5 [0-172] 5 [0-134] 0.59 
Disease 
type 
Crohn’s disease, n (%) 79 (66) 62 (52) 
0.004 Ulcerative Colitis, n (%) 40 (34) 49 (41) 
IBD Unclassified, n (%) - 8 (7) 
Table 5.1: Demographic characteristics, disease duration and type of the included 
white Caucasian and Bangladeshi patients. Values are expressed as median [range] 
unless otherwise indicated. 
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5.3.5 Disease type and time to diagnosis 
More patients of Bangladeshi descent were diagnosed with Crohn’s disease than UC or 
inflammatory bowel disease of uncertain type (IBDU) than their matched patients of 
white Caucasian descent (Table 5.1). There was no difference in the time to diagnosis 
between Bangladeshis or white Caucasians for either UC or Crohn’s disease (Table 5.1).  
 
5.3.6 Phenotype and natural history of Crohn’s disease 
There were no differences in the phenotype of Crohn’s disease according to the Montreal 
Classification between Bangladeshis and white Caucasian descent at diagnosis (Table 
5.2). Over the period of follow up, there were no differences in the time to, or the 
proportions of, patients whose Crohn’s disease became more extensive (increased 
Location (L) or developed upper GI disease + L4) or changed behaviour (increased B) 
between groups. However, patients of Bangladeshi descent (Hazard ratio (HR) [95%CI] 
9.2 [1.7, 48.1], p=0.009) were more likely to develop perianal disease earlier in their 























A1: Age≤16, n (%) 33 (42) 29 (48) 
0.74 A2: 17-40, n (%) 43 (54) 29 (48) 
A3: >40, n (%)  3 (4) 2 (3) 
L1: Ileal, n (%)  26 (33) 20 (32) 
0.47 L2: Colonic, n (%)  19 (24) 14 (23) 
L3: Ileocolonic, n (%)   30 (38) 26 (42) 
+ L4: Upper GI, n (%)   14 (18) 13 (21) 0.39 
B1: Inflammatory, n (%)  50 (63) 34 (55) 
0.93 B2: Stricturing, n (%)  12 (15) 7 (11) 
B3: Penetrating, n (%) 16 (20) 9 (15) 
+ p: Perianal, n (%) 18 (23) 10 (16) 0.46 
Disease course Increase in Montreal Classification location (L)  3 (4) 4 (6) 
0.92‡ Time to increase in L (months) 55 [6-227] 92 [17-251] 
New upper GI disease (+L4)  4 (5) 1 (2) 
0.09‡ Time to develop L4 (months) 56 [6-324] 79 [13-312] 
Increase in Montreal Classification behaviour (B)  17 (22) 12 (19) 
0.81‡ Time to increase in B (months) 56 [6-324] 64 [1-311] 
New perianal disease (+p) 13 (16) 2 (3) 




5-ASA, n (%) 74/79 (94) 49/57 (86) 0.13 
Budesonide, n (%) 25/78 (32) 15/53 (28) 0.65 
Prednisolone, n (%) 52 (66) 38 (61) 0.35 
Number of courses of corticosteroids 1 [0-5] 0 [0-7] 0.02 
Thiopurines, n (%) 60/79 (76) 39/62 (63) 
0.01‡ Time to thiopurines (months)  20 [1-199] 37 [0-312] 
Methotrexate, n (%)   14 (18) 6 (10) 
0.12‡ Time to methotrexate (months) 54 [6-324] 77 [8-312] 
Anti-TNF, n (%) 26/79 (33) 13/60 (22) 
0.02‡ Time to anti-TNF (months)  20 [1-199] 37 [0-312] 
Surgery  Intestinal surgery, n (%) 18 (30) 27 (44) 
0.03‡ Time to intestinal surgery (months)  47 [0-190] 42 [0-312] 
Perianal surgery, n (%) 16 (20) 5 (8) 
0.04‡ Time to perianal surgery 51 [0-324] 75 [1.5-
312] 
Vitamin D insufficiency, n (%) 44/57 (77) 16/36 (44) p<0.01 
Vitamin D deficiency, n (%) 21/57 (37) 3/36 (8) p<0.01 
Mean [SD] Vitamin D levels, ng/L 34.5 [22.4] 56.1 [25.3] p<0.01 
Table 5.2: Phenotype and disease course of Crohn’s disease patients of white Caucasian and 
Bangladeshi descent.  ‡ denotes Kaplan-Meier analysis, log rank test. Values are expressed as 




The disease course, as described by the need for treatment escalation differed between the 
two ethnic groups. Bangladeshi patients required more courses of corticosteroids than 
white Caucasians (table 5.2). They also tended to require thiopurines and anti-TNFs 
earlier in their disease course as compared to white Caucasians (figure 5.3b and 5.3c).  
Interestingly, White Caucasian patients required surgery (mostly a right hemicolectomy) 
earlier in their disease course than Bangladeshi patients and patients of Bagladeshi 
descent were more likely to have undergone surgery for perianal disease (figure 5.3d). 
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Figure 5.3: Kaplan Meier analysis (graph) according to ethnicity and Cox regression 
analysis (table) of time to thiopurine (a), time to biologic (b), time to intestinal 
surgery (c) and time to new perianal disease (d) of patients with Crohn’s disease. The 
solid lines represent the disease course among patients of Bangladeshi descent and the 
dotted lines represent the disease course among white Caucasian patients. 
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5.3.7 Vitamin D and Crohn’s disease course 
Taking into account previous data supporting that vitamin D deficiency is prevalent 
among South Asian patients [388] and the possible role of vitamin D in the pathogenesis 
[228] and course of Crohn’s disease [245] we attempted to define the prevalence of 
vitamin D deficiency and insufficiency in our patients and whether this plays a role in the 
disease outcome.  
The mean [SD] vitamin D levels (ng/L) were significantly lower among Crohn’s disease 
patients of Bangladeshi descent (34.5 [22.4]) when compared to white Caucasian patients 
(56.1 [25.3]) p<0.01. Similarly the prevalence of Vitamin D deficiency and insufficiency 
were both significantly higher among patients of Bangladeshi descent (Table 5.2). (Please 
see discussion)  
However, the disease progression, described according to progression in phenotype 
according to the Montreal classification, need for corticosteroids, number of courses of 
corticosteroids, time to medical treatment escalation and time to surgery was similar 
between Crohn’s disease patients who were deficient or sufficient in vitamin D. (Table 










Table 5.3 Disease course of Crohn’s disease patients who are deficient or not 
deficient in vitamin D. ‡ denotes Kaplan – Meier analysis, log rank test, Values are 









 Vit D deficient 
(n=24) 
Not Vit D 
deficient (n=69) p value 
Disease 
course 
Progress in MC location (L), n (%)  1 (4.2) 5 (7.2) 0.63‡ Time to progress in L (months) 65.8 [18-311] 68.3 [6.5-324] 
New upper GI disease (+L4), n (%)  2 (8.3) 2 (2.9) 0.84‡ Time to develop L4 (months) 74.5 [18-311] 68.3 [6.5-324] 
Progress in MC behaviour (B), n (%)  4 (16.7) 20 (29) 0.23‡ Time to progress in B (months) 65.8 [18-311] 56.8 [5.1-324] 




Prednisolone, n (%) 17 (70.8) 42 (60.9) 0.38 
Number of courses of steroids 1 [0 - 4] 1 [0-5 ] 0.69 
Thiopurines, n (%)  18 (75) 50 (72.5) 0.43‡ Time to thiopurines (months)  20.5 [0-134] 30.1 [0-204] 
Methotrexate, n (%)  5 (20.8) 6 (8.7) 0.11‡ Time to methotrexate (months) 61.8 [8-312] 66.3 [6-324] 
Anti-TNF, n (%)  7 (29.2) 17 (24.6) 0.74‡ Time to anti-TNF (months)  19 [0-106] 34.3 [0-256] 
Surgery  Intestinal surgery, n (%) 11 (45.8) 32 (46.4) 0.94‡ Time to intestinal surgery (months)  51 [0-178] 44 [0-190] 
Perianal surgery, n (%) 3 (12.5) 10 (14.5) 0.82‡ Time to perianal surgery 65.8 [0-324] 66.3 [0-324] 
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Table 5.4 Disease course of Crohn’s disease patients who are insufficient or 
sufficient in vitamin D. ‡ denotes Kaplan – Meier analysis, log rank test. Values are 
expressed as median [range] unless otherwise indicated. MC stands for Montreal 
Classification 
 
5.3.8 Phenotype and disease course of ulcerative colitis 
UC patients of Bangladeshi descent were more likely to suffer from extensive disease 
compared to white Caucasian patients (60% vs 33%, p=0.02) at diagnosis. The likelihood 
of disease extension during the follow up period was similar between groups. There were 
no differences in the number of courses of corticosteroids and the time to or proportions 
 Vit D 
insufficient 
(n=60) 
Vit D sufficient 
(n=33) p value 
Disease 
course 
Progress in MC location (L), n (%)  5 (8.3) 1 (3) 0.24‡ Time to progress in L (months) 62.2 [6.5-324] 80.5 [19-204] 
New upper GI disease (L4), n (%)  3 (5) 1 (3) 0.55‡ Time to develop L4 (months) 64.8 [6.5-324] 80.5 [19-204] 
Progress in MC behaviour (B), n (%)  15 (25) 9 (27.3) 0.98‡ Time to progress in B (months) 56.5 [5-324] 67.1 [7-204] 




Prednisolone, n (%) 37 (61.7) 22 (66.7) 0.63 
Number of courses of steroids 1 [0-5] 1 [0-5] 0.81 
Thiopurines, n (%)  43 (71.7) 25 (75.8) 0.76‡ Time to thiopurines (months)  25.2 [0-199] 33.5 [0-204] 
Methotrexate, n (%)  7 (11.7) 4 (12.1) 0.86‡ Time to methotrexate (months) 56.2 [6.5-324] 77.9 [19-204] 
Anti-TNF, n (%)  16 (26.7) 8 (24.3) 0.57‡ Time to anti-TNF (months)  46.6 [6.5-311] 68.3 [11-204] 
Surgery  Intestinal surgery, n (%) 28 (46.7) 15 (45.5) 0.90‡ Time to intestinal surgery (months)  44.5 [0-190] 45.0 [0-141] 
Perianal surgery, n (%) 10 (16.7) 3 (9.1) 0.26‡ Time to perianal surgery 56.3 [0-324] 80.5 [0-204] 
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of patients that required escalation of medical therapy or surgical intervention 




Table 5.5: Phenotype and disease course of UC patients of white Caucasian and 
Bangladeshi descent. ‡ denotes Kaplan – Meier analysis, log rank test. Values are 












E1: Proctitis, n (%) 1 (2.5) 15/45 [31%] 
0.002 E2: Left , n (%) 15 (37.5) 14/45 [29%] 
E3: Total, n (%) 24 (60) 16/45 [33%] 
Disease 
course 
Extension of UC, n (%)  2 (5) 6/49 [12%] 0.61‡ Time to extension of UC (months)  40 [9-239] 48 [5-288] 
Medication 
ever  
5-ASA, n (%) 34 (85) 47 [96%] 0.07 
Prednisolone, n (%)  29 (43) 38 [78%] 0.58 
Number of courses of steroids 2 [0-6] 1 [0-13] 0.86 
Thiopurines, n (%)  25 (63) 24 [49%] 
0.23‡ Time to thiopurines (months)  25 [3-239] 54 [3-288] 
Methotrexate, n (%)  9 (23) 7 [14%] 0.34‡ Time to methotrexate (months) 49 [9-239] 56 [5-288] 
Calcineurin inhibitor, n (%) 3 (8) 6 [12%] 
0.55‡ Time to calcineurin inhibitor (months) 52 [0-239] 56 [3-288] 
Surgery  Intestinal surgery, n (%) 3 (7.5) 5 (10.2) 0.68‡ Time to intestinal surgery (months)  48 [9-239] 56 [3-288] 
Vitamin D insufficiency, n (%) 21/27 (77.8) 8/17 (47.1) 0.04 
Vitamin D deficiency, n (%) 14/27 (51.9) 5/17 (29.4) 0.14 
Mean [SD] Vitamin D levels, ng/L 33.5 [23.1] 49.4 [28.5] 0.048 
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5.3.9 Vitamin D and the course of UC 
There was no difference in the proportion of patients of Bangladeshi descent when 
compared to white Caucasians who were vitamin D deficient (Vitamin D < 25ng/L) 
(Table 5.5). However, more patients of Bangladeshi descent were insufficient (Vitamin D 
< 50 ng/L) in vitamin D when compared to white Caucasians (77.8% vs 47.1%, p=0.04) 
and the mean [SD] (ng/L) levels of vitamin D were significantly lower among patients of 
Bangladeshi descent (33.5 [23.1] vs 49.4 [28.5] p<0.05). 
Patients who were deficient in vitamin D were significantly more likely to require 
corticosteroids for the management of their disease compared to those who were not 
deficient (Table 5.7). There was no difference in the proportion of patients who required 
or the time to escalation of medical management to immunosuppressants between groups. 
However, there was a trend towards more often and sooner need for surgery among the 
vitamin D deficient patients (Table 5.7). Although there was a trend towards more often 
and sooner disease extension among patients who were not deficient or insufficient in 
vitamin D, there was no difference in the final Montreal Classification of UC between 
groups. This is accounted for by the fact that more vitamin D deficient or insufficient 









Table 5.6 Disease course of patients with UC who are insufficient or sufficient in 
vitamin D. ‡ denotes Kaplan – Meier analysis, log rank test. Values are expressed as 
median [range] unless otherwise indicated. 
 
Table 5.7 Disease course of patients with UC who are deficient or not in vitamin D.  
‡ denotes Kaplan – Meier analysis, log rank test. Values are expressed as median [range] 
unless otherwise indicated. 
 













Prednisolone, n (%) 22 (75.9) 12 (80) 0.76 
Number of courses of steroids 1 [0-6] 2 [0-4] 0.45 
Thiopurines, n (%)  16 (55.2) 10 (66.7) 0.41‡ Time to thiopurines (months)  31.8 [3-239] 21.6 [7-124] 
Methotrexate, n (%)  6 (20.7) 3 (20) 0.82‡ Time to methotrexate (months) 72.0 [10-239] 54.7 [9-154] 
Surgery  Surgery, n (%) 4 (13.8) 1 (6.7) 0.56‡ Time to surgery (months)  66.7 [10-239] 51.1 [10-239] 
 Vitamin D 
deficiency 
(n=19) 






Increase in disease extent, n (%) 0 (0) 4 (16) 




Prednisolone, n (%) 18 (94.7) 16 (64) 0.02 
Number of courses of steroids 2 [0-6] 1 [0-4] 0.26 
Thiopurines, n (%)  12 (63.2) 14 (56) 0.74‡ Time to thiopurines (months)  23.4 [5-166] 31.8 [3-239] 
Methotrexate, n (%)  6 (31.6) 3 (12) 0.18‡ Time to methotrexate (months) 76.5 [10-214] 54.7 [9-239] 
Surgery  Surgery, n (%) 4 (21.1) 1 (4) 0.10‡ Time to surgery (months)  76.5 [10-214] 51.1 [9-239] 
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5.3.10 Extraintestinal manifestations 
A significant cause of morbidity and work disability among patients with IBD is the 
presence of extra – intestinal manifestations. [392] Moreover, iron deficiency anaemia 
has been associated with active disease in IBD patients. [176] 
The prevalence of organ specific extra-intestinal manifestations of IBD (arthropathy, 
cutaneous involvement, ocular involvement, PSC) was equal between the two ethnic 
groups. Significantly more of the patients of Bangladeshi (39% [47/119]) than white 
Caucasian (20% [24/119]) descent were anaemic (p<0.001). Furthermore, among 
anaemic patients, haematinics consistent with iron deficiency were more common in the 
Bangladeshi patients (p=0.03). (Table 5.8) 
 
 




p - value 
EIM  Prevalence, n (%) 18 (15) 25 (21) 0.2 
Type EIM Arthropathy, n (%) 16 (13) 15 (13) 1 
Cutaneous, n (%)  1 (1) 6 (5) 0.12 
Ocular, n (%) 1 (1) 3 (3) 0.62 
PSC, n (%) 0 (0) 1 (1) 1 
Vitamin D ng/L 34.2 [22.5] 53.3 [26.0] <0.001 
Anaemia Prevalence, n (%) 47 (39) 24 (20) 0.001 
Haemoglobin, g/dl  12.6 [2.0] 13.4 [1.5] <0.001 
Haematocrit 0.38 [0.06] 0.4 [0.04] 0.01 
Mean cell volume, fl 84.1 [6.8] 88.6 [6.8] <0.001 
Anaemia 
type 
Iron deficiency, n (%) 38 (81) 12 (50) 
0.03 Anaemia of chronic disease, n (%) 7 (15) 9 (38) 
Undetermined, n (%) 2 (4) 3 (13) 
Table 5.8: Extra-intestinal manifestations (EIM) of IBD among patients of Bangladeshi 
and white Caucasian descent. All variables are expressed as mean [standard deviation] 
unless otherwise indicated 
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5.4 Discussion 
5.4.1 The course of IBD in white Caucasian and patients of Bangladeshi descent 
living in East London 
Compared with patients of white Caucasian descent, patients of Bangladeshi descent are 
more likely to be diagnosed with Crohn’s disease than UC or IBDU. Our findings 
contrast with previous reports of IBD phenotype in South Asians living in Leicester in the 
UK [393] , and in a large group of mixed South Asian patients, the majority of whom 
were of Indian descent, from North-West London: these two ethnic groups, when 
compared to non-matched Northern European control patients, tended to be more 
frequently diagnosed with UC. [387] Although Bangladeshis and South Asians have 
similar genetic backgrounds, our results could be explained by the fact that they may 
have differences in lifestyle related environmental factors such as smoking habit, alcohol 
consumption and diet.  
More men than women of Bangladeshi descent were diagnosed with Crohn’s disease, 
whereas there was no difference in disease distribution according to genders in white 
Caucasian patients, possibly because Bagladeshi men are more frequently smokers as 
compared to women who rarely ever smoke. [394]  
 
5.4.1.1 The natural history and phenotype of Crohn’s disease 
Previous studies on the phenotype of Crohn’s disease in South Asian patients living in 
North West London suggest a predominant colonic inflammatory phenotype at diagnosis. 
[387] We found no differences in the phenotype of Crohn’s disease at diagnosis between 
the two ethnic groups, however, more Bangladeshis than white Caucasians developed 
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new perianal disease. The higher overall prevalence of perianal disease among patients of 
Bangladeshi descent is likely to be the explanation for the delay in intestinal surgery 
among this patient group, as in the presence of perianal disease, medical management 
with thiopurines or anti-TNFs is a more appropriate choice than surgery. In fact, in our 
patient group, patients of Bangladeshi descent received these treatments more often and 
earlier in their disease course as compared to white Caucasians. Apart from perianal 
disease, the earlier escalation of treatment might signify a more aggressive disease course 
in terms of frequency of exacerbations as this is implied by the higher number of steroid 
courses among patients of Bangladeshi descent. Overall, the progression of Crohn’s 
disease to a stricturing or penetrating phenotype, regardless of ethnicity and allowing for 
the duration of disease, appears similar to that frequently cited from Northern Europe. 
[395]  
 
5.4.1.2 The phenotype and natural history of ulcerative colitis 
Patients of Bangladeshi descent were more likely to suffer from extensive ulcerative 
colitis as compared to white Caucasian patients. Our result is in agreement with other 
studies of South Asian immigrants in UK. [387, 396] 
 Despite the difference in the disease extent, no differences were observed between the 
two ethnic groups in terms of need for escalation of medical management and surgical 
intervention. Given the fact that the decision making on the need for further investigation 
and treatment is based on the assessment of symptoms as these are reported in a clinical 
encounter and taking into account that symptom awareness and reporting is reportedly 
low among ethnic minorities in England and especially among those for whom English is 
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not the main language spoken at home, [397] under-reporting of symptoms among UC 
patients of Bangladeshi descent – and a number of our patients, mainly females do not 
speak English -  could account for the lack of need for treatment intensification compared 
to white Caucasians who are more likely to suffer from less extensive disease. However, 
this is speculation. 
 
5.4.1.3 Extra-intestinal manifestations 
In agreement with other studies, [398]  our results suggest that there is no difference in 
the prevalence of organ specific extra-intestinal manifestations between the two ethnic 
groups. However, iron deficient anaemia was more prevalent among patients of 
Bangladeshi descent. Chronic active inflammation related to more aggressive disease 
course, [176] dietary deficiency secondary to low socio-economic status and non 
adherence to oral iron supplementation or treatment of active inflammation, [341] could 
possibly account for the difference observed. 
 
5.4.2 Vitamin D levels in adult white Caucasian and adult IBD patients of 
Bangladeshi descent living in East London. 
In our population, Bangladeshi patients were more frequently insufficient or deficient in 
Vitamin D, and had lower mean vitamin D levels when compared to white Caucasian 
IBD patients. Although there are no other studies investigating vitamin D levels in 
Bagladeshi IBD patients, our results are in agreement with a recent study that compared 
white Caucasian IBD patients with South Asians and obtained similar results to ours, 
with the South Asian patients having lower mean vitamin D levels and being more 
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frequently vitamin D deficient. [388] Similarly, another recent retrospective study 
suggests that all South Asian IBD patients were at least insufficient in vitamin D. [399]  
 
Our result could be accounted for by possibly less exposure to sunlight likely related to 
the adherence of Bangladeshi patients to their traditional dress codes and less dietary 
intake of vitamin D among the Bangladeshi patients. Although we did not collect data on 
dietary habits and sunlight exposure among the Bangladeshi patients, it has been 
documented that South Asian non-IBD controls in UK have a higher prevalence of 
hypovitaminosis D, which is related to their lower sunlight exposure and dietary intake 
compared to white Caucasians. [400] These results confirming the vitamin D differences 
between South Asians and Caucasian patients without IBD in UK validate the originality 
of the difference in vitamin D levels observed between the two ethnic groups. They 
indicate that the possibility of the difference being driven by the more aggressive disease 
course that is documented among the Bangladeshi patients in our study is unlikely.  
According to our results, vitamin D deficiency did not affect the course of Crohn’s 
disease; but vitamin D deficient patients with UC were more likely to require treatment 
with corticosteroids or surgery and had more extensive disease on diagnosis. Our 
outcome is comparable to that of others that proved a significant association between 
vitamin D deficiency and the need for treatment with corticosteroids in a series of 34 
patients, [401] showing a possible association between vitamin D status and disease 
course. However in our study almost all vitamin D deficient patients required treatment 
with corticosteroids while the corresponding percentage in the study of Blanck et al was 
47%. [401] This could be possibly explained by the difference in the ethnical 
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composition of our cohort which included a significant proportion of Bangladeshi 
patients who have more aggressive disease compared to the group of patients included by 
Blanck et al where South Asian patients represented only 7% of the whole. [401] 
Overall, our study is limited by the lack of serial vitamin D measurements and the 
possible and likely unrecorded seasonal variation of vitamin D levels which have been 
documented to peak in August and trough in February. [402]  
 
5.4.3 Strengths 
A small number of studies evaluating the difference in the disease course according to 
ethnicity have been so far published and our study is the first study of ethnicity in groups 
matched for age and disease duration. We decided, unlike others [387] to compare for a 
single ethnicity rather than an array of different mixed ethnicities living in the same 
geographic area and in an attempt to minimize tertiary center bias we only included 
patients living in the boroughs of inner East London that would receive IBD care in our 
center irrespectable of our tertiary center status.  
 
5.4.4 Limitations 
Because of the retrospective data collection in our study, our results are possibly subject 
to interpretation bias and bias because of missing data for certain variables, for example 
the smoking habit of our patients. Our sample size is relatively small and as a 
consequence of this our results might be subject to type II error. Although our choice to 
compare matched groups derived from an intension to obtain more easily interpretable 
results, comparing all the white Caucasians with all the Bangladeshi patients living in 
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inner East London boroughs and statistically adjusting for age and disease duration could 
have resulted in better statistical power as 234 white Caucasian and 121 Bangladeshi 
patients would have been included. We elected not to use the Bonferroni correction for 
multiple comparisons because our study of hypothesis driven and our endpoints were all 
part of the natural history of IBD, therefore using the Bonferroni correction to reduce 



































6.1 Summary of findings 
This study explores a number of inter-related aspects of the effect of nutrients and 
environmental factors in the course of inflammatory bowel disease in children and adults. 
(see figure 6.1) In particular, we focus on enteral nutrition and its role on disease outcome 
and on a co-stimulatory molecule. We describe data on the outcome of Crohn’s disease 
among adult patients after EEN administration and we also explore the role of ethnicity 
on the course of IBD taking into account the links between ethnicity and vitamin D 
deficiency.  
We present data that suggest that a co-stimulatory molecule, CD58 is present in the 
intestinal epithelium of Crohn’s disease and UC patients and that in vitro, this molecule is 
down-regulated in the intestinal epithelial cell lines after exposure to enteral nutrition. 
Although further study will be required (including animal models), a down-regulation of 
co-stimulatory activity could be one of the mechanisms by which enteral nutrition exerts 
its beneficial effect in the treatment of active Crohn’s disease and CD58 might also be a 
novel therapeutic target. More complex mechanistic studies with IEC and T cell co-
cultures as well as animal studies are required to give a clearer indication as to whether 
this effect impacts on T cell activation and IBD activity. 
We have shown that 57% of our paediatric Crohn’s disease patients achieve clinical 
remission with exclusive enteral nutrition. These patients have a better clinical outcome 
over the course of 5 years; they take longer to clinically relapse and longer to require 
treatment with corticosteroids and escalation of treatment to thiopurines. Additionally, 
they are less likely to develop stricturing complications of Crohn’s disease. However, our 
conclusion is limited by the fact that we use the physician’s global assessment as an 
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indicator of disease activity and not a more quantitative measure of disease activity such 
as the CDAI.  
We present data to suggest that Vitamin D-deficient paediatric patients treated with EEN 
are more likely to require treatment with corticosteroids and thiopurines. This is an 
indication, rather than a robust conclusion as it is based on a single vitamin D level 
measurement. It has been shown that a single measurement of Vitamin D in 
epidemiological studies can be predictive of one’s status over the course of 1-3 years 
[403] however our conclusions may be further affected by the effect of reverse causality 
between disease activity and vitamin D status. [404] 
EEN has been well tolerated among adult patients. In our small and underpowered study 
(due to its rarity of use in adult practice) there was no difference in the disease outcomes 
of adult patients with CD after EEN when white Caucasian patients were compared with 
South Asians. 
Therefore, we devised another study focusing solidly in the comparison of disease course 
in different ethnic groups. Patients of Bangladeshi descent were more likely to be 
diagnosed with IBD at a younger age, were more likely to suffer from Crohn’s disease 
and when diagnosed with UC they were more likely to suffer from extensive disease 
when compared to their matched white Caucasian patients. Crohn’s disease patients of 
Bangladeshi descent had a more aggressive disease course: they would also more often 
and sooner require treatment with thiopurines, anti-TNF or surgery. They would more 
frequently develop new perianal complications. Ethnicity was the only factor 
independently associated with all markers of disease progression. Crohns disease patients 
had similar disease course in terms of need for escalation of medical treatment, need for 
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surgery and progression of phenotype according to their Montreal Classification 
irrespective of their vitamin D status. However, among UC patients, those who were 
deficient in vitamin D had more extensive disease on diagnosis and were more likely to 
require treatment with corticosteroids or surgery. 
 
6.2 Future directions 
The studies published on the effects of nutrients in IBD represent a broad spectrum of the 
current and past research.  However, the data presented in this thesis create new 
directions for further research in the future, as the work presented in this thesis could be 
expanded in a way that will answer further clinically relevant research questions. 
 
We are currently collecting data on the effect of EEN and the response to EEN on 
children’s growth, but this will be presented in a separate thesis. Although others have 
shown that EEN improves growth the first two years after initial administration, there are 
no data to suggest whether this effect is sustained in the longer term and whether the 
initial response or failure to respond to EEN is a determinant. In our study, we present the 
impact of the initial response to EEN on the clinical outcomes of the disease. Our 
measure of disease activity has been the physician’s global assessment. We also used 
treatment escalation as a surrogate marker of disease activity. However, a prospective 
study would enable the use of more objective markers of disease activity, such as the 
PCAI and faecal calprotectin. It would also enable the serial measurement of vitamin D 
levels, enabling a more accurate answer on the impact of vitamin D levels on the initial 
response to EEN and the course of disease activity. This would allow us to quantify the 
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time spent in remission over the course of follow up and its comparison between 
responders and non responders to EEN resulting in a much clearer answer on whether the 
initial response to EEN defines the long term disease outcome. In this context the 
connection between EEN administration, cumulative time spent in remission and growth 
could be more accurately investigated as well. 
We used the change in a patient’s Montreal classification as a surrogate marker of disease 
progression. The current concept in the evaluation of Crohn’s disease progression 
considers the Lemann index [405] as a more accurate marker of the cumulative intestinal 
damage over time. The Lemann index is calculated based on specific endoscopic and 
imaging findings [405] and has already been used to evaluate the impact of anti-TNF 
therapy in CD progression. [406] In a prospective longitudinal study the intestinal 
damage could be assessed accurately with the use of the Lemann score. This would 
provide accurate quantitation of disease progression over time and a clearer conclusion 
on the effect of initial response to EEN on the long term clinical outcome.   
An important challenging question on EEN is whether it has a direct immunomodulatory 
role. In a more invasive setting, allowing for ileal biopsies to be taken before and after 
EEN administration, the role of EEN as an epigenetic factor that interferes in the 
methylation of different genes in the intestinal mucosa could be investigated. The quality 
of genes implicated could give an answer on the role of EEN in the immunology of 




Work is required to further evaluate the effect of EEN on the expression of CD58 in the 
intestinal epithelium in order to extract more information on how EEN exerts its 
beneficial effect on patients with Crohn’s disease and in order to determine whether 
CD58 could be a therapeutic target in Crohn’s disease. Studies on animal models of IBD 
would be particularly helpful on assessing the effect of EEN on the expression of CD48 
(the CD58 analogue for mice) in murine models of colitis eg DSS colitis. Additionally, a 
trial of treatment with blocking anti-CD48 antibodies in murine models of IBD would 
provide preliminary information on a possible beneficial effect of alefacept in human 
patients with Crohn’s disease or Ulcerative Colitis.  
 
The results of clinical studies of the role of vitamin D in IBD are so far conflicting. Better 
designed prospective studies using serial vitamin D measurements will provide more 
information on the role of vitamin D in the clinical course of IBD. However, one of the 
most important factors influencing the credibility of any clinical result is its 
pathophysiological explanation: investigating the effect of vitamin D on the expression 
and function of TLR4 on the intestinal epithelium, on the antigen presentation in the 
mucosal dendritic cells using animal models of IBD and on the composition and 
metabonomics of the faecal microbiota would answer important questions. In the clinical 
setting serial measurements of Vitamin D among patients with IBD would give more 
convincing answers about the role of serum levels of Vitamin D in the disease course, or 
may provide a different cut off target range for IBD patients as the current levels of 
sufficiency or insufficiency have been estimated based on the role of vitamin D in bone 
health. Additionally, clinical studies on IBD patients who are are in remission or have 
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active disease and are administered vitamin D supplementation could give valuable 
information about the role of Vitamin D status and supplementation on the disease 
activity. At the same time the study of the faecal microbiome and metabonome of these 
patients in active and inactive disease status and vitamin D sufficient or deficient status 
would provide interesting data on whether vitamin D modifies the intestinal microbiota 
and metabonomics  Furthermore, taking intestinal or colonic mucosa biopsies and 
studying their epigenetic profile could give significant information on the role of vitamin 
D as an epigenetic regulator of disease activity and direct clues on the genes and 
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Variables collected for the long term follow up of children with Crohn’s disease who 





Montreal Classification (Disease location, disease behaviour, presence of perianal or 
upper GI disease) 
Tolerance to EEN 
Method of EEN administration (NG vs oral) 
CRP, ESR, Albumin on diagnosis 
Remission achieved with EEN (Yes/No) 
CRP, ESR, ALbumin 6 weeks after initiation of treatment with EEN 
Time to clinical relapse  
Steroids during course of follow up (yes/no) 
Number of steroids courses during follow up 
Time to first course of steroids during follow up 
Thiopurines required during follow up (yes/no) 
Time to first use of thiopurines 
Anti-TNF required during follow up (yes/no) 
Time to first use of anti-TNF 
Surgery required during follow up (yes/no) 
Time to first operation  
 261 
Vitamin D checked during follow up (yes/no) 
Date vitamin D checked 
Vitamin D level 
Vitamin D deficiency (yes/no) 
Vitamin D insufficiency (yes/no)  
Change of Montreal classification during follow up (yes/no) 
Date / time to change of Montreal Classification 
Final Montreal Classification (Location, Behavior, L4, perianal) 
Location expansion (yes/no) 
New L4 (yes/no) 
New perianal disease (yes/no) 
New stricture (yes/no) 
New penetration (yes/no) 





















Modulen Protocol for newly diagnosed children with CD at Barts’ Health 
The whole Modulen program is 10.5 weeks (3 to 4 days in hospital on Modulen 
only, 6 weeks Modulen only and 4 weeks of Modulen and food) 
Building up on the Modulen in hospital 
• Usually stay in hospital for 3'4 days to allow for gradual build 
up of Modulen e.g.: 
o Day 0: ‘The last supper’ and the taste test: If they’ve just 
been told of the diagnosis that day, it’s a good idea for them 
to have something tasty to eat before the program begins. If 
they come in especially to start Modulen then this isn’t 
necessary.  The taste test involves the nurses making up one 
cup of Modulen, dividing it into three cups and then adding 
a different flavour of Nesquik to each. The patient should 
then decide which flavour they like best. 
o Day 1: 1/3 total volume e.g. 3 cups 
o Day 2: 2/3 total volume e.g. 6 cups 
o Day 3: Total volume e.g. 9cups, then home that night or 
the following morning 
 
• If unable to drink Modulen then insert NG. 
6 weeks of Modulen only 
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• Add ½ ' 1 teaspoon of Nesquick to each cup. It seems to help 
compliance to stick to 1 Nesquick flavour  (Can also use Crusha 
syrup or the flavour modules from Nestle' although we don’t 
usually do this) 
• Nothing else except for water and sugar'free gum/mint (No 
sugar'free sweets, no flavoured water/ squash etc etc etc) 
• Tell family to avoid cooking/eating in front of child during first 
couple of weeks to help with compliance 
• It’s good if the families buy their own flasks/ bottles to put 
Modulen in as the shaker cups aren’t that sturdy 
4 weeks of Modulen and food re?introduction 
• Introduce a new food every 2 days: follow information sheet 
guidance 
• On week 1, give full volume Modulen, then reduce each week 
e.g. week 1: 9 cups, week 2: 6 cups, week 3: 4 cups, week 4: 2 cups 
Requirements 
 




Often need to concentrate the feed because the fluid requirement will be lower 
than the energy requirement 
Making Modulen 
20% = 1kcal/ml (standard concentration) 
Add 6 scoops to the shaker cup and then add 210ml cool, boiled water 
This gives a final volume of 250ml 
25% = 1.25kcal/ml 
Add 8 scoops to the shaker cup and then add 180ml cool, boiled water 
This gives a final volume of 250ml 
30%= 1.5kcal/ml 
Add 10 scoops to the shaker cup and then add 160ml cool, boiled water 
This gives a final volume of 250ml 
Follow up 
 
Patients are followed up by the gastro team in the IBD clinic on a Wednesday.  
The gastro team will bleep if they feel a patient needs to be seen. 
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REINTRODUCTION OF FOODS FOLLOWING EEN 
 
One food at a time should be re-introduced into the diet. The portion size to be taken each 
day should be 1-1,5 times the normal amount.  
 
If after re-introducing a certain food, symptoms reoccur or worsen, then this food should 
be removed from patient’s diet and can be attempted to be re-introduced again at a later 
date. No further food should be re-introduced until symptoms have cleared or improved. 
 
Once a food has been tested and found satisfactory, it can be included in any subsequent 
meal. 
 






Yeast (Take 2 brewers yeast tablets or use Marmite) 
Milk 










After re-introducing the above foods in their stated order, the following should be 
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Survival analysis of time to clinical relapse between responders and non responders 
to EEN after excluding the patients who did not tolerate EEN 
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Survival analysis of time to first use of corticosteroids among responders and non 
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Survival analysis of time to first use of thiopurines among responders and non 
responders to EEN after excluding patients that did not tolerate EEN. 
 
 
 
 
 
